0001558370-20-012511 10-Q 61 20200930 20201104 20201104 Annovis Bio, Inc. 0001477845 2834 262540421 DE 1231 10-Q 34 001-39202 201285717 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 QR Pharma, Inc. 20091202 10-Q 1 anvs-20200930x10q.htm 10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 10-Q


QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2020

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

COMMISSION FILE NUMBER 001-39202


Annovis Bio, Inc.

(Exact name of registrant as specified in its charter)

Delaware

26-2540421

(State or other jurisdiction of
incorporation or organization)

(I.R.S. Employer
Identification No.)

1055 Westlakes Drive, Suite 300

Berwyn, PA 19312

(Address of registrant’s principal executive offices)

(610) 727-3913

Registrant’s telephone number, including area code


Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

    

Trading Symbol

    

Name of Each Exchange on Which Registered

Common Stock, par value $0.0001 per share

ANVS

NYSE American

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes  No.

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes  No.

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes  No.

The number of outstanding shares of the registrant’s common stock as of November 2, 2020 was: 6,891,608.


ANNOVIS BIO, INC.

QUARTERLY REPORT ON FORM 10-Q

FOR THE QUARTER ENDED SEPTEMBER 30, 2020

PART I – FINANCIAL INFORMATION

   

Page

Item 1.

Financial Statements

3

Balance Sheets as of September 30, 2020 (Unaudited) and December 31, 2019

3

Statements of Operations for the Three and Nine Months Ended September 30, 2020 and 2019 (Unaudited)

4

Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) for the Three and Nine Months Ended September 30, 2020 and 2019 (Unaudited)

5

Statements of Cash Flows for the Nine Months Ended September 30, 2020 and 2019 (Unaudited)

6

Notes to Financial Statements (Unaudited)

7

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

18

Item 3.

Quantitative and Qualitative Disclosure About Market Risk

24

Item 4.

Controls and Procedures

25

PART II – OTHER INFORMATION

Item 1.

Legal Proceedings

26

Item 1A.

Risk Factors

26

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

26

Item 3.

Defaults Upon Senior Securities

26

Item 4.

Mine Safety Disclosures

26

Item 5.

Other Information

26

Item 6.

Exhibits

27

Signatures

28

2


PART I

FINANCIAL INFORMATION

Item 1. Financial Statements

Annovis Bio, Inc.

Balance Sheets

    

September 30, 

December 31, 

    

2020

    

2019

(unaudited)

Assets

 

  

 

  

Current assets:

 

  

 

  

Cash and cash equivalents

$

8,840,607

$

1,858

Grant receivable

 

424,952

 

735,075

Prepaid expenses and other current assets

 

136,442

 

10,579

Total current assets

 

9,402,001

 

747,512

Long-term assets:

 

  

 

  

Deferred offering costs

 

 

369,595

Total long-term assets

 

 

369,595

Total assets

$

9,402,001

$

1,117,107

Liabilities, Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

 

  

 

  

Current liabilities:

 

  

 

  

Accounts payable

$

139,778

$

1,233,877

Accrued expenses

 

141,280

 

776,871

Total current liabilities

 

281,058

 

2,010,748

Long-term liabilities:

 

  

 

  

Derivative liability

 

 

106,000

Convertible promissory notes, net of unamortized deferred financing fees of $7,431 and debt discount of $22,762 at December 31, 2019

 

 

499,807

Total long-term liabilities

 

 

605,807

Total liabilities

 

281,058

 

2,616,555

Commitments and contingencies (Note 8)

 

  

 

  

Redeemable convertible preferred stock—$0.0001 par value:

 

  

 

  

Series A - 0 and 5,133,159 shares authorized, issued and outstanding at September 30, 2020 and December 31, 2019, respectively

 

 

6,509,303

Series A-1 - 0 and 1,111,111 shares authorized at September 30, 2020 and December 31, 2019, respectively, and 0 and 630,722 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively

 

 

567,649

Stockholders’ equity (deficit):

 

  

 

  

Preferred stock - $0.0001 par value, 2,000,000 and 0 shares authorized at September 30, 2020 and December 31, 2019, respectively

Common stock - $0.0001 par value, 35,000,000 and 10,150,000 shares authorized at September 30, 2020 and December 31, 2019, respectively, and 6,871,608 and 282,614 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively

 

687

 

28

Additional paid-in capital

 

21,654,718

 

200,600

Accumulated deficit

 

(12,534,462)

 

(8,777,028)

Total stockholders’ equity (deficit)

 

9,120,943

 

(8,576,400)

Total liabilities and stockholders’ equity (deficit)

$

9,402,001

$

1,117,107

See accompanying notes to financial statements.

3


Annovis Bio, Inc.

Statements of Operations

(unaudited)

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2020

    

2019

    

2020

    

2019

Operating expenses:

  

 

  

  

 

  

Research and development

$

718,898

$

2,013

$

1,641,822

$

14,074

General and administrative

 

884,859

 

239,781

 

3,088,726

 

720,586

Total operating expenses

 

1,603,757

 

241,794

 

4,730,548

 

734,660

Operating loss

 

(1,603,757)

 

(241,794)

 

(4,730,548)

 

(734,660)

Other income (expense):

 

  

 

  

 

  

 

  

Change in fair value of derivative liability

 

 

 

(26,500)

 

(26,500)

Interest income (expense), net

 

10,500

 

(12,327)

 

47,012

 

(28,564)

Grant income

 

586,903

 

 

952,602

 

Total other income (expense)

 

597,403

 

(12,327)

 

973,114

 

(55,064)

Loss before income taxes

 

(1,006,354)

 

(254,121)

 

(3,757,434)

 

(789,724)

Income tax expense (benefit)

 

 

 

 

Net loss

$

(1,006,354)

$

(254,121)

$

(3,757,434)

$

(789,724)

Basic and diluted loss per common share

$

(0.15)

$

(0.90)

$

(0.61)

$

(2.79)

Weighted average number of common shares outstanding, basic and diluted

 

6,871,554

 

282,614

 

6,113,400

 

282,614

See accompanying notes to financial statements.

4


Annovis Bio, Inc.

Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit)

(unaudited)

    

Redeemable Convertible Preferred Stock

    

Stockholders’ Equity (Deficit)

Total

Additional

Stockholders’

Series A

Series A-1

Common Stock

Paid-In

Accumulated

Equity

    

Shares

    

Amount

    

Shares

Amount

    

    

Shares

    

Amount

    

Capital

    

Deficit

    

(Deficit)

Nine Months Ended September 30, 2020

Balance, December 31, 2019

 

5,133,159

$

6,509,303

 

630,722

$

567,649

 

282,614

$

28

$

200,600

$

(8,777,028)

$

(8,576,400)

Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering

 

(5,133,159)

 

(6,509,303)

 

(630,722)

 

(567,649)

 

4,117,089

 

412

 

7,076,540

 

 

7,076,952

Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering

 

 

 

 

 

118,470

 

12

 

672,512

 

 

672,524

Issuance of common stock in initial public offering, net of offering costs

 

 

 

2,300,000

230

11,955,565

11,955,795

Exercise of stock options

 

 

 

 

 

27,286

 

3

 

4,603

 

 

4,606

Net loss

 

 

 

 

 

 

 

 

(441,590)

 

(441,590)

Balance, March 31, 2020

 

 

 

 

 

6,845,459

 

685

 

19,909,820

 

(9,218,618)

 

10,691,887

Exercise of stock options

 

 

 

 

21,149

 

2

 

4,609

 

 

4,611

Share-based compensation expense

 

 

 

 

 

1,111,272

1,111,272

Net loss

 

 

 

 

 

 

 

(2,309,490)

 

(2,309,490)

Balance, June 30, 2020

6,866,608

687

21,025,701

(11,528,108)

9,498,280

Issuance of common stock to consultants and advisors

 

 

 

5,000

21,950

21,950

Share-based compensation expense

 

 

 

 

607,067

607,067

Net loss

 

 

 

 

(1,006,354)

(1,006,354)

Balance, September 30, 2020

$

$

6,871,608

$

687

$

21,654,718

$

(12,534,462)

$

9,120,943

Nine Months Ended September 30, 2019

Balance, December 31, 2018

5,133,159

$

6,509,303

 

630,722

$

567,649

 

282,614

$

28

$

192,117

$

(7,786,048)

$

(7,593,903)

Share-based compensation expense

 

 

 

 

 

 

 

8,859

 

 

8,859

Net loss

 

 

 

 

 

 

 

 

(190,903)

 

(190,903)

Balance, March 31, 2019

5,133,159

6,509,303

630,722

567,649

282,614

28

200,976

(7,976,951)

(7,775,947)

Net loss

 

 

 

 

 

 

 

 

(344,700)

 

(344,700)

Balance, June 30, 2019

 

5,133,159

6,509,303

 

630,722

567,649

 

282,614

28

200,976

(8,321,651)

(8,120,647)

Net loss

 

 

 

 

 

 

 

 

(254,121)

 

(254,121)

Balance, September 30, 2019

 

5,133,159

$

6,509,303

 

630,722

$

567,649

 

282,614

$

28

$

200,976

$

(8,575,772)

$

(8,374,768)

See accompanying notes to financial statements.

5


Annovis Bio, Inc.

Statements of Cash Flows

(unaudited)

Nine Months Ended September 30, 

2020

2019

Cash flows from operating activities:

  

 

  

Net loss

$

(3,757,434)

$

(789,724)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

Amortization of deferred financing fees

 

129

 

813

Amortization of debt discount

 

396

 

2,582

Share-based compensation expense, including stock issued to consultants and advisors

 

1,740,289

 

8,859

Change in fair value of derivative liability

 

26,500

 

26,500

Changes in assets and liabilities:

 

 

Grant receivable

 

310,123

 

Prepaid expenses and other current assets

 

(125,863)

 

(26,614)

Accounts payable

 

(897,739)

 

215,282

Accrued expenses

 

(501,275)

 

138,288

Net cash used in operating activities

 

(3,204,874)

 

(424,014)

Cash flows from financing activities:

 

  

 

  

Proceeds from initial public offering of common stock, net of offering costs

 

12,034,406

 

Proceeds from issuance of convertible promissory notes

530,000

Proceeds from exercise of stock options

 

9,217

 

Payment of deferred offering costs

 

 

(76,747)

Payment of deferred financing fees

 

 

(8,301)

Net cash provided by financing activities

 

12,043,623

 

444,952

Net increase in cash

 

8,838,749

 

20,938

Cash and cash equivalents, beginning of period

 

1,858

 

35,312

Cash and cash equivalents, end of period

$

8,840,607

$

56,250

Supplemental disclosure of cash flow information

 

  

 

  

Deferred offering costs in accounts payable and accrued expenses

$

$

204,584

Deferred financing fees in accounts payable and accrued expenses

$

$

321

Conversion of redeemable convertible preferred stock to common stock

$

7,076,952

$

Conversion of convertible promissory notes, including embedded derivative, to common stock

$

672,524

$

See accompanying notes to financial statements.

6


Table of Contents

Annovis Bio, Inc.

Notes to Financial Statements

(Unaudited)

(1) Nature of Business and Liquidity

Annovis Bio, Inc. (the “Company” or “Annovis”) was incorporated on April 29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (“AD”), Parkinson’s disease (“PD”) and Alzheimer’s disease in Down syndrome (“AD-DS”). The Company’s lead compound, ANVS401, is a small molecule administered orally that attacks neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby improving axonal transport.

Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital.

The Company has a history of incurring net losses and had an accumulated deficit of $12,534,462 as of September 30, 2020. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company’s primary source of capital has been the issuance of equity securities.

On January 28, 2020, the Company announced the pricing of its initial public offering (the “IPO”) of 2,000,000 shares of its common stock at an initial offering price of $6.00 per share. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 300,000 shares of common stock at the public offering price. The Company’s common stock commenced trading on the NYSE American on January 29, 2020 under the ticker symbol “ANVS”. The IPO closed on January 31, 2020 at which time the underwriters exercised their option to purchase 300,000 additional shares of the Company’s common stock bringing the total number of shares of common stock sold by the Company to 2,300,000 shares. The gross proceeds from the IPO, including proceeds from the exercise of the underwriters’ option to purchase additional shares, were approximately $13.8 million. The net proceeds of the IPO were approximately $12.0 million after deducting underwriting discounts, commissions and offering expenses payable by the Company, including offering costs paid in 2019. In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. Upon the closing of the IPO, outstanding redeemable convertible preferred stock and convertible promissory notes converted into shares of Company common stock totaling 4,117,089 and 118,470, respectively.

As of the date these financial statements are issued, management believes that the current cash and cash equivalents and funding from existing grants are sufficient to fund operations and capital requirements for at least the next 12 months. The Company will need to raise additional capital to complete clinical development of and to commercially develop its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation of Interim Unaudited Financial Statements

The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting only of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at September 30, 2020, and its results of operations and its cash flows for the three and

7


nine months ended September 30, 2020 and 2019. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2019 and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP") and the rules and regulations of the Securities and Exchange Commission ("SEC"). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.

(b) Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.

Significant items subject to such estimates and assumptions include share-based compensation expense, the valuation of the derivative liability and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.

(c) Basic and Diluted Net Income (Loss) per Share

Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes, warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.

(d) Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation (“FDIC”). Total cash was $8,840,607 and $1,858 as of September 30, 2020 and December 31, 2019, respectively.

(e)  Offering Costs Associated with IPO

Included in long-term assets as of September 30, 2020 and December 31, 2019, were deferred offering costs of $0 and $369,595, respectively, incurred in connection with the Company’s IPO which primarily consisted of direct incremental legal, printing, listing and accounting fees. Offering costs of $601,635 were offset against proceeds received in the IPO and charged to additional paid-in capital in the nine months ended September 30, 2020. Of these offering costs, $78,611 was paid during the year ended December 31, 2019.

(f) Fair Value of Financial Instruments

The Company’s financial instruments include cash and cash equivalents, accounts payable, accrued expenses, a derivative liability and debt. Cash and cash equivalents and the derivative liability are reported at fair value. The recorded carrying amount of accounts payable and accrued expenses reflect their fair value due to their short-term

8


nature. The carrying value of the interest-bearing debt approximates fair value based upon the borrowing rates currently available to the Company for loans with similar terms and maturities.

(g) Research and Development

Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.

(h) Grant Income

Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.

(i) Share-Based Compensation

Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.

Determining the appropriate fair value of share-based awards requires the use of subjective assumptions including, in the case of stock options, the expected life of the option and expected share price volatility. The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.

The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.

Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.

(j) Income Taxes

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits.

9


(k) Recent Accounting Pronouncements

In March 2018, the FASB issued ASU 2018-5—Income Taxes (Topic 740): Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 118. This ASU provided guidance related to Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 118 (“SAB 118”), which addresses the accounting implications of the Tax Cuts and Jobs Act of 2107 (the “Tax Act”). SAB 118 allows a company to record provisional amounts during a measurement period not to extend beyond one year of the enactment date and was effective upon issuance. The Company has analyzed the Tax Act, and in certain areas, has made reasonable estimates of the effects on its financial statements and tax disclosures.

In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820)—Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018-13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. The adoption of ASU 2018-13 in the first quarter of 2020 did not have a significant impact on the Company's financial statements.

In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019-12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating ASU 2019-12 but does not believe the adoption of this standard will have a significant impact on its financial statements.

(l) Reverse Stock Split

On July 31, 2019, the board of directors (the “Board”) and shareholders of the Company approved a reverse stock split of the Company’s common stock at a ratio of one share for every 1.4 shares previously held. All common stock share and per-share data included in these financial statements have been retroactively adjusted to reflect the reverse stock split.

(3) Fair Value Measurements

The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.

10


The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019:

    

    

Fair Value Measurement at

September 30, 2020

Carrying Value

Level 1

Level 2

Level 3

Cash and cash equivalents

$

8,840,607

$

8,840,607

$

$

    

    

Fair Value Measurement at

December 31, 2019

Carrying Value

Level 1

Level 2

Level 3

Cash and cash equivalents

$

1,858

$

1,858

$

$

Derivative liability

$

106,000

$

$

$

106,000

The derivative liability was associated with the March 2019 issuance of convertible promissory notes (see Note 7). The Company computed the fair value at the date of issuance of $26,500 related to the embedded share settlement feature providing for conversion of the notes at a 20% discount to the price of the shares issued in a qualified financing. The Company estimated the fair value using a probability weighted approach. Using the same methodology, the Company determined the fair value of the derivative liability immediately prior to the closing of the IPO was $132,500 and at December 31, 2019 was $106,000. The change in the fair value of the derivative liability is reflected in the statements of operations.

(4) Grant Receivable

In September 2019, as modified in September 2020, the Company received a Notice of Award for a $1.9 million grant from the National Institute on Aging of the National Institutes of Health (the “NIH”) to cover costs of long-term chronic toxicology studies of ANVS401 in rats and dogs. The Company began the long-term chronic toxicology studies in November 2019. The Company recorded a grant receivable of $424,952 and $735,075 as of September 30, 2020 and December 31, 2019, respectively, to reflect unreimbursed, eligible costs incurred under the grant.

The Company recognized grant income of $586,903 and $952,602 for the three and nine months ended September 30, 2020, respectively, in connection with the NIH grant and received payments under the grant of $1,262,725 during the nine months ended September 30, 2020.

(5) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

    

September 30, 

December 31, 

2020

2019

Prepaid insurance

$

110,057

$

Prepaid expenses

 

19,941

 

4,135

Security deposit

 

6,444

 

6,444

Total prepaid expenses and other current assets

$

136,442

$

10,579

11


(6) Accrued Expenses

Accrued expenses consisted of the following:

    

September 30, 

December 31, 

2020

2019

Payroll and related benefits

$

16,493

$

131,530

Accrued interest expense

 

 

36,041

Accrued professional fees

 

86,454

 

103,300

Accrued license payments

 

38,333

 

506,000

$

141,280

$

776,871

See Note 8 for further detail on the accrued license payments.

(7) Convertible Promissory Notes

In March 2019, the Company issued convertible promissory notes (the “Notes”) to various investors in the aggregate principal amount of $530,000. Interest accrued at 8% compounded annually on all Notes, and the maturity date was defined as the earlier of a Liquidity Event or upon the written demand of the holders of a majority of the outstanding principal amount of the Notes made any time after December 31, 2023. A Liquidity Event was defined as (i) the date of the closing of a merger or reorganization of the Company with another entity; (ii) the sale of substantially all of the assets of the Company in which the Company’s stockholders own less than 50% of the equity securities after the event; or (iii) a liquidation of the Company.

The Company incurred costs of $8,622 in connection with the issuance of the Notes. In addition, on issuance, the Company recognized a discount associated with the Notes of $26,500 related to the fair value of an embedded derivative reflecting the share-settlement provision upon the closing of a qualified financing. Unamortized deferred financing fees and debt discount were deducted from the face amount of the Notes on the balance sheets. The Company amortized the deferred financing fees and debt discount over the term of the Notes as additional interest expense using the effective interest method. The effective interest rate on the Notes was 9.8%. The Company made no cash payments for interest during the nine months ended September 30, 2020 or 2019.

On January 31, 2020, the Company closed its IPO. In accordance with the terms of the Notes, the outstanding Notes plus accrued interest converted into 118,470 shares of Company common stock at a 20% discount to the initial offering price of shares issued in the IPO.

(8) Commitments and Contingencies

(a) Leases

The Company leases its office facilities under a month-to-month operating lease. Total rental expense was $10,394 and $10,007 for the three months ended September 30, 2020 and 2019, respectively and $31,209 and $24,344 for the nine months ended September 30, 2020 and 2019, respectively.

(b) License Agreements

In November 2008, the Company licensed the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics. Currently, the intellectual property rights are owned by a subsidiary of Horizon Therapeutics, PLC (the “Licensor”). Payments by the Company under the license agreement include a one-time non-refundable fee of $50,000, a minimum annual commitment of $40,000 commencing in 2009, milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Company is responsible for the development and commercialization of the licensed products.

12


In May 2012, such license agreement was amended. The minimum annual commitment was increased to $46,000 and may be deferred by the Company until the Company raises at least $2 million in equity financing, then the aggregate annual payments of all amounts will become payable. During the period ended September 30, 2020, the Company paid $448,000 to the Licensor under the license agreement in satisfaction of deferred annual license commitments through November 2019.

At September 30, 2020 and December 31, 2019, the Company had accrued $38,333 and $506,000, respectively, in license payments under the term of this license, included in accrued liabilities. Expenses related to the license agreement are recognized in general and administrative expense in the statements of operations.

In further consideration for the licenses granted, the Company shall make the following milestone payments to the Licensor based upon the attainment of each milestone event indicated below.

Milestone Event

    

Amount

Commencement of Phase II

$

230,000

Commencement of Phase III

$

575,000

Filing of an NDA for Regulatory Approval (or equivalent in Europe or Japan)

$

1,150,000

Receipt of Regulatory Approval in the United States

$

5,750,000

Receipt of Regulatory Approval outside the United States

$

5,750,000

No milestones have been achieved as of September 30, 2020.

Royalties shall be paid to the Licensor assessed on net sales of licensed products on a country-by-country basis in an amount equal to 5.75%. Should the Company be required to obtain a license from a third party in order to sell a licensed product, the Company may deduct 50% of the royalties on such licensed product paid to the third party subject to certain minimums.

In addition to the royalties the Company shall pay the Licensor 9.2% of all sublicense income attributable to licensed products.

The Licensor also granted the Company a buy-out option which may be exercised at any time during the term of the agreement. The option price will be as follows: $500,000 if exercised prior to the commencement of the first Phase II clinical trial; $1,000,000 if exercised on or after the commencement of the first Phase II clinical trial and prior to the commencement of the first Phase III clinical trial; $5,000,000 if exercised on or after the commencement of the first Phase III clinical trial and prior to the filing of a New Drug Application (“NDA”) with the U.S. Food and Drug Administration (the “FDA”) for the first licensed product; and $8,000,000 if exercised on or after the filing of an NDA for the first licensed product.

The Company has the right to terminate the agreement at any time by giving 90 days advance notice subject to the payment of any amounts due under the agreement at that time. If the Company does not terminate the agreement or exercise the buy-out option, the term of the agreement shall continue until the expiration of the Company’s obligation to make royalty payments. Such royalty payments continue for each product in each country until the later of the expiration of the related patent or 10 years after the initial sale of the product in the respective country. The agreement may also be terminated for cause by either party upon the breach of the material obligations of the other party or the bankruptcy or liquidation of the other party.

(c) Employment Agreements

In March 2020, the Company entered into employment agreements with its executive officers. The maximum aggregate severance payments under the agreements are approximately $720,000.

13


(d) Litigation

The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows. At September 30, 2020 and December 31, 2019, the Company did not have any pending legal actions.

(9) Redeemable Convertible Preferred Stock and Stockholders’ Equity

(a) Overview

The Company closed its IPO on January 31, 2020, issuing 2,300,000 shares of common stock. In connection with the closing of the Company’s IPO, the then-outstanding 5,133,159 shares of Series A and 630,722 shares of Series A-1 redeemable convertible preferred stock converted into an aggregate of 4,117,089 shares of Company common stock. Each share of redeemable convertible preferred stock was converted into the number of shares of common stock determined by dividing the original issue price by the applicable conversion price. The Series A-1 conversion price was $1.26, and the Series A conversion price was $0.70, as adjusted for the reverse stock split discussed in Note 2.

The Company’s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020 to authorize the issuance of two classes of stock to be designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 37,000,000, each with a par value of $0.0001 per share. Of these shares, 35,000,000 shall be common stock and 2,000,000 shall be preferred stock.

(b) Common Stock

1.           Dividends

Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.

2.           Liquidation

Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.

3.           Voting

The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.

(c) Preferred Stock

Preferred stock may be issued from time to time by the Board in one or more series.

(d) Warrants

In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. The warrants have a five-year term and are not exercisable prior to January 29, 2021. All of the warrants were outstanding at September 30, 2020, and the Company accounts for the warrants as a component of stockholders’ equity.

14


(10) Share-Based Compensation

Effective upon the closing of the Company’s IPO on January 31, 2020, the Company’s 2019 Equity Incentive Plan (the “2019 Plan”) became effective, succeeding the Company’s previous plan (see Note 1). The previous plan had 352,282 options outstanding as of the effective date of the 2019 Plan. Under the 2019 Plan, 1,000,000 additional shares are authorized to be issued, and no new awards may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. As of September 30, 2020, 186,283 shares were available for future grants.

During the nine months ended September 30, 2020, the Company granted options to purchase 600,000 shares of common stock at an exercise price of $3.13 per share and 210,000 shares of common stock at an exercise price of $4.39 per share. Under the grant agreements, 50,000 of the options vest after one year and the remainder of the options were vested and exercisable upon grant. These options have a 10-year term. There were no options issued during the nine months ended September 30, 2019.

The options granted during the nine months ended September 30, 2020 were valued using the Black Scholes option pricing model using the following weighted average assumptions: expected term of 5.0 years; risk free interest rate of 0.3% to 0.4%; expected volatility of 80.0%; and dividend yield of 0.0%. The weighted-average grant date fair value of options issued by the Company during the nine months ended September 30, 2020 was $2.19 per share.

During the nine months ended September 30, 2020, the Company granted stock awards of 5,000 shares to consultants and advisors for services rendered with an aggregate fair value of $21,950, based on the closing price of the Company’s common stock on the NYSE American on the date of grant. There were no stock awards issued during the nine months ended September 30, 2019.

Share-based compensation expense, including the fair value of stock awards to consultants and advisors for services rendered, for the three months ended September 30, 2020 and 2019 was $629,017 and $0, respectively, and for the nine months ended September 30, 2020 and 2019 was $1,740,289 and $8,859, respectively.

As of September 30, 2020, there were 1,113,847 options outstanding, of which 1,063,847 were vested and exercisable. As of December 31, 2019, there were 352,282 options outstanding, all of which were vested and exercisable.

(11) Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share:

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

    

2020

    

2019

    

2020

    

2019

Numerator

 

  

 

  

  

 

  

Net loss

$

(1,006,354)

$

(254,121)

$

(3,757,434)

$

(789,724)

Denominator

 

  

 

  

 

  

 

  

Weighted-average common shares outstanding, basic and diluted

 

6,871,554

 

282,614

 

6,113,400

 

282,614

Net loss per share, basic and diluted

$

(0.15)

$

(0.90)

$

(0.61)

$

(2.79)

The Company reported a net loss for the three and nine months ended September 30, 2020 and 2019, therefore, the basic and diluted net loss per share are the same in the respective period because the inclusion of potential common

15


shares would have an anti-dilutive effect. Potential shares of common stock that are excluded from the computation of diluted weighted-average shares outstanding are as follows:

September 30, 

    

2020

    

2019

Redeemable convertible preferred stock, as converted

 

 

4,117,089

Stock options

1,113,847

353,565

Warrants

 

100,000

 

In addition, common shares issuable upon the conversion of the $530,000 Notes were excluded for all periods in which the Notes were outstanding.

(12) Income Taxes

The Company’s income tax benefit (expense) was $0.0 million for the three and nine months ended September 30, 2020 and 2019. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss ("NOL") that would have been recognized in the three and nine months ended September 30, 2020 and 2019 was offset by changes in the valuation allowance.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on the Company due to its tax losses generated during all prior years.

Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. The Company has completed financings since its inception, including its January 31, 2020 IPO, which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code or could result in a change in control in the future.

As of September 30, 2020, and December 31, 2019, the Company had not recorded any liability for uncertain tax positions, accrued interest or penalties thereon, and no amounts have been recognized in the Company’s statements of operations.

(13) Related-Party Transactions

As discussed in Note 7, in March 2019 the Company issued Notes in the aggregate principal amount of $530,000. Three of the Company’s directors purchased an aggregate of $305,000 of the Notes. On January 31, 2020, the Company closed its IPO, and the outstanding Notes plus accrued interest held by directors converted into 71,429 shares of Company common stock.

(14) Subsequent Events and Impact of COVID-19 Pandemic

In March 2020, the clinical trial sites participating in the Company's Phase 2a trial in AD patients in collaboration with the Alzheimer's Disease Cooperative Study temporarily suspended enrollment of new patients because of the ongoing COVID-19 pandemic. Prior to suspension of enrollment, 14 patients had been enrolled and completed treatment, out of a total trial size of 24 patients. Most of the trial sites have reopened and treatment has begun in the 15th patient. In addition, not all the sites which are expected to participate in the Company’s Phase 2a clinical trial in AD and PD have opened for recruitment and treatment of patients due to restrictions related to COVID-19. Although

16


the Company currently believes its clinical trials will be completed on time, the extent to which the COVID-19 pandemic could have a material impact on the clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain.

17


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Cautionary Note Regarding Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” and or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Quarterly Report on Form 10-Q, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.

The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:

our business strategies;
the timing of regulatory submissions;
our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain;
risks relating to the timing and costs of clinical trials and the timing and costs of other expenses;
risks related to market acceptance of products;
risks associated with our reliance on third-party organizations;
our competitive position;
assumptions regarding the size of the available market, product pricing and timing of commercialization of our product candidates;
our intellectual property position and our ability to maintain and protect our intellectual property rights;
our results of operations, financial condition, liquidity, prospects, and growth strategies;
our cash needs and financing plans;
the industry in which we operate; and
the trends that may affect the industry or us.

You should refer to Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2019 for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Those factors are updated, as applicable, in “Factors that May Affect Future Results” below. As a result of the risks, uncertainties and assumptions described above and elsewhere, we cannot assure you that the forward-looking statements in this Quarterly Report on Form 10-Q will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the

18


significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to new information, actual results or changes in our expectations, except as required by law.

The following Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with: (i) the interim financial statements and related notes thereto which are included in this Quarterly Report on Form 10-Q; and (ii) our annual financial statements for the year ended December 31, 2019 which are included in our Annual Report on Form 10-K for the year ended December 31, 2019.

Company Overview

We are a clinical stage, drug platform company addressing neurodegeneration such as Alzheimer’s disease (“AD”), Parkinson’s disease (“PD”) and Alzheimer’s disease in Down Syndrome (“AD-DS”). Our lead compound, ANVS401, is a small molecule administered orally that attacks neurodegeneration by entering the brain and inhibiting the translation of neurotoxic proteins—amyloid precursor protein APP/Aβ (“APP”), tau/phospho-tau (“tau”) and α-Synuclein (“αSYN”)—thereby improving axonal transport. Human studies in four mildly cognitive impaired patients have shown that ANVS401 lowered the levels of neurotoxic proteins and inflammatory factors. In preclinical studies, lower neurotoxic protein levels led to improved axonal transport, reduced inflammation, lower nerve cell death and improved function.

We are presently conducting a Phase 2a clinical trial in 24 AD patients in collaboration with the Alzheimer’s Disease Cooperative Study (“ADCS”) and a second Phase 2a clinical trial of ANVS401 with 14 AD patients and 54 PD patients (the “AD/PD Trial”), which began treating patients in August 2020.

In March 2020, the clinical trial sites participating in our Phase 2a trial in AD patients in collaboration with the ADCS temporarily suspended enrollment of new patients because of the ongoing COVID-19 pandemic. Prior to suspension of enrollment, 14 patients had been enrolled and completed treatment. Most of the trial sites have reopened and treatment has begun in the 15th patient. In addition, not all the sites which are expected to participate in the AD/PD Trial have opened for recruitment and treatment of patients due to restrictions related to COVID-19. Although we currently believe our clinical trials will be completed on time, the extent to which the COVID-19 pandemic could have a material impact on our clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain.

We have never been profitable and have incurred net losses since inception. Our accumulated deficit at September 30, 2020 was $12,534.5 thousand. We expect to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when, or if, we will be able to achieve or maintain profitability.

19


Results of Operations

Operating expenses and other income (expense) were comprised of the following:

Three Months Ended

Nine Months Ended

 

September 30, 

September 30, 

    

2020

    

2019

2020

    

2019

 

(in thousands)

(in thousands)

 

Operating expenses:

Research and development

$

718.9

    

$

2.0

$

1,641.8

    

$

14.1

    

General and administrative

 

884.9

 

239.8

 

3,088.7

 

720.6

Other income (expense):

Change in fair value of derivative liability

 

 

 

(26.5)

 

(26.5)

Interest income (expense), net

 

10.5

 

(12.3)

 

47.0

 

(28.6)

Grant income

 

586.9

 

 

952.6

 

Three and Nine Months Ended September 30, 2020 and 2019

Research and Development Expenses

Research and development expenses increased by $716.9 thousand and $1,627.7 thousand for the three and nine months ended September 30, 2020, respectively, compared to the prior year periods. The increase for the three months ended September 30, 2020 was primarily the result of an increase of $313.5 thousand in costs associated with our long-term toxicology studies in rats and dogs which began in November of 2019, an increase of $194.7 in costs related to our AD/PD Trial which began treating patients in August 2020, an increase in share-based compensation expense of $138.7 thousand and an increase of $65.0 thousand in personnel expenses . The increase for the nine months ended September 30, 2020 was primarily the result of an increase of $549.2 thousand in costs associated with our long-term toxicology studies in rats and dogs which began in November of 2019, an increase of $810.2 thousand in costs related to our AD/PD Trial which began treating patients in August 2020, an increase in share-based compensation expense of $138.7 thousand and an increase of $65.0 thousand in personnel expenses. We expect research and development expenses in 2020 and 2021 will be higher as compared to 2019 due to the costs of our AD/PD Trial and the completion of our long-term toxicology studies.

General and Administrative Expenses

General and administrative expenses increased by $645.1 thousand and $2,368.1 thousand for the three and nine months ended September 30, 2020, respectively, compared to the prior year periods. The increase for the three months ended September 30, 2020 was primarily the result of increases of $490.3 thousand in share-based compensation expense, $94.2 thousand in other personnel expenses and $83.0 thousand in insurance expense, partially offset by a reduction of $17.9 thousand in professional fees. The increase for the nine months ended September 30, 2020 was primarily the result of increases of $1,592.7 thousand in share-based compensation expense, $427.0 thousand in other personnel expenses, $224.0 thousand in insurance expense and $102.9 thousand in stock listing fees and other financial printing and filing fees. We expect general and administrative expenses in 2020 and 2021 will be higher as compared to 2019 due to increased personnel expenses and additional costs associated with being a public company.

Change in Fair Value of Derivative Liability

The derivative liability represents an embedded derivative in our convertible promissory notes which were issued in March 2019. At each balance sheet date, we estimated the fair value of the derivative liability and recognized any change in our statements of operations. The fair value of the derivative liability was adjusted to $132.5 thousand immediately prior to the closing of the IPO on January 31, 2020. Effective upon the closing of the IPO, the derivative liability was eliminated, and the amount was reclassified to additional paid-in capital on the balance sheet.

20


Interest Income (Expense), Net

Interest income (expense), net increased $22.8 thousand and $75.6 thousand for the three and nine months ended September 30, 2020, respectively, compared to the prior year periods. The increases were primarily the result of interest income generated on cash and cash equivalents from the proceeds of our IPO which closed on January 31, 2020. We expect interest income (expense), net will be higher in 2020 and 2021 as compared to 2019 due to higher expected cash balances and the conversion to common stock of our convertible promissory notes upon the closing of the IPO.

Grant Income

Grant income increased $586.9 thousand and $952.6 thousand for the three and nine months ended September 30, 2020, respectively, compared to the prior year periods. The increases were the result of income recognized related to a grant from the NIH to reimburse the costs of our long-term toxicology studies in rats and dogs, which studies began in November 2019.

Liquidity and Capital Resources

Since our inception in 2008, we have devoted most of our cash resources to research and development and general and administrative activities. We have financed our operations primarily with the proceeds from the sale of common stock, redeemable convertible preferred stock, and convertible promissory notes and funding from research grants. To date, we have not generated any revenues from the sale of products, and we do not anticipate generating any revenues from the sales of products for the foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. As of September 30, 2020, our principal source of liquidity was our cash, which totaled $8,840.6 thousand.

Equity Financings

We closed our IPO on January 31, 2020, raising gross proceeds of $13,800.0 thousand and net proceeds of $12,034.4 thousand, after deducting underwriting discounts and commissions and offering expenses, in the nine months ended September 30, 2020.

Debt Financings

At September 30, 2020 and December 31, 2019, we had outstanding $0 and $530.0 thousand principal amount of convertible promissory notes, which were issued in March 2019. Upon the closing of our IPO on January 31, 2020, the outstanding convertible promissory notes plus accrued interest converted into 118,470 shares of our common stock at a 20% discount to the public offering price.

Cash Flows

The following table summarizes our cash flows from operating, investing and financing activities.

Nine Months Ended

September 30, 

    

2020

    

2019

(in thousands)

Statement of Cash Flows Data:

 

  

    

  

Total net cash provided by (used in):

 

  

 

  

Operating activities

$

(3,204.9)

$

(424.0)

Financing activities

 

12,043.6

 

444.9

Increase (decrease) in cash and cash equivalents

$

8,838.7

$

20.9

21


Operating Activities

For the nine months ended September 30, 2020, cash used in operations was $3,204.9 thousand compared to $424.0 thousand for the same period in the prior year. The increase in cash used in operations was primarily the result of the payment of accounts payable, accrued license fees, other accrued expenses and prepaid insurance and the initial costs of our AD/PD Trial in the nine months ended September 30, 2020.

We expect cash used in operating activities to increase in 2020 and 2021 as compared to 2019 due to an expected increase in our operating losses associated with ongoing development of our product candidates, including our AD/PD Trial, and additional costs associated with being a public company.

Financing Activities

Cash provided by financing activities was $12,043.6 thousand during the nine months ended September 30, 2020, attributable to net proceeds from our IPO of $12,034.4 thousand, after deducting underwriting discounts and commissions and offering expenses, and $9.2 thousand proceeds from the exercise of stock options.

Cash provided by financing activities was $444.9 thousand during the nine months ended September 30, 2019, attributable to $530.0 thousand proceeds from the sale of convertible promissory notes partially offset by the payment of $76.7 thousand of deferred offering costs and $8.3 thousand of fees on the issuance of the convertible promissory notes.

Funding Requirements

We expect that current cash and cash equivalents and funding from existing grants will be sufficient to fund our operations and capital requirements for at least the next 12 months. We believe that these available funds will be sufficient to complete our Phase 2a clinical trials for ANVS401 and commence the planning of a Phase 3 study for this product candidate. However, it is difficult to predict our spending for our product candidates prior to obtaining FDA approval. Moreover, changing circumstances may cause us to expend cash significantly faster than we currently anticipate, and we may need to spend more cash than currently expected because of circumstances beyond our control.

To the extent that our capital resources are insufficient to meet our future operating and capital requirements, we will need to finance our cash needs through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. We have no committed external sources of funds. Additional equity or debt financing or collaboration and licensing arrangements may not be available on acceptable terms, if at all.

Contractual Obligations and Other Commitments

This item is not required for smaller reporting companies.

Factors that May Affect Future Results

You should refer to Part I, Item 1A “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2019 for a discussion of important factors that may affect our future results. The following factors are new or updated risk factors as compared to our 10-K based on recent developments.

Disruptions associated with widespread health emergencies could harm our ability to complete or could materially delay our clinical trials.

The emergence of widespread health emergencies or pandemics, such as COVID-19, could lead to quarantines, business shutdowns, labor shortages, disruptions to the healthcare system, and overall economic instability. If the suppliers, CROs, hospitals, clinical trial sites, regulators, consultants and other third parties with whom we conduct business were to experience shutdowns or other business disruptions, our ability to enroll patients and conduct our clinical trials in the manner and on the timelines presently planned could be materially and negatively impacted. In

22


March 2020, the clinical trial sites participating in our Phase 2a trial in AD patients in collaboration with the ADCS temporarily suspended enrollment of new patients because of the ongoing COVID-19 pandemic. Prior to suspension of enrollment, 14 patients had been enrolled and completed treatment, out of a total trial size of 24 patients. Most of the trial sites have reopened and treatment has begun in the 15th patient. In addition, not all the sites which are expected to participate in the Company’s Phase 2a clinical trial in AD and PD have opened for recruitment and treatment of patients due to restrictions related to COVID-19.Although we currently believe our clinical trials will be completed on time, the extent to which the COVID-19 pandemic could have a material impact on our clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain.

Recent U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits net operating loss (“NOL”) carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on us due to our tax losses generated during all prior years.

U.S. tax legislation enacted in 2017 significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate, limiting interest deductions, and revising the rules governing NOLs. The legislation could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the U.S. Treasury and Internal Revenue Service, any of which could lessen or increase certain adverse impacts of the legislation. In addition, it is unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax liabilities.

While some of the changes made by the tax legislation may adversely affect us in one or more reporting periods and prospectively, other changes may be beneficial.

The market price of our common stock may be volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.

The market price of our common stock is highly volatile and may be subject to wide fluctuations in response to a variety of factors, including the following:

any delay in the enrollment and ultimate completion of our Phase 2a trials of ANVS401;
if we are required to conduct more than one Phase 3 trial in any one indication;
any delay in submitting an NDA and any adverse development or perceived adverse development with respect to the FDA’s review of that NDA;
failure to successfully develop and commercialize ANVS401 or any future product candidate;
inability to obtain additional funding;
regulatory or legal developments in the United States and other countries applicable to ANVS401 or any other product candidate;
adverse regulatory decisions;
changes in the structure of healthcare payment systems;

23


inability to obtain adequate product supply for ANVS401 or any other product candidate, or the inability to do so at acceptable prices;
introduction of new products, services or technologies by our competitors;
failure to meet or exceed financial projections we provide to the public;
failure to meet or exceed the estimates and projections of the investment community;
changes in the market valuations of companies similar to ours;
market conditions in the pharmaceutical and biotechnology sectors, and the issuance of new or changed securities analysts’ reports or recommendations;
announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;
significant lawsuits, including patent or shareholder litigation, and disputes or other developments relating to our proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;
additions or departures of key scientific or management personnel;
sales of our common stock by us or our shareholders in the future;
trading volume of our common stock; and
general economic, industry and market conditions, including, but not limited to, the impact of the COVID-19 pandemic.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements, as defined by applicable SEC regulations.

Discussion of Critical Accounting Policies and Significant Judgments and Estimates

The preparation of financial statements in conformity with GAAP requires us to use judgment in making certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities and the reported amounts of revenues and expenses in our financial statements and accompanying notes. Critical accounting policies are those that are most important to the portrayal of our financial condition and results of operations and require difficult, subjective and complex judgments by management in order to make estimates about the effect of matters that are inherently uncertain. During the three and nine months ended September 30, 2020, there were no significant changes to our critical accounting policies from those described in our annual financial statements for the year ended December 31, 2019, which we included in our Annual Report on Form 10-K for the year ended December 31, 2019.

Item 3. Quantitative and Qualitative Disclosure About Market Risk

This item is not required for smaller reporting companies.

24


Item 4. Controls and Procedures

(a) Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as the end of the period covered by this Quarterly Report on Form 10-Q. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that the information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.

(b) Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(f) and 15d-15(f) of the Exchange Act that occurred during the period covered by this Quarterly Report on Form 10-Q that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

25


PART II

OTHER INFORMATION

Item 1. Legal Proceedings

From time to time, we may become subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition.

Item 1A. Risk Factors

This item is not required for smaller reporting companies.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults upon Senior Securities

None.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

None.

26


Item 6. Exhibits

101.INS

XBRL Instance Document

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

XBRL Taxonomy Extension Labels Linkbase Document

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

27


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Signature

    

Title

    

Date

 

 

 

/s/ MARIA MACCECCHINI

President and Chief Executive Officer (principal

November 4, 2020

Maria Maccecchini

executive officer)

 

 

 

/s/ JEFFREY MCGROARTY

Chief Financial Officer (principal financial and

November 4, 2020

Jeffrey McGroarty

accounting officer)

28


EX-31.1 2 anvs-20200930ex311fbf266.htm EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Maria Maccecchini, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Annovis Bio, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(c)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 4, 2020

/s/ Maria Maccecchini

Maria Maccecchini

President and Chief Executive Officer


EX-31.2 3 anvs-20200930ex3122e98b5.htm EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jeffrey McGroarty, certify that:

1.I have reviewed this Quarterly Report on Form 10-Q of Annovis Bio, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
(a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
(b)evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
(c)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5.The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
(a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
(b)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 4, 2020

/s/ Jeffrey McGroarty

Jeffrey McGroarty

Chief Financial Officer


EX-32.1 4 anvs-20200930ex321818541.htm EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Annovis Bio, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Maria Maccecchini, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 4, 2020

/s/ Maria Maccecchini

Maria Maccecchini

President and Chief Executive Officer


EX-32.2 5 anvs-20200930ex32239b507.htm EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Annovis Bio, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jeffrey McGroarty, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.the Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: November 4, 2020

/s/ Jeffrey McGroarty

Jeffrey McGroarty

Chief Financial Officer


EX-101.INS 6 anvs-20200930.xml EX-101.INS 0001477845 us-gaap:RedeemableConvertiblePreferredStockMember 2020-09-30 0001477845 us-gaap:RedeemableConvertiblePreferredStockMember 2019-12-31 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2020-09-30 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2020-09-30 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2020-03-31 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2020-03-31 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2019-12-31 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2019-12-31 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2019-09-30 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2019-09-30 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2019-06-30 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2019-06-30 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2019-03-31 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2019-03-31 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2018-12-31 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2018-12-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001477845 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001477845 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001477845 us-gaap:CommonStockMember us-gaap:OverAllotmentOptionMember 2020-01-31 2020-01-31 0001477845 us-gaap:CommonStockMember us-gaap:IPOMember 2020-01-28 2020-01-28 0001477845 us-gaap:CommonStockMember 2020-07-01 2020-09-30 0001477845 anvs:ConsultantsMember 2019-01-01 2019-09-30 0001477845 us-gaap:RetainedEarningsMember 2020-09-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-09-30 0001477845 us-gaap:RetainedEarningsMember 2020-06-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001477845 2020-06-30 0001477845 us-gaap:RetainedEarningsMember 2020-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001477845 2020-03-31 0001477845 us-gaap:RetainedEarningsMember 2019-12-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001477845 us-gaap:RetainedEarningsMember 2019-09-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001477845 us-gaap:RetainedEarningsMember 2019-06-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001477845 2019-06-30 0001477845 us-gaap:RetainedEarningsMember 2019-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001477845 us-gaap:RetainedEarningsMember 2018-12-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001477845 us-gaap:CommonStockMember 2020-09-30 0001477845 us-gaap:CommonStockMember 2020-06-30 0001477845 us-gaap:CommonStockMember 2020-03-31 0001477845 us-gaap:CommonStockMember 2019-12-31 0001477845 us-gaap:CommonStockMember 2019-09-30 0001477845 us-gaap:CommonStockMember 2019-06-30 0001477845 us-gaap:CommonStockMember 2019-03-31 0001477845 us-gaap:CommonStockMember 2018-12-31 0001477845 us-gaap:CommonStockMember us-gaap:IPOMember 2020-01-28 0001477845 anvs:GrantTwoMember srt:ExecutiveOfficerMember 2020-01-01 2020-09-30 0001477845 anvs:GrantOneMember srt:ExecutiveOfficerMember 2020-01-01 2020-09-30 0001477845 anvs:EquityIncentivePlan2019Member 2020-01-31 0001477845 srt:MinimumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001477845 srt:MaximumMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001477845 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001477845 srt:ExecutiveOfficerMember 2020-01-01 2020-09-30 0001477845 us-gaap:CommonStockMember anvs:InitialPublicOfferingAndOverAllotmentOptionMember 2020-01-31 2020-01-31 0001477845 2019-01-01 2019-12-31 0001477845 us-gaap:RetainedEarningsMember 2020-07-01 2020-09-30 0001477845 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001477845 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001477845 2020-01-01 2020-03-31 0001477845 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0001477845 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0001477845 2019-04-01 2019-06-30 0001477845 us-gaap:RetainedEarningsMember 2019-01-01 2019-03-31 0001477845 us-gaap:ConvertibleDebtMember 2020-01-01 2020-09-30 0001477845 us-gaap:ConvertibleDebtMember 2019-01-01 2019-09-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2020-09-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2019-12-31 0001477845 2019-03-31 0001477845 2019-07-01 2019-09-30 0001477845 us-gaap:ConvertibleDebtMember 2020-09-30 0001477845 us-gaap:ConvertibleDebtMember 2019-09-30 0001477845 us-gaap:ConvertibleDebtMember anvs:RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember 2019-03-31 0001477845 us-gaap:ConvertibleDebtMember 2019-03-31 0001477845 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001477845 2019-09-30 0001477845 2018-12-31 0001477845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2020-09-30 0001477845 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0001477845 us-gaap:WarrantMember 2020-01-01 2020-09-30 0001477845 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-09-30 0001477845 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001477845 us-gaap:ConvertibleDebtSecuritiesMember 2019-01-01 2019-09-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-07-01 2020-09-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001477845 2020-04-01 2020-06-30 0001477845 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001477845 2019-01-01 2019-03-31 0001477845 2020-11-02 0001477845 us-gaap:OverAllotmentOptionMember 2020-01-28 2020-01-28 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2020-01-31 2020-01-31 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2020-01-31 2020-01-31 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember us-gaap:IPOMember 2020-01-01 2020-03-31 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember us-gaap:IPOMember 2020-01-01 2020-03-31 0001477845 us-gaap:AdditionalPaidInCapitalMember us-gaap:IPOMember 2020-01-01 2020-03-31 0001477845 us-gaap:IPOMember 2020-01-01 2020-03-31 0001477845 us-gaap:ConvertibleDebtMember anvs:RelatedPartyTransactionConversionOfPromissoryNotesToCommonStockMember us-gaap:CommonStockMember 2020-01-31 2020-01-31 0001477845 us-gaap:CommonStockMember us-gaap:IPOMember 2020-01-01 2020-03-31 0001477845 2019-07-31 2019-07-31 0001477845 anvs:ConsultantsMember 2020-01-01 2020-09-30 0001477845 us-gaap:ConvertibleDebtMember anvs:RelatedPartyTransactionIssuanceOfConvertiblePromissoryNotesMember 2019-03-01 2019-03-31 0001477845 anvs:SeriesaRedeemableConvertiblePreferredStockMember 2020-01-31 0001477845 anvs:Series1RedeemableConvertiblePreferredStockMember 2020-01-31 0001477845 anvs:UnderwritersWarrantsMember 2020-01-31 0001477845 anvs:AlzheimerDiseaseCooperativeStudyMember 2020-03-31 0001477845 srt:ExecutiveOfficerMember 2020-09-30 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:LicenseAgreementTermsAmendedMay2012Member 2012-05-31 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:LicenseAgreementTermsAmendedMay2012Member 2020-01-01 2020-09-30 0001477845 anvs:HorizonTherapeuticsPlcMember us-gaap:LicenseAgreementTermsMember 2008-11-01 2008-11-30 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:LicenseAgreementTermsAmendedMay2012Member 2012-05-01 2012-05-31 0001477845 2019-01-01 2019-09-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2020-07-01 2020-09-30 0001477845 2020-07-01 2020-09-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2020-01-01 2020-09-30 0001477845 anvs:NationalInstituteOnAgingOfNationalInstitutesOfHealthMember 2019-09-30 0001477845 2019-03-01 2019-03-31 0001477845 us-gaap:CommonStockMember us-gaap:IPOMember 2020-01-31 2020-01-31 0001477845 2020-01-01 2020-09-30 0001477845 2020-01-31 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:LicenseAgreementTermsAmendedMay2012Member anvs:RegulatoryApprovalUnitedStatesMember 2020-09-30 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:LicenseAgreementTermsAmendedMay2012Member anvs:RegulatoryApprovalOutsideUnitedStatesMember 2020-09-30 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:LicenseAgreementTermsAmendedMay2012Member anvs:FilingOfNewDrugApplicationOrEquivalentMember 2020-09-30 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:LicenseAgreementTermsAmendedMay2012Member anvs:CommencementOfPhaseTwoMember 2020-09-30 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:LicenseAgreementTermsAmendedMay2012Member anvs:CommencementOfPhaseThreeMember 2020-09-30 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:ScenarioBuyOutOptionIfExercisedPriorToCommencementOfFirstPhaseTwoClinicalTrialAndPriorToCommencementOfFirstPhaseThreeClinicalTrialMember anvs:LicenseAgreementTermsAmendedMay2012Member 2020-01-01 2020-09-30 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:ScenarioBuyOutOptionIfExercisedPriorToCommencementOfFirstPhaseThreeClinicalTrialAndPriorToFilingOfNewDrugApplicationU.s.FoodAndDrugAdministrationMember anvs:LicenseAgreementTermsAmendedMay2012Member 2020-01-01 2020-09-30 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:ScenarioBuyOutOptionIfExercisedOnOrAfterFilingOfNewDrugApplicationForFirstLicensedProductMember anvs:LicenseAgreementTermsAmendedMay2012Member 2020-01-01 2020-09-30 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:ScenarioBuyOutOptionIfExercisedOnOrAfterCommencementOfFirstPhaseTwoClinicalTrialMember anvs:LicenseAgreementTermsAmendedMay2012Member 2020-01-01 2020-09-30 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:LicenseAgreementTermsAmendedMay2012Member 2020-09-30 0001477845 anvs:HorizonTherapeuticsPlcMember anvs:LicenseAgreementTermsAmendedMay2012Member 2019-12-31 0001477845 2020-09-30 0001477845 2019-12-31 iso4217:USD xbrli:shares anvs:Vote anvs:item xbrli:pure xbrli:shares iso4217:USD 776871 776871 141280 141280 506000 506000 38333 38333 500000 8000000 5000000 1000000 575000 230000 1150000 5750000 5750000 37000000 672524 0.20 0.20 7076952 0 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">(5)&nbsp;Prepaid Expenses and Other Current Assets</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Prepaid expenses and other current assets consisted of the following:</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Prepaid insurance</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 110,057</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Prepaid expenses</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 19,941</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 4,135</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Security deposit</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 6,444</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 6,444</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Total prepaid expenses and other current assets</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 136,442</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 10,579</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 1pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font> </p><div /></div> </div> 369595 369595 0 0 601635 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(h)&nbsp;Grant Income</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">(4)&nbsp;Grant Receivable</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In September&nbsp;2019, as modified in September 2020, the Company received a Notice of Award for a $1.9&nbsp;million grant from the National Institute on Aging of the National Institutes of Health&nbsp;(the &#x201C;NIH&#x201D;) to cover costs of long-term chronic toxicology studies of ANVS401 in rats and dogs. The Company began the long-term chronic toxicology studies in November&nbsp;2019. The Company recorded a grant receivable of $424,952 and $735,075 as of September 30, 2020 and December&nbsp;31, 2019, respectively, to reflect unreimbursed, eligible costs incurred under the grant.</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company recognized grant income of $586,903 and $952,602 for the three&nbsp;and nine months ended September 30, 2020, respectively, in connection with the NIH grant and received payments under the grant of $1,262,725 during the nine months ended September 30, 2020.</font> </p><div /></div> </div> 1900000 952602 952602 586903 586903 321 204584 -310123 46000 40000 P90D P10Y 2000000 0.0575 0.50 0.092 720000 2 14 1 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(e)&nbsp; Offering Costs Associated with IPO</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Included in long-term assets as of September 30, 2020 and December&nbsp;31, 2019, were deferred offering costs of $0 and $369,595, respectively, incurred in connection with the Company&#x2019;s IPO which primarily consisted of direct incremental legal, printing, listing and accounting fees. Offering costs of $601,635 were offset against proceeds received in the IPO and charged to additional paid-in capital in the nine months ended September 30, 2020. Of these offering costs, $78,611 was paid during the year ended December 31, 2019.</font> </p><div /></div> </div> 8301 76747 448000 50000 1.25 1.25 10579 10579 136442 136442 1262725 0.70 1.26 3 21950 0.7143 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(l)&nbsp;Reverse Stock Split</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On July&nbsp;31, 2019, the board of directors (the &#x201C;Board&#x201D;) and shareholders of the Company approved a reverse stock split of the Company&#x2019;s common stock at a ratio of one share for every 1.4 shares previously held. All common stock share and per-share data included in these financial statements have been retroactively adjusted to reflect the reverse stock split.</font> </p><div /></div> </div> 118470 118470 118470 71429 4117089 4117089 4117089 672524 672512 12 7076952 7076540 412 567649 6509303 630722 5133159 630722 5133159 P45D 24 false --12-31 Q3 2020 2020-09-30 10-Q 0001477845 6891608 Yes true true Non-accelerated Filer Yes Annovis Bio, Inc. false true Common Stock, par value $0.0001 per share NYSE ANVS <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <a name="_Hlk39142016"></a><font style="display:inline;">(6)&nbsp;Accrued Expenses</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Accrued expenses consisted of the following:</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Payroll and related benefits</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 16,493</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 131,530</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Accrued interest expense</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 36,041</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Accrued professional fees</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 86,454</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 103,300</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Accrued license payments</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 38,333</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 506,000</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 141,280</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 776,871</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">See Note&nbsp;8 for further detail on the accrued license payments.</font> </p><div /></div> </div> 1233877 139778 103300 86454 200600 21654718 8859 8859 1111272 1111272 607067 607067 2582 396 813 129 4117089 353565 1113847 100000 1117107 9402001 747512 9402001 369595 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(a)&nbsp;Basis of Presentation of Interim Unaudited Financial Statements</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting only of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at September 30, 2020, and its results of operations and its cash flows for the three&nbsp;and nine months ended September 30, 2020 and 2019. The interim results of operations are not necessarily indicative of the results to be expected for a full&nbsp;year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the&nbsp;year ended December&nbsp;31, 2019 and notes thereto contained in the Company&#x2019;s Annual Report on Form&nbsp;10&#8209;K for the&nbsp;year ended December&nbsp;31, 2019. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201C;U.S.&nbsp;GAAP") and the rules and regulations of the Securities and Exchange Commission ("SEC"). Any reference in these notes to applicable guidance is meant to refer to U.S.&nbsp;GAAP as found in the Accounting Standards Codification (&#x201C;ASC&#x201D;) and Accounting Standards Update (&#x201C;ASU&#x201D;) of the Financial Accounting Standards Board (&#x201C;FASB&#x201D;). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S.&nbsp;GAAP have been omitted pursuant to such rules&nbsp;and regulations relating to interim financial statements.</font> </p><div /></div> </div> 1858 1858 1858 8840607 8840607 8840607 1858 8840607 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(d)&nbsp;Cash and Cash Equivalents</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company considers all highly liquid investments with original maturities of three&nbsp;months or less to be cash equivalents. At times, the Company&#x2019;s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation (&#x201C;FDIC&#x201D;). Total cash was $8,840,607 and $1,858 as of September 30, 2020 and December&nbsp;31, 2019, respectively.</font> </p><div /></div> </div> 35312 56250 1858 8840607 20938 8838749 7.50 7.50 100000 100000 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">(8)&nbsp;Commitments and Contingencies</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(a)&nbsp;Leases</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company leases its office facilities under a&nbsp;month-to-month operating lease. Total rental expense was $10,394 and $10,007 for the three&nbsp;months ended September 30, 2020 and 2019, respectively and $31,209 and $24,344 for the nine&nbsp;months ended September 30, 2020 and 2019, respectively.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(b)&nbsp;License Agreements</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In November&nbsp;2008, the Company licensed the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics. Currently, the intellectual property rights are owned by a subsidiary of Horizon Therapeutics, PLC (the &#x201C;Licensor&#x201D;). Payments by the Company under the license agreement include a one-time non-refundable fee of $50,000, a minimum annual commitment of $40,000 commencing in 2009, milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Company is responsible for the development and commercialization of the licensed products.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In May&nbsp;2012, such license agreement was amended. The minimum annual commitment was increased to $46,000 and may be deferred by the Company until the Company raises at least $2&nbsp;million in equity financing, then the aggregate annual payments of all amounts will become payable. During the period ended September 30, 2020, the Company paid $448,000 to the Licensor under the license agreement in satisfaction of deferred annual license commitments through November 2019.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">At September 30, 2020 and December&nbsp;31, 2019, the Company had accrued $38,333 and $506,000, respectively, in license payments under the term of this license, included in accrued liabilities. Expenses related to the license agreement are recognized in general and administrative expense in the statements of operations.</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In further consideration for the licenses granted, the Company shall make the following milestone payments to the Licensor based upon the attainment of each milestone event indicated below.</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:84.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Milestone Event</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Amount</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Commencement of Phase II</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 230,000</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Commencement of Phase III</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 575,000</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Filing of an NDA for Regulatory Approval (or equivalent in Europe or Japan)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 1,150,000</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Receipt of Regulatory Approval in the United States</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 5,750,000</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Receipt of Regulatory Approval outside the United States</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 5,750,000</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">No milestones have been achieved as of September 30, 2020.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Royalties shall be paid to the Licensor assessed on net sales of licensed products on a country-by-country basis in an amount equal to 5.75%. Should the Company be required to obtain a license from a third party in order to sell a licensed product, the Company may deduct 50% of the royalties on such licensed product paid to the third party subject to certain minimums.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In addition to the royalties the Company shall pay the Licensor 9.2% of all sublicense income attributable to licensed products.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Licensor also granted the Company a buy-out option which may be exercised at any time during the term of the agreement. The option price will be as follows: $500,000 if exercised prior to the commencement of the first Phase&nbsp;II clinical trial; $1,000,000 if exercised on or after the commencement of the first Phase&nbsp;II clinical trial and prior to the commencement of the first Phase&nbsp;III clinical trial; $5,000,000 if exercised on or after the commencement of the first Phase&nbsp;III clinical trial and prior to the filing of a New Drug Application (&#x201C;NDA&#x201D;) with the U.S. Food and Drug Administration (the &#x201C;FDA&#x201D;) for the first licensed product; and $8,000,000 if exercised on or after the filing of an NDA for the first licensed product.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company has the right to terminate the agreement at any time by giving 90&nbsp;days advance notice subject to the payment of any amounts due under the agreement at that time. If the Company does not terminate the agreement or exercise the buy-out option, the term of the agreement shall continue until the expiration of the Company&#x2019;s obligation to make royalty payments. Such royalty payments continue for each product in each country until the later of the expiration of the related patent or 10&nbsp;years after the initial sale of the product in the respective country. The agreement may also be terminated for cause by either party upon the breach of the material obligations of the other party or the bankruptcy or liquidation of the other party.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(c)&nbsp;Employment Agreements</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In March&nbsp;2020, the Company entered into employment agreements with its executive officers. The maximum aggregate severance payments under the agreements are approximately&nbsp;$720,000.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(d)&nbsp;Litigation</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company&#x2019;s liquidity, financial condition and cash flows. At September 30, 2020 and December&nbsp;31, 2019, the Company did not have any pending legal actions.</font> </p><div /></div> </div> 0.0001 0.0001 0.0001 10150000 35000000 35000000 282614 6871608 282614 6871608 28 687 106000 499807 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">(7)&nbsp;Convertible Promissory Notes</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In March&nbsp;2019, the Company issued convertible promissory notes (the &#x201C;Notes&#x201D;) to various investors in the aggregate principal amount of $530,000. Interest accrued at 8% compounded annually on all Notes,&nbsp;and the maturity date was defined as the earlier of a Liquidity Event or upon the written demand of the holders of a majority of the outstanding principal amount of the Notes&nbsp;made any time after December&nbsp;31, 2023. A Liquidity Event was defined as (i)&nbsp;the date of the closing of a merger or reorganization of the Company with another entity; (ii)&nbsp;the sale of substantially all of the assets of the Company in which the Company&#x2019;s stockholders own less than 50% of the equity securities after the event; or (iii)&nbsp;a liquidation of the Company.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company incurred costs of $8,622 in connection with the issuance of the Notes. In addition, on issuance, the Company recognized a discount associated with the Notes&nbsp;of $26,500 related to the fair value of an embedded derivative reflecting the share-settlement provision upon the closing of a qualified financing. Unamortized deferred financing fees and debt discount were deducted from the face amount of the Notes&nbsp;on the balance sheets. The Company amortized the deferred financing fees and debt discount over the term of the Notes&nbsp;as additional interest expense using the effective interest method. The effective interest rate on the Notes&nbsp;was&nbsp;9.8%. The Company made no cash payments for interest during the nine&nbsp;months ended September 30, 2020 or 2019.</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On January&nbsp;31, 2020, the Company closed its IPO. In accordance with the terms of the Notes, the outstanding Notes&nbsp;plus accrued interest converted into 118,470 shares of Company common stock at a 20% discount to the initial offering price of shares issued in the IPO.</font> </p><div /></div> </div> 530000 530000 305000 530000 530000 530000 530000 0.098 0.08 26500 22762 <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Prepaid insurance</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 110,057</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Prepaid expenses</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 19,941</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 4,135</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Security deposit</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 6,444</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 6,444</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Total prepaid expenses and other current assets</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 136,442</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 10,579</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> 8622 7431 106000 106000 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">(10)&nbsp;Share-Based Compensation</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Effective upon the closing of the Company&#x2019;s IPO on January&nbsp;31, 2020, the Company&#x2019;s 2019 Equity Incentive Plan (the &#x201C;2019 Plan&#x201D;) became effective, succeeding the Company&#x2019;s previous plan (see Note&nbsp;1). The previous plan had 352,282 options outstanding as of the effective date of the 2019 Plan. Under the 2019 Plan, 1,000,000&nbsp;additional shares are authorized to be issued, and no new awards may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. As of September 30, 2020, 186,283&nbsp;shares were available for future grants.</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">During the nine months ended September 30, 2020, the Company granted options to purchase 600,000 shares of common stock at an exercise price of $3.13 per share and 210,000 shares of common stock at an exercise price of $4.39 per share. Under the grant agreements, 50,000 of the options vest after one year and the remainder of the options were vested and exercisable upon grant.&nbsp;&nbsp;These options have a 10-year term. There were no options issued during the nine&nbsp;months ended September 30, 2019.&nbsp; </font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The options granted during the nine months ended September 30, 2020 were valued using the Black Scholes option pricing model using the following weighted average assumptions:&nbsp;&nbsp;expected term of 5.0 years; risk free interest rate of 0.3% to 0.4%; expected volatility of 80.0%; &nbsp;and dividend yield of 0.0%. &nbsp;</font><font style="display:inline;font-family:inherit;color:#000000;">The weighted-average grant date fair value of options issued by the Company during the nine months ended September 30, 2020 was&nbsp;$2.19 per share.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">During the nine months ended September 30, 2020, the Company granted stock awards of 5,000 shares to consultants and advisors for services rendered with an aggregate fair value of $21,950, based on the closing price of the Company&#x2019;s common stock on the NYSE American on the date of grant.&nbsp;&nbsp;There were no stock awards issued during the nine months ended September 30, 2019.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Share&#8209;based compensation expense, including the fair value of stock awards to consultants and advisors for services rendered, for the three&nbsp;months ended September 30, 2020 and 2019 was $629,017 and $0, respectively, and for the nine&nbsp;months ended September 30, 2020 and 2019 was $1,740,289 and $8,859, respectively.</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">As of September 30, 2020, there were 1,113,847 options outstanding, of which 1,063,847 were vested and exercisable.&nbsp;&nbsp;As of December&nbsp;31, 2019, there were 352,282 options outstanding, all of which were vested and exercisable.</font> </p><div /></div> </div> -2.79 -2.79 -0.90 -0.90 -0.61 -0.61 -0.15 -0.15 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(c)&nbsp;Basic and Diluted Net Income (Loss) per Share</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes, warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">(11) Net Loss Per Share</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The following table sets forth the computation of basic and diluted net loss per share:</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:22.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Three Months Ended </font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:22.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Nine Months Ended </font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:22.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:22.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Numerator</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Net loss</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (1,006,354)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (254,121)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (3,757,434)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (789,724)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Denominator</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Weighted-average common shares outstanding, basic and diluted</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 6,871,554</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 282,614</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 6,113,400</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 282,614</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Net loss per share, basic and diluted</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (0.15)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (0.90)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (0.61)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (2.79)</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company reported a net loss for the three&nbsp;and nine months ended September 30, 2020 and 2019, therefore, the basic and diluted net loss per share are the same in the respective period because the inclusion of potential common shares would have an anti-dilutive effect. Potential shares of common stock that are excluded from the computation of diluted weighted-average shares outstanding are as follows:</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:77.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:20.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:77.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:77.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Redeemable convertible preferred stock, as converted</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 4,117,089</font></p> </td> </tr> <tr> <td valign="bottom" style="width:77.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Stock options</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 1,113,847</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 353,565</font></p> </td> </tr> <tr> <td valign="bottom" style="width:77.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Warrants</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 100,000</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In addition, common shares issuable upon the conversion of the $530,000 Notes&nbsp;were excluded for all periods in which the Notes&nbsp;were outstanding.</font> </p><div /></div> </div> 26500 106000 132500 131530 16493 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">(3)&nbsp;Fair Value Measurements</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Level 1&#x2014;Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Level 2&#x2014;Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Level 3&#x2014;Valuations based on unobservable inputs and models that are supported by little or no market activity.</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of September 30, 2020 and December&nbsp;31, 2019:</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:51.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="8" valign="bottom" style="width:33.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Fair Value Measurement at </font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:33.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;2020</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Carrying Value</font></p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Level 1</font></p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Level 2</font></p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Level 3</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Cash and cash equivalents</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 8,840,607</font></p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 8,840,607</font></p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:51.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="8" valign="bottom" style="width:32.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Fair Value Measurement at&nbsp; </font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:32.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Carrying Value</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Level 1</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Level 2</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Level 3</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Cash and cash equivalents</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 1,858</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 1,858</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Derivative liability</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 106,000</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>106,000 </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The derivative liability was associated with the March&nbsp;2019 issuance of convertible promissory notes (see Note&nbsp;7). The Company computed the fair value at the date of issuance of $26,500 related to the embedded share settlement feature providing for conversion of the notes at a 20% discount to the price of the shares issued in a qualified financing. The Company estimated the fair value using a probability weighted approach. Using the same methodology, the Company determined the fair value of the derivative liability immediately prior to the closing of the IPO was $132,500 and at December&nbsp;31, 2019 was $106,000. The change in the fair value of the derivative liability is reflected in the statements of operations.</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(f)&nbsp;Fair Value of Financial Instruments</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company&#x2019;s financial instruments include cash and cash equivalents, accounts payable, accrued expenses, a derivative liability and debt. Cash and cash equivalents and the derivative liability are reported at fair value. The recorded carrying amount of accounts payable and accrued expenses reflect their fair value due to their short-term nature. The carrying value of the interest-bearing debt approximates fair value based upon the borrowing rates currently available to the Company for loans with similar terms and maturities.</font> </p><div /></div> </div> 720586 239781 3088726 884859 735075 735075 424952 424952 -789724 -254121 -3757434 -1006354 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">(12) Income Taxes</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company&#x2019;s income tax benefit (expense) was $0.0&nbsp;million for the three and nine&nbsp;months ended September 30, 2020 and&nbsp;&nbsp;2019. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future&nbsp;years. Accordingly, the benefit of the net operating loss ("NOL") that would have been recognized in the three&nbsp;and nine months ended September 30, 2020 and 2019 was offset by changes in the valuation allowance.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on the Company due to its tax losses generated during all prior years.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. The Company has completed financings since its inception, including its January 31, 2020 IPO, which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code or could result in a change in control in the future.</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">As of September 30, 2020, and December&nbsp;31, 2019, the Company had not recorded any liability for uncertain tax positions, accrued interest or penalties thereon, and no amounts have been recognized in the Company&#x2019;s statements of operations.</font> </p><div /></div> </div> 0 0 0 0 0 0 0 0 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(j)&nbsp;Income Taxes</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company is subject to the provisions of ASC 740,&nbsp;Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits.</font> </p><div /></div> </div> 215282 -897739 138288 -501275 26614 125863 -28564 -12327 47012 10500 0 0 36041 2616555 281058 1117107 9402001 2010748 281058 605807 444952 12043623 -424014 -3204874 -190903 -190903 -789724 -789724 -344700 -344700 -254121 -254121 -254121 -254121 -441590 -441590 -3757434 -3757434 -2309490 -2309490 -1006354 -1006354 -1006354 -1006354 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(k)&nbsp;Recent Accounting Pronouncements</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In March&nbsp;2018, the FASB issued ASU 2018&#8209;5&#x2014;Income Taxes (Topic 740): Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No.&nbsp;118. This ASU provided guidance related to Securities and Exchange Commission (&#x201C;SEC&#x201D;) Staff Accounting Bulletin No.&nbsp;118 (&#x201C;SAB&nbsp;118&#x201D;), which addresses the accounting implications of the Tax Cuts and Jobs Act of 2107 (the &#x201C;Tax Act&#x201D;). SAB&nbsp;118 allows a company to record provisional amounts during a measurement period not to extend beyond one&nbsp;year of the enactment date and was effective upon issuance. The Company has analyzed the Tax Act, and in certain areas, has made reasonable estimates of the effects on its financial statements and tax disclosures.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In August&nbsp;2018, the FASB issued ASU No.&nbsp;2018&#8209;13, Fair Value Measurement (Topic 820)&#x2014;Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level&nbsp;3 fair value measurement held at the end of reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level&nbsp;3 fair value measurements. The other provisions of ASU 2018&#8209;13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal&nbsp;years beginning after December&nbsp;15, 2019 with early adoption permitted. The adoption of ASU 2018-13 in the first quarter of 2020 did not have a significant impact on the Company's financial statements.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In December&nbsp;2019, the FASB issued ASU No.&nbsp;2019&#8209;12,&nbsp;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019&#8209;12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal&nbsp;years, and interim periods within those fiscal&nbsp;years, beginning after December&nbsp;15, 2020, with early adoption permitted. The Company is currently evaluating ASU 2019&#8209;12 but does not believe the adoption of this standard will have a significant impact on its financial statements.</font> </p><div /></div> </div> -55064 -12327 973114 597403 734660 241794 4730548 1603757 -734660 -241794 -4730548 -1603757 24344 10007 31209 10394 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <a name="Notes_97879"></a><font style="display:inline;">(1)&nbsp;Nature of Business and Liquidity<a name="a1NatureofBusinessandLiquidity_97879"></a></font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Annovis Bio,&nbsp;Inc. (the &#x201C;Company&#x201D; or &#x201C;Annovis&#x201D;) was incorporated on April&nbsp;29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer&#x2019;s disease (&#x201C;AD&#x201D;), Parkinson&#x2019;s disease (&#x201C;PD&#x201D;) and Alzheimer&#x2019;s disease in Down syndrome (&#x201C;AD-DS&#x201D;). The Company&#x2019;s lead compound, ANVS401, is a small molecule administered orally that attacks neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby improving axonal transport.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company&#x2019;s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company&#x2019;s future operations are dependent on the success of the Company&#x2019;s efforts to raise additional capital.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company has a history of incurring net losses and had an accumulated deficit of $12,534,462 as of September 30, 2020. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company&#x2019;s primary source of capital has been the issuance of equity securities.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On January&nbsp;28, 2020, the Company announced the pricing of its initial public offering (the &#x201C;IPO&#x201D;) of 2,000,000 shares of its common stock at an initial offering price of $6.00 per share. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 300,000 shares of common stock at the public offering price. The Company&#x2019;s common stock commenced trading on the NYSE American on January&nbsp;29, 2020 under the ticker symbol &#x201C;ANVS&#x201D;. The IPO closed on January&nbsp;31, 2020 at which time the underwriters exercised their option to purchase 300,000 additional shares of the Company&#x2019;s common stock bringing the total number of shares of common stock sold by&nbsp;the Company&nbsp;to 2,300,000 shares. The gross proceeds from the IPO, including proceeds from the exercise of the underwriters&#x2019; option to purchase additional shares, were approximately&nbsp;$13.8 million. The net proceeds of the IPO were approximately $12.0 million after deducting underwriting discounts, commissions and offering expenses payable by&nbsp;the Company, including offering costs paid in 2019. In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. Upon the closing of the IPO, outstanding redeemable convertible preferred stock and convertible promissory notes&nbsp;converted into shares of Company common stock totaling 4,117,089 and 118,470, respectively.</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">As of the date these financial statements are issued, management believes that the current cash and cash equivalents and funding from existing grants are sufficient to fund operations and capital requirements for at least the next 12&nbsp;months. The Company will need to raise additional capital to complete clinical development of and to commercially develop its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In further consideration for the licenses granted, the Company shall make the following milestone payments to the Licensor based upon the attainment of each milestone event indicated below.</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 80.00%;"> <tr> <td valign="bottom" style="width:84.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:84.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Milestone Event</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:13.00%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Amount</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Commencement of Phase II</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 230,000</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Commencement of Phase III</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 575,000</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Filing of an NDA for Regulatory Approval (or equivalent in Europe or Japan)</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 1,150,000</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Receipt of Regulatory Approval in the United States</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 5,750,000</font></p> </td> </tr> <tr> <td valign="bottom" style="width:84.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Receipt of Regulatory Approval outside the United States</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:11.72%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 5,750,000</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> 4135 19941 78611 0.0001 0.0001 0.0001 0 2000000 2000000 110057 530000 12034406 13800000 9217 -789724 -3757434 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">(13) Related-Party Transactions</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">As discussed in Note&nbsp;7, in March&nbsp;2019 the Company issued Notes&nbsp;in the aggregate principal amount of $530,000. &nbsp;Three of the Company&#x2019;s directors purchased an aggregate of $305,000 of the Notes. On January&nbsp;31, 2020, the Company closed its IPO, and the outstanding Notes&nbsp;plus accrued interest held by directors converted into 71,429 shares of Company common stock.</font> </p><div /></div> </div> 14074 2013 1641822 718898 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(g)&nbsp;Research and Development</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.</font> </p><div /></div> </div> -8777028 -12534462 -12534462 0 12000000 <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.48%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Payroll and related benefits</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 16,493</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 131,530</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Accrued interest expense</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 36,041</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Accrued professional fees</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 86,454</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 103,300</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Accrued license payments</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 38,333</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 506,000</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:73.22%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.56%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 141,280</font></p> </td> <td valign="bottom" style="width:02.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 776,871</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:77.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:77.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="3" valign="bottom" style="width:20.84%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:77.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:77.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Redeemable convertible preferred stock, as converted</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 4,117,089</font></p> </td> </tr> <tr> <td valign="bottom" style="width:77.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Stock options</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 1,113,847</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 353,565</font></p> </td> </tr> <tr> <td valign="bottom" style="width:77.10%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Warrants</font></p> </td> <td valign="bottom" style="width:02.06%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 100,000</font></p> </td> <td valign="bottom" style="width:02.08%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:22.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Three Months Ended </font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:22.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Nine Months Ended </font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:22.44%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="5" valign="bottom" style="width:22.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:11.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2020</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="2" valign="bottom" style="width:09.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Numerator</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Net loss</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (1,006,354)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (254,121)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (3,757,434)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:2pt double #000000 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (789,724)</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Denominator</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;&nbsp;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 0pt 0pt 6pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Weighted-average common shares outstanding, basic and diluted</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 6,871,554</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 282,614</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 6,113,400</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">&nbsp;</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 282,614</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.82%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Net loss per share, basic and diluted</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (0.15)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (0.90)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:10.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (0.61)</font></p> </td> <td valign="bottom" style="width:01.64%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.60%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> (2.79)</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> <div> <div> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of September 30, 2020 and December&nbsp;31, 2019:</font> </p> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:51.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="8" valign="bottom" style="width:33.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Fair Value Measurement at </font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:33.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">September&nbsp;30,&nbsp;2020</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Carrying Value</font></p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:10.52%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Level 1</font></p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.42%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Level 2</font></p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.46%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Level 3</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.86%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Cash and cash equivalents</font></p> </td> <td valign="bottom" style="width:01.90%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 8,840,607</font></p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 8,840,607</font></p> </td> <td valign="bottom" style="width:01.92%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.14%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.28%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:01.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.16%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.30%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <div style="width:100%;"><table cellpadding="0" cellspacing="0" align="center" style="border-collapse:collapse;width: 100.00%;"> <tr> <td valign="bottom" style="width:51.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> <font style="display:inline;font-size:1pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;height:1.00pt;padding:0pt;"> <p style="margin:0pt;font-family:Times New Roman,Times,serif;height:1.00pt;overflow:hidden;font-size:0pt;"> &nbsp;</p> </td> </tr> <tr> <td valign="bottom" style="width:51.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;font-size:8pt;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p> </td> <td colspan="8" valign="bottom" style="width:32.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Fair Value Measurement at&nbsp; </font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="8" valign="bottom" style="width:32.94%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">December&nbsp;31,&nbsp;2019</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-size:8pt;">&nbsp;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:11.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Carrying Value</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Level 1</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.62%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Level 2</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td colspan="2" valign="bottom" style="width:09.66%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt solid #000000 ;border-right:1pt none #D9D9D9 ;background-color: #auto;padding:0pt;"> <p style="margin:0pt;text-align:center;color:#000000;font-family:Times New Roman,Times,serif;font-size: 8pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;font-weight:bold;color:#000000;font-size:8pt;">Level 3</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Cash and cash equivalents</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 1,858</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 1,858</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;background-color: #CCEEFF;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> </tr> <tr> <td valign="bottom" style="width:51.96%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">Derivative liability</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.54%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:09.50%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> 106,000</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.02%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.24%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.38%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt 3pt 0pt 0pt;text-align:right;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;"> &nbsp;&#x2014;</font></p> </td> <td valign="bottom" style="width:02.04%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> &nbsp;</p> </td> <td valign="bottom" style="width:01.26%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;padding:0pt;"> <p style="margin:0pt;color:#000000;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;font-family:Times New Roman,Times,serif;color:#000000;">$</font></p> </td> <td valign="bottom" style="width:08.40%;border-top:1pt none #D9D9D9 ;border-left:1pt none #D9D9D9 ;border-bottom:1pt none #D9D9D9 ;border-right:1pt none #D9D9D9 ;;color:#000000;font-family:Times New Roman,Times,serif;font-size:10pt;padding-right:3pt;text-align:right;" nowrap="nowrap"><div style="float:left"></div>106,000 </td> </tr> </table></div> <p style="margin:0pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> 6444 6444 8859 8859 0 1740289 1740289 629017 P1Y 0.000 P5Y 0.800 0.004 0.003 1000000 186283 0 600000 210000 352282 352282 1113847 1063847 50000 2.19 P10Y 3.13 4.39 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(i)&nbsp;Share-Based Compensation</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Determining the appropriate fair value of share-based awards requires the use of subjective assumptions including, in the case of stock options, the expected life of the option and expected share price volatility. The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.</font> </p><div /></div> </div> 6.00 282614 282614 282614 282614 282614 6845459 6866608 6871608 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">(2)&nbsp;Summary of Significant Accounting Policies</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(a)&nbsp;Basis of Presentation of Interim Unaudited Financial Statements</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting only of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at September 30, 2020, and its results of operations and its cash flows for the three&nbsp;and nine months ended September 30, 2020 and 2019. The interim results of operations are not necessarily indicative of the results to be expected for a full&nbsp;year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the&nbsp;year ended December&nbsp;31, 2019 and notes thereto contained in the Company&#x2019;s Annual Report on Form&nbsp;10&#8209;K for the&nbsp;year ended December&nbsp;31, 2019. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201C;U.S.&nbsp;GAAP") and the rules and regulations of the Securities and Exchange Commission ("SEC"). Any reference in these notes to applicable guidance is meant to refer to U.S.&nbsp;GAAP as found in the Accounting Standards Codification (&#x201C;ASC&#x201D;) and Accounting Standards Update (&#x201C;ASU&#x201D;) of the Financial Accounting Standards Board (&#x201C;FASB&#x201D;). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S.&nbsp;GAAP have been omitted pursuant to such rules&nbsp;and regulations relating to interim financial statements.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(b)&nbsp;Use of Estimates</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The preparation of financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Significant items subject to such estimates and assumptions include share-based compensation expense, the valuation of the derivative liability and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(c)&nbsp;Basic and Diluted Net Income (Loss) per Share</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes, warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(d)&nbsp;Cash and Cash Equivalents</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company considers all highly liquid investments with original maturities of three&nbsp;months or less to be cash equivalents. At times, the Company&#x2019;s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation (&#x201C;FDIC&#x201D;). Total cash was $8,840,607 and $1,858 as of September 30, 2020 and December&nbsp;31, 2019, respectively.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(e)&nbsp; Offering Costs Associated with IPO</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Included in long-term assets as of September 30, 2020 and December&nbsp;31, 2019, were deferred offering costs of $0 and $369,595, respectively, incurred in connection with the Company&#x2019;s IPO which primarily consisted of direct incremental legal, printing, listing and accounting fees. Offering costs of $601,635 were offset against proceeds received in the IPO and charged to additional paid-in capital in the nine months ended September 30, 2020. Of these offering costs, $78,611 was paid during the year ended December 31, 2019.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(f)&nbsp;Fair Value of Financial Instruments</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company&#x2019;s financial instruments include cash and cash equivalents, accounts payable, accrued expenses, a derivative liability and debt. Cash and cash equivalents and the derivative liability are reported at fair value. The recorded carrying amount of accounts payable and accrued expenses reflect their fair value due to their short-term nature. The carrying value of the interest-bearing debt approximates fair value based upon the borrowing rates currently available to the Company for loans with similar terms and maturities.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(g)&nbsp;Research and Development</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(h)&nbsp;Grant Income</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(i)&nbsp;Share-Based Compensation</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Determining the appropriate fair value of share-based awards requires the use of subjective assumptions including, in the case of stock options, the expected life of the option and expected share price volatility. The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represent management&#x2019;s best estimates and involve inherent uncertainties and the application of management&#x2019;s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(j)&nbsp;Income Taxes</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company is subject to the provisions of ASC 740,&nbsp;Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(k)&nbsp;Recent Accounting Pronouncements</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In March&nbsp;2018, the FASB issued ASU 2018&#8209;5&#x2014;Income Taxes (Topic 740): Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No.&nbsp;118. This ASU provided guidance related to Securities and Exchange Commission (&#x201C;SEC&#x201D;) Staff Accounting Bulletin No.&nbsp;118 (&#x201C;SAB&nbsp;118&#x201D;), which addresses the accounting implications of the Tax Cuts and Jobs Act of 2107 (the &#x201C;Tax Act&#x201D;). SAB&nbsp;118 allows a company to record provisional amounts during a measurement period not to extend beyond one&nbsp;year of the enactment date and was effective upon issuance. The Company has analyzed the Tax Act, and in certain areas, has made reasonable estimates of the effects on its financial statements and tax disclosures.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In August&nbsp;2018, the FASB issued ASU No.&nbsp;2018&#8209;13, Fair Value Measurement (Topic 820)&#x2014;Disclosure Framework&#x2014;Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level&nbsp;3 fair value measurement held at the end of reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level&nbsp;3 fair value measurements. The other provisions of ASU 2018&#8209;13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal&nbsp;years beginning after December&nbsp;15, 2019 with early adoption permitted. The adoption of ASU 2018-13 in the first quarter of 2020 did not have a significant impact on the Company's financial statements.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In December&nbsp;2019, the FASB issued ASU No.&nbsp;2019&#8209;12,&nbsp;Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019&#8209;12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal&nbsp;years, and interim periods within those fiscal&nbsp;years, beginning after December&nbsp;15, 2020, with early adoption permitted. The Company is currently evaluating ASU 2019&#8209;12 but does not believe the adoption of this standard will have a significant impact on its financial statements.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(l)&nbsp;Reverse Stock Split</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">On July&nbsp;31, 2019, the board of directors (the &#x201C;Board&#x201D;) and shareholders of the Company approved a reverse stock split of the Company&#x2019;s common stock at a ratio of one share for every 1.4 shares previously held. All common stock share and per-share data included in these financial statements have been retroactively adjusted to reflect the reverse stock split.</font> </p><div /></div> </div> -7593903 192117 28 -7786048 -7775947 200976 28 -7976951 -8120647 200976 28 -8321651 -8374768 200976 28 -8575772 -8576400 -8576400 200600 28 -8777028 10691887 19909820 685 -9218618 9498280 21025701 687 -11528108 9120943 9120943 21654718 687 -12534462 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">(9)&nbsp;Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(a)&nbsp;Overview</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company closed its IPO on January&nbsp;31, 2020, issuing 2,300,000 shares of common stock. In connection with the closing of the Company&#x2019;s IPO, the then-outstanding 5,133,159 shares of Series&nbsp;A and 630,722 shares of Series&nbsp;A&#8209;1 redeemable convertible preferred stock converted into an aggregate of 4,117,089 shares of Company common stock. Each share of redeemable convertible preferred stock was converted into the number of shares of common stock determined by dividing the original issue price by the applicable conversion price. The Series&nbsp;A&#8209;1 conversion price was $1.26, and the Series&nbsp;A conversion price was $0.70, as adjusted for the reverse stock split discussed in Note&nbsp;2.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The Company&#x2019;s Amended and Restated Certificate of Incorporation was adopted on January&nbsp;31, 2020 to authorize the issuance of two classes of stock to be designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 37,000,000, each with a par value of $0.0001 per share. Of these shares, 35,000,000 shall be common stock and 2,000,000 shall be preferred stock.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(b)&nbsp;Common Stock</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-weight:normal;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Dividends</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-weight:normal;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Liquidation</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.</font> </p> <p style="margin:0pt 0pt 12pt 36pt;text-indent: -36pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-weight:normal;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Voting</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(c)&nbsp;Preferred Stock</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Preferred stock may be issued from time to time by the Board in one or more series.</font> </p> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(d)&nbsp;Warrants</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. The warrants have a five-year term and are not exercisable prior to January&nbsp;29, 2021. All of the warrants were outstanding at September 30, 2020, and the Company accounts for the warrants as a component of stockholders&#x2019; equity.</font> </p><div /></div> </div> 0 5000 5000 2300000 2000000 2300000 2300000 300000 300000 27286 21149 21950 21950 11955795 11955565 230 4606 4603 3 4611 4609 2 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;">(14) Subsequent Events and Impact of COVID-19 Pandemic</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">In March 2020, the clinical trial sites participating in the Company's Phase 2a trial in AD patients in collaboration with the Alzheimer's Disease Cooperative Study temporarily suspended enrollment of new patients because of the ongoing COVID-19 pandemic. Prior to suspension of enrollment, 14 patients had been enrolled and completed treatment, out of a total trial size of 24 patients. Most of the trial sites have reopened and treatment has begun in the 15</font><font style="display:inline;font-size:5pt;top:-4pt;position:relative;line-height:100%">th</font><font style="display:inline;"> patient. In addition, not all the sites which are expected to participate in the Company&#x2019;s Phase 2a clinical trial in AD and PD have opened for recruitment and treatment of patients due to restrictions related to COVID-19. Although the Company currently believes its clinical trials will be completed on time, the extent to which the COVID-19 pandemic could have a material impact on the clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain. </font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p> <p style="margin:0pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">&nbsp;</font> </p><div /></div> </div> 567649 6509303 567649 6509303 567649 6509303 567649 6509303 567649 567649 6509303 6509303 0 0 0 0 0 0 0 0.0001 0.0001 1111111 5133159 0 0 630722 5133159 630722 5133159 630722 5133159 630722 5133159 630722 630722 5133159 5133159 0 0 0 0 0 630722 5133159 0 0 -26500 -26500 -26500 -26500 <div> <div> <p style="margin:0pt 0pt 12pt;font-family:Times New Roman,Times,serif;font-weight:bold;font-size: 10pt;"> <font style="display:inline;font-style:italic;">(b)&nbsp;Use of Estimates</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">The preparation of financial statements in conformity with U.S.&nbsp;GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.</font> </p> <p style="margin:0pt 0pt 12pt;text-indent:36pt;font-family:Times New Roman,Times,serif;font-size: 10pt;"> <font style="display:inline;">Significant items subject to such estimates and assumptions include share-based compensation expense, the valuation of the derivative liability and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.</font> </p><div /></div> </div> P5Y 282614 282614 282614 282614 6113400 6113400 6871554 6871554 EX-101.SCH 7 anvs-20200930.xsd EX-101.SCH 00100 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Statements of Changes in Redeemable Convertible Preferred Stock link:presentationLink link:calculationLink link:definitionLink 00301 - Statement - Statements of Changes in Stockholders’ Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - Nature of Business and Liquidity link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Grant Receivable link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Convertible Promissory Notes link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Share-Based Compensation link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Related-Party Transactions link:presentationLink link:calculationLink link:definitionLink 11401 - Disclosure - Subsequent Events and Impact of COVID-19 Pandemic link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 30603 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Commitments and Contingencies (Tables) link:presentationLink link:calculationLink link:definitionLink 31103 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - Nature of Business and Liquidity (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Grant Receivable (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Convertible Promissory Notes (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Commitments and Contingencies - Leases (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Commitments and Contingencies - License Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Commitments and Contingencies - Employment Agreements (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Share-Based Compensation (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Related-Party Transactions (Details) link:presentationLink link:calculationLink link:definitionLink 41401 - Disclosure - Subsequent Events and Impact of COVID-19 Pandemic (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 anvs-20200930_cal.xml EX-101.CAL EX-101.DEF 9 anvs-20200930_def.xml EX-101.DEF EX-101.LAB 10 anvs-20200930_lab.xml EX-101.LAB EX-101.PRE 11 anvs-20200930_pre.xml EX-101.PRE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information - shares
9 Months Ended
Sep. 30, 2020
Nov. 02, 2020
Document and Entity Information    
Entity Registrant Name Annovis Bio, Inc.  
Document Type 10-Q  
Document Period End Date Sep. 30, 2020  
Entity Current Reporting Status Yes  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol ANVS  
Security Exchange Name NYSE  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period true  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   6,891,608
Entity Central Index Key 0001477845  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2020  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.20.2
Balance Sheets - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Current assets:    
Cash and cash equivalents $ 8,840,607 $ 1,858
Grant receivable 424,952 735,075
Prepaid expenses and other current assets 136,442 10,579
Total current assets 9,402,001 747,512
Long-term assets:    
Deferred offering costs 0 369,595
Total long-term assets   369,595
Total assets 9,402,001 1,117,107
Current liabilities:    
Accounts payable 139,778 1,233,877
Accrued expenses 141,280 776,871
Total current liabilities 281,058 2,010,748
Long-term liabilities:    
Derivative liability   106,000
Convertible promissory notes, net of unamortized deferred financing fees of $7,431 and debt discount of $22,762 at December 31, 2019   499,807
Total long-term liabilities   605,807
Total liabilities 281,058 2,616,555
Commitments and contingencies (Note 8)
Stockholders’ equity (deficit):    
Preferred stock - $0.0001 par value, 2,000,000 and 0 shares authorized at September 30, 2020 and December 31, 2019, respectively
Common stock - $0.0001 par value, 35,000,000 and 10,150,000 shares authorized at September 30, 2020 and December 31, 2019, respectively, and 6,871,608 and 282,614 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively 687 28
Additional paid-in capital 21,654,718 200,600
Accumulated deficit (12,534,462) (8,777,028)
Total stockholders’ equity (deficit) 9,120,943 (8,576,400)
Total liabilities and stockholders’ equity (deficit) 9,402,001 1,117,107
Series A Redeemable convertible preferred stock    
Long-term liabilities:    
Redeemable convertible preferred stock 0 6,509,303
Series A-1 Redeemable convertible preferred stock    
Long-term liabilities:    
Redeemable convertible preferred stock $ 0 $ 567,649
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.20.2
Balance Sheets (Parenthetical) - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Unamortized deferred financing fees   $ 7,431
Debt discount   $ 22,762
Preferred stock, par value (dollars per share) $ 0.0001 $ 0.0001
Preferred stock, authorized (shares) 2,000,000 0
Common stock, par value (dollars per share) $ 0.0001 $ 0.0001
Common stock, authorized (shares) 35,000,000 10,150,000
Common stock, issued (shares) 6,871,608 282,614
Common stock, outstanding (shares) 6,871,608 282,614
Redeemable convertible preferred stock    
Par value $ 0.0001 $ 0.0001
Series A Redeemable convertible preferred stock    
Shares authorized 0 5,133,159
Shares issued 0 5,133,159
Shares outstanding 0 5,133,159
Series A-1 Redeemable convertible preferred stock    
Shares authorized 0 1,111,111
Shares issued 0 630,722
Shares outstanding 0 630,722
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Statements of Operations - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Operating expenses:        
Research and development $ 718,898 $ 2,013 $ 1,641,822 $ 14,074
General and administrative 884,859 239,781 3,088,726 720,586
Total operating expenses 1,603,757 241,794 4,730,548 734,660
Operating loss (1,603,757) (241,794) (4,730,548) (734,660)
Other income (expense):        
Change in fair value of derivative liability     (26,500) (26,500)
Interest income (expense), net 10,500 (12,327) 47,012 (28,564)
Grant income 586,903   952,602  
Total other income (expense) 597,403 (12,327) 973,114 (55,064)
Loss before income taxes (1,006,354) (254,121) (3,757,434) (789,724)
Income tax expense (benefit) 0 0 0 0
Net loss $ (1,006,354) $ (254,121) $ (3,757,434) $ (789,724)
Basic and diluted loss per common share $ (0.15) $ (0.90) $ (0.61) $ (2.79)
Weighted average number of common shares outstanding, basic and diluted 6,871,554 282,614 6,113,400 282,614
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.20.2
Statements of Changes in Redeemable Convertible Preferred Stock
3 Months Ended
Mar. 31, 2020
USD ($)
shares
Series A Redeemable convertible preferred stock  
Increase (Decrease) in Temporary Equity [Roll Forward]  
Balance $ 6,509,303
Balance, shares | shares 5,133,159
Balance $ 0
Balance, shares | shares 0
Series A Redeemable convertible preferred stock | IPO  
Increase (Decrease) in Temporary Equity [Roll Forward]  
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering $ (6,509,303)
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares | shares (5,133,159)
Series A-1 Redeemable convertible preferred stock  
Increase (Decrease) in Temporary Equity [Roll Forward]  
Balance $ 567,649
Balance, shares | shares 630,722
Balance $ 0
Series A-1 Redeemable convertible preferred stock | IPO  
Increase (Decrease) in Temporary Equity [Roll Forward]  
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering $ (567,649)
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares | shares (630,722)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.20.2
Statements of Changes in Stockholders’ Equity (Deficit) - USD ($)
Common Stock
IPO
Common Stock
Additional Paid In Capital.
IPO
Additional Paid In Capital.
Accumulated deficit
IPO
Total
Balance at Dec. 31, 2018   $ 28   $ 192,117 $ (7,786,048)   $ (7,593,903)
Balance, shares at Dec. 31, 2018   282,614          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Share based compensation expense       8,859     8,859
Net loss         (190,903)   (190,903)
Balance at Mar. 31, 2019   $ 28   200,976 (7,976,951)   (7,775,947)
Balance, shares at Mar. 31, 2019   282,614          
Balance at Dec. 31, 2018   $ 28   192,117 (7,786,048)   (7,593,903)
Balance, shares at Dec. 31, 2018   282,614          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss             (789,724)
Balance at Sep. 30, 2019   $ 28   200,976 (8,575,772)   (8,374,768)
Balance, shares at Sep. 30, 2019   282,614          
Balance at Mar. 31, 2019   $ 28   200,976 (7,976,951)   (7,775,947)
Balance, shares at Mar. 31, 2019   282,614          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss         (344,700)   (344,700)
Balance at Jun. 30, 2019   $ 28   200,976 (8,321,651)   (8,120,647)
Balance, shares at Jun. 30, 2019   282,614          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss         (254,121)   (254,121)
Balance at Sep. 30, 2019   $ 28   200,976 (8,575,772)   (8,374,768)
Balance, shares at Sep. 30, 2019   282,614          
Balance at Dec. 31, 2019   $ 28   200,600 (8,777,028)   (8,576,400)
Balance, shares at Dec. 31, 2019   282,614          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering $ 412   $ 7,076,540     $ 7,076,952  
Conversion of redeemable convertible preferred stock to common stock upon completion of initial public offering, shares 4,117,089            
Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering $ 12   672,512     672,524  
Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering, shares 118,470            
Issuance of common stock in initial public offering, net of offering costs $ 230   $ 11,955,565     $ 11,955,795  
Issuance of common stock in initial public offering, net of offering costs, shares 2,300,000            
Exercise of stock options   $ 3   4,603     4,606
Exercise of stock options, shares   27,286          
Net loss         (441,590)   (441,590)
Balance at Mar. 31, 2020   $ 685   19,909,820 (9,218,618)   10,691,887
Balance, shares at Mar. 31, 2020   6,845,459          
Balance at Dec. 31, 2019   $ 28   200,600 (8,777,028)   (8,576,400)
Balance, shares at Dec. 31, 2019   282,614          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net loss             (3,757,434)
Balance at Sep. 30, 2020   $ 687   21,654,718 (12,534,462)   9,120,943
Balance, shares at Sep. 30, 2020   6,871,608          
Balance at Mar. 31, 2020   $ 685   19,909,820 (9,218,618)   10,691,887
Balance, shares at Mar. 31, 2020   6,845,459          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Exercise of stock options   $ 2   4,609     4,611
Exercise of stock options, shares   21,149          
Share based compensation expense       1,111,272     1,111,272
Net loss         (2,309,490)   (2,309,490)
Balance at Jun. 30, 2020   $ 687   21,025,701 (11,528,108)   9,498,280
Balance, shares at Jun. 30, 2020   6,866,608          
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Issuance of common stock to consultants and advisors       21,950     21,950
Issuance of common stock to consultants and advisors, shares   5,000          
Share based compensation expense       607,067     607,067
Net loss         (1,006,354)   (1,006,354)
Balance at Sep. 30, 2020   $ 687   $ 21,654,718 $ (12,534,462)   $ 9,120,943
Balance, shares at Sep. 30, 2020   6,871,608          
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.20.2
Statements of Cash Flows - USD ($)
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Cash flows from operating activities:    
Net loss $ (3,757,434) $ (789,724)
Adjustments to reconcile net loss to net cash used in operating activities:    
Amortization of deferred financing fees 129 813
Amortization of debt discount 396 2,582
Share-based compensation expense, including stock issued to consultants and advisors 1,740,289 8,859
Change in fair value of derivative liability 26,500 26,500
Changes in assets and liabilities:    
Grant receivable 310,123  
Prepaid expenses and other current assets (125,863) (26,614)
Accounts payable (897,739) 215,282
Accrued expenses (501,275) 138,288
Net cash used in operating activities (3,204,874) (424,014)
Cash flows from financing activities:    
Proceeds from initial public offering of common stock, net of offering costs 12,034,406  
Proceeds from issuance of convertible promissory notes   530,000
Proceeds from exercise of stock options 9,217  
Payment of deferred offering costs   (76,747)
Payment of deferred financing fees   (8,301)
Net cash provided by financing activities 12,043,623 444,952
Net increase in cash 8,838,749 20,938
Cash and cash equivalents, beginning of period 1,858 35,312
Cash and cash equivalents, end of period 8,840,607 56,250
Supplemental disclosure of cash flow information    
Deferred offering costs in accounts payable and accrued expenses   204,584
Deferred financing fees in accounts payable and accrued expenses   $ 321
Conversion of redeemable convertible preferred stock to common stock 7,076,952  
Conversion of convertible promissory notes, including embedded derivative, to common stock $ 672,524  
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.20.2
Nature of Business and Liquidity
9 Months Ended
Sep. 30, 2020
Nature of Business and Liquidity  
Nature of Business and Liquidity

(1) Nature of Business and Liquidity

Annovis Bio, Inc. (the “Company” or “Annovis”) was incorporated on April 29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (“AD”), Parkinson’s disease (“PD”) and Alzheimer’s disease in Down syndrome (“AD-DS”). The Company’s lead compound, ANVS401, is a small molecule administered orally that attacks neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby improving axonal transport.

Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital.

The Company has a history of incurring net losses and had an accumulated deficit of $12,534,462 as of September 30, 2020. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company’s primary source of capital has been the issuance of equity securities.

On January 28, 2020, the Company announced the pricing of its initial public offering (the “IPO”) of 2,000,000 shares of its common stock at an initial offering price of $6.00 per share. In addition, the Company granted the underwriters a 45-day option to purchase up to an additional 300,000 shares of common stock at the public offering price. The Company’s common stock commenced trading on the NYSE American on January 29, 2020 under the ticker symbol “ANVS”. The IPO closed on January 31, 2020 at which time the underwriters exercised their option to purchase 300,000 additional shares of the Company’s common stock bringing the total number of shares of common stock sold by the Company to 2,300,000 shares. The gross proceeds from the IPO, including proceeds from the exercise of the underwriters’ option to purchase additional shares, were approximately $13.8 million. The net proceeds of the IPO were approximately $12.0 million after deducting underwriting discounts, commissions and offering expenses payable by the Company, including offering costs paid in 2019. In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. Upon the closing of the IPO, outstanding redeemable convertible preferred stock and convertible promissory notes converted into shares of Company common stock totaling 4,117,089 and 118,470, respectively.

As of the date these financial statements are issued, management believes that the current cash and cash equivalents and funding from existing grants are sufficient to fund operations and capital requirements for at least the next 12 months. The Company will need to raise additional capital to complete clinical development of and to commercially develop its product candidates. There is no assurance that such financing will be available when needed or on acceptable terms.

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies
9 Months Ended
Sep. 30, 2020
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation of Interim Unaudited Financial Statements

The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting only of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at September 30, 2020, and its results of operations and its cash flows for the three and nine months ended September 30, 2020 and 2019. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2019 and notes thereto contained in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2019. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP") and the rules and regulations of the Securities and Exchange Commission ("SEC"). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.

(b) Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.

Significant items subject to such estimates and assumptions include share-based compensation expense, the valuation of the derivative liability and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.

(c) Basic and Diluted Net Income (Loss) per Share

Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes, warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.

(d) Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation (“FDIC”). Total cash was $8,840,607 and $1,858 as of September 30, 2020 and December 31, 2019, respectively.

(e)  Offering Costs Associated with IPO

Included in long-term assets as of September 30, 2020 and December 31, 2019, were deferred offering costs of $0 and $369,595, respectively, incurred in connection with the Company’s IPO which primarily consisted of direct incremental legal, printing, listing and accounting fees. Offering costs of $601,635 were offset against proceeds received in the IPO and charged to additional paid-in capital in the nine months ended September 30, 2020. Of these offering costs, $78,611 was paid during the year ended December 31, 2019.

(f) Fair Value of Financial Instruments

The Company’s financial instruments include cash and cash equivalents, accounts payable, accrued expenses, a derivative liability and debt. Cash and cash equivalents and the derivative liability are reported at fair value. The recorded carrying amount of accounts payable and accrued expenses reflect their fair value due to their short-term nature. The carrying value of the interest-bearing debt approximates fair value based upon the borrowing rates currently available to the Company for loans with similar terms and maturities.

(g) Research and Development

Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.

(h) Grant Income

Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.

(i) Share-Based Compensation

Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.

Determining the appropriate fair value of share-based awards requires the use of subjective assumptions including, in the case of stock options, the expected life of the option and expected share price volatility. The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.

The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.

Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.

(j) Income Taxes

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits.

(k) Recent Accounting Pronouncements

In March 2018, the FASB issued ASU 2018‑5—Income Taxes (Topic 740): Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 118. This ASU provided guidance related to Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 118 (“SAB 118”), which addresses the accounting implications of the Tax Cuts and Jobs Act of 2107 (the “Tax Act”). SAB 118 allows a company to record provisional amounts during a measurement period not to extend beyond one year of the enactment date and was effective upon issuance. The Company has analyzed the Tax Act, and in certain areas, has made reasonable estimates of the effects on its financial statements and tax disclosures.

In August 2018, the FASB issued ASU No. 2018‑13, Fair Value Measurement (Topic 820)—Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018‑13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. The adoption of ASU 2018-13 in the first quarter of 2020 did not have a significant impact on the Company's financial statements.

In December 2019, the FASB issued ASU No. 2019‑12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019‑12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating ASU 2019‑12 but does not believe the adoption of this standard will have a significant impact on its financial statements.

(l) Reverse Stock Split

On July 31, 2019, the board of directors (the “Board”) and shareholders of the Company approved a reverse stock split of the Company’s common stock at a ratio of one share for every 1.4 shares previously held. All common stock share and per-share data included in these financial statements have been retroactively adjusted to reflect the reverse stock split.

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements
9 Months Ended
Sep. 30, 2020
Fair Value Measurements  
Fair Value Measurements

(3) Fair Value Measurements

The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

 

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

 

 

    

Fair Value Measurement at

 

 

 

 

 

September 30, 2020

 

 

Carrying Value

 

Level 1

 

Level 2

 

Level 3

Cash and cash equivalents

 

$

8,840,607

 

$

8,840,607

 

$

 —

 

$

 —

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

 

 

    

Fair Value Measurement at 

 

 

 

 

 

December 31, 2019

 

 

Carrying Value

 

Level 1

 

Level 2

 

Level 3

Cash and cash equivalents

 

$

1,858

 

$

1,858

 

$

 —

 

$

 —

Derivative liability

 

$

106,000

 

$

 —

 

$

 —

 

$

106,000

 

The derivative liability was associated with the March 2019 issuance of convertible promissory notes (see Note 7). The Company computed the fair value at the date of issuance of $26,500 related to the embedded share settlement feature providing for conversion of the notes at a 20% discount to the price of the shares issued in a qualified financing. The Company estimated the fair value using a probability weighted approach. Using the same methodology, the Company determined the fair value of the derivative liability immediately prior to the closing of the IPO was $132,500 and at December 31, 2019 was $106,000. The change in the fair value of the derivative liability is reflected in the statements of operations.

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.20.2
Grant Receivable
9 Months Ended
Sep. 30, 2020
Grant Receivable  
Grant Receivable

(4) Grant Receivable

In September 2019, as modified in September 2020, the Company received a Notice of Award for a $1.9 million grant from the National Institute on Aging of the National Institutes of Health (the “NIH”) to cover costs of long-term chronic toxicology studies of ANVS401 in rats and dogs. The Company began the long-term chronic toxicology studies in November 2019. The Company recorded a grant receivable of $424,952 and $735,075 as of September 30, 2020 and December 31, 2019, respectively, to reflect unreimbursed, eligible costs incurred under the grant.

The Company recognized grant income of $586,903 and $952,602 for the three and nine months ended September 30, 2020, respectively, in connection with the NIH grant and received payments under the grant of $1,262,725 during the nine months ended September 30, 2020.

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.20.2
Prepaid Expenses and Other Current Assets
9 Months Ended
Sep. 30, 2020
Prepaid Expenses and Other Current Assets  
Prepaid Expenses and Other Current Assets

(5) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

 

 

 

 

 

 

 

 

 

 

    

September 30, 

 

December 31, 

 

 

 

2020

 

2019

 

Prepaid insurance

 

$

110,057

 

$

 —

 

Prepaid expenses

 

 

19,941

 

 

4,135

 

Security deposit

 

 

6,444

 

 

6,444

 

Total prepaid expenses and other current assets

 

$

136,442

 

$

10,579

 

 

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued Expenses
9 Months Ended
Sep. 30, 2020
Accrued Expenses  
Accrued Expenses

(6) Accrued Expenses

Accrued expenses consisted of the following:

 

 

 

 

 

 

 

 

 

 

    

September 30, 

 

December 31, 

 

 

 

2020

 

2019

 

Payroll and related benefits

 

$

16,493

 

$

131,530

 

Accrued interest expense

 

 

 —

 

 

36,041

 

Accrued professional fees

 

 

86,454

 

 

103,300

 

Accrued license payments

 

 

38,333

 

 

506,000

 

 

 

$

141,280

 

$

776,871

 

 

See Note 8 for further detail on the accrued license payments.

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.20.2
Convertible Promissory Notes
9 Months Ended
Sep. 30, 2020
Convertible Promissory Notes.  
Convertible Promissory Notes

(7) Convertible Promissory Notes

In March 2019, the Company issued convertible promissory notes (the “Notes”) to various investors in the aggregate principal amount of $530,000. Interest accrued at 8% compounded annually on all Notes, and the maturity date was defined as the earlier of a Liquidity Event or upon the written demand of the holders of a majority of the outstanding principal amount of the Notes made any time after December 31, 2023. A Liquidity Event was defined as (i) the date of the closing of a merger or reorganization of the Company with another entity; (ii) the sale of substantially all of the assets of the Company in which the Company’s stockholders own less than 50% of the equity securities after the event; or (iii) a liquidation of the Company.

The Company incurred costs of $8,622 in connection with the issuance of the Notes. In addition, on issuance, the Company recognized a discount associated with the Notes of $26,500 related to the fair value of an embedded derivative reflecting the share-settlement provision upon the closing of a qualified financing. Unamortized deferred financing fees and debt discount were deducted from the face amount of the Notes on the balance sheets. The Company amortized the deferred financing fees and debt discount over the term of the Notes as additional interest expense using the effective interest method. The effective interest rate on the Notes was 9.8%. The Company made no cash payments for interest during the nine months ended September 30, 2020 or 2019.

On January 31, 2020, the Company closed its IPO. In accordance with the terms of the Notes, the outstanding Notes plus accrued interest converted into 118,470 shares of Company common stock at a 20% discount to the initial offering price of shares issued in the IPO.

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies
9 Months Ended
Sep. 30, 2020
Commitments and Contingencies  
Commitments and Contingencies

(8) Commitments and Contingencies

(a) Leases

The Company leases its office facilities under a month-to-month operating lease. Total rental expense was $10,394 and $10,007 for the three months ended September 30, 2020 and 2019, respectively and $31,209 and $24,344 for the nine months ended September 30, 2020 and 2019, respectively.

(b) License Agreements

In November 2008, the Company licensed the rights to certain chemical compounds, know-how and intellectual property rights that may be suitable for the development of human therapeutics. Currently, the intellectual property rights are owned by a subsidiary of Horizon Therapeutics, PLC (the “Licensor”). Payments by the Company under the license agreement include a one-time non-refundable fee of $50,000, a minimum annual commitment of $40,000 commencing in 2009, milestone payments upon attainment of certain milestone events, royalties based on net sales of products covered by the patent-related rights and a portion of any sublicense income received by the Company. The Company is responsible for the development and commercialization of the licensed products.

In May 2012, such license agreement was amended. The minimum annual commitment was increased to $46,000 and may be deferred by the Company until the Company raises at least $2 million in equity financing, then the aggregate annual payments of all amounts will become payable. During the period ended September 30, 2020, the Company paid $448,000 to the Licensor under the license agreement in satisfaction of deferred annual license commitments through November 2019.

At September 30, 2020 and December 31, 2019, the Company had accrued $38,333 and $506,000, respectively, in license payments under the term of this license, included in accrued liabilities. Expenses related to the license agreement are recognized in general and administrative expense in the statements of operations.

In further consideration for the licenses granted, the Company shall make the following milestone payments to the Licensor based upon the attainment of each milestone event indicated below.

 

 

 

 

 

Milestone Event

    

Amount

Commencement of Phase II

 

$

230,000

Commencement of Phase III

 

$

575,000

Filing of an NDA for Regulatory Approval (or equivalent in Europe or Japan)

 

$

1,150,000

Receipt of Regulatory Approval in the United States

 

$

5,750,000

Receipt of Regulatory Approval outside the United States

 

$

5,750,000

 

No milestones have been achieved as of September 30, 2020.

Royalties shall be paid to the Licensor assessed on net sales of licensed products on a country-by-country basis in an amount equal to 5.75%. Should the Company be required to obtain a license from a third party in order to sell a licensed product, the Company may deduct 50% of the royalties on such licensed product paid to the third party subject to certain minimums.

In addition to the royalties the Company shall pay the Licensor 9.2% of all sublicense income attributable to licensed products.

The Licensor also granted the Company a buy-out option which may be exercised at any time during the term of the agreement. The option price will be as follows: $500,000 if exercised prior to the commencement of the first Phase II clinical trial; $1,000,000 if exercised on or after the commencement of the first Phase II clinical trial and prior to the commencement of the first Phase III clinical trial; $5,000,000 if exercised on or after the commencement of the first Phase III clinical trial and prior to the filing of a New Drug Application (“NDA”) with the U.S. Food and Drug Administration (the “FDA”) for the first licensed product; and $8,000,000 if exercised on or after the filing of an NDA for the first licensed product.

The Company has the right to terminate the agreement at any time by giving 90 days advance notice subject to the payment of any amounts due under the agreement at that time. If the Company does not terminate the agreement or exercise the buy-out option, the term of the agreement shall continue until the expiration of the Company’s obligation to make royalty payments. Such royalty payments continue for each product in each country until the later of the expiration of the related patent or 10 years after the initial sale of the product in the respective country. The agreement may also be terminated for cause by either party upon the breach of the material obligations of the other party or the bankruptcy or liquidation of the other party.

(c) Employment Agreements

In March 2020, the Company entered into employment agreements with its executive officers. The maximum aggregate severance payments under the agreements are approximately $720,000.

(d) Litigation

The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows. At September 30, 2020 and December 31, 2019, the Company did not have any pending legal actions.

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.20.2
Redeemable Convertible Preferred Stock and Stockholders' Equity
9 Months Ended
Sep. 30, 2020
Redeemable Convertible Preferred Stock and Stockholders' Equity  
Redeemable Convertible Preferred Stock and Stockholders' Equity

(9) Redeemable Convertible Preferred Stock and Stockholders’ Equity

(a) Overview

The Company closed its IPO on January 31, 2020, issuing 2,300,000 shares of common stock. In connection with the closing of the Company’s IPO, the then-outstanding 5,133,159 shares of Series A and 630,722 shares of Series A‑1 redeemable convertible preferred stock converted into an aggregate of 4,117,089 shares of Company common stock. Each share of redeemable convertible preferred stock was converted into the number of shares of common stock determined by dividing the original issue price by the applicable conversion price. The Series A‑1 conversion price was $1.26, and the Series A conversion price was $0.70, as adjusted for the reverse stock split discussed in Note 2.

The Company’s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020 to authorize the issuance of two classes of stock to be designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 37,000,000, each with a par value of $0.0001 per share. Of these shares, 35,000,000 shall be common stock and 2,000,000 shall be preferred stock.

(b) Common Stock

1.           Dividends

Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board.

2.           Liquidation

Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.

3.           Voting

The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.

(c) Preferred Stock

Preferred stock may be issued from time to time by the Board in one or more series.

(d) Warrants

In conjunction with the IPO, the Company granted the underwriters 100,000 warrants to purchase shares of Company common stock at an exercise price of $7.50 per share, which is 125% of the initial public offering price. The warrants have a five-year term and are not exercisable prior to January 29, 2021. All of the warrants were outstanding at September 30, 2020, and the Company accounts for the warrants as a component of stockholders’ equity.

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation
9 Months Ended
Sep. 30, 2020
Share-Based Compensation  
Share-Based Compensation

(10) Share-Based Compensation

Effective upon the closing of the Company’s IPO on January 31, 2020, the Company’s 2019 Equity Incentive Plan (the “2019 Plan”) became effective, succeeding the Company’s previous plan (see Note 1). The previous plan had 352,282 options outstanding as of the effective date of the 2019 Plan. Under the 2019 Plan, 1,000,000 additional shares are authorized to be issued, and no new awards may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. As of September 30, 2020, 186,283 shares were available for future grants.

During the nine months ended September 30, 2020, the Company granted options to purchase 600,000 shares of common stock at an exercise price of $3.13 per share and 210,000 shares of common stock at an exercise price of $4.39 per share. Under the grant agreements, 50,000 of the options vest after one year and the remainder of the options were vested and exercisable upon grant.  These options have a 10-year term. There were no options issued during the nine months ended September 30, 2019. 

 

The options granted during the nine months ended September 30, 2020 were valued using the Black Scholes option pricing model using the following weighted average assumptions:  expected term of 5.0 years; risk free interest rate of 0.3% to 0.4%; expected volatility of 80.0%;  and dividend yield of 0.0%.  The weighted-average grant date fair value of options issued by the Company during the nine months ended September 30, 2020 was $2.19 per share.

During the nine months ended September 30, 2020, the Company granted stock awards of 5,000 shares to consultants and advisors for services rendered with an aggregate fair value of $21,950, based on the closing price of the Company’s common stock on the NYSE American on the date of grant.  There were no stock awards issued during the nine months ended September 30, 2019.

Share‑based compensation expense, including the fair value of stock awards to consultants and advisors for services rendered, for the three months ended September 30, 2020 and 2019 was $629,017 and $0, respectively, and for the nine months ended September 30, 2020 and 2019 was $1,740,289 and $8,859, respectively.

As of September 30, 2020, there were 1,113,847 options outstanding, of which 1,063,847 were vested and exercisable.  As of December 31, 2019, there were 352,282 options outstanding, all of which were vested and exercisable.

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss Per Share
9 Months Ended
Sep. 30, 2020
Net Loss Per Share  
Net Loss Per Share

(11) Net Loss Per Share

The following table sets forth the computation of basic and diluted net loss per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30, 

 

September 30, 

 

    

2020

    

2019

    

2020

    

2019

Numerator

 

 

  

 

 

  

 

 

  

 

 

  

Net loss

 

$

(1,006,354)

 

$

(254,121)

 

$

(3,757,434)

 

$

(789,724)

Denominator

 

 

  

 

 

  

 

 

  

 

 

  

Weighted-average common shares outstanding, basic and diluted

 

 

6,871,554

 

 

282,614

 

 

6,113,400

 

 

282,614

Net loss per share, basic and diluted

 

$

(0.15)

 

$

(0.90)

 

$

(0.61)

 

$

(2.79)

 

The Company reported a net loss for the three and nine months ended September 30, 2020 and 2019, therefore, the basic and diluted net loss per share are the same in the respective period because the inclusion of potential common shares would have an anti-dilutive effect. Potential shares of common stock that are excluded from the computation of diluted weighted-average shares outstanding are as follows:

 

 

 

 

 

 

 

 

September 30, 

 

    

2020

    

2019

Redeemable convertible preferred stock, as converted

 

 —

 

4,117,089

Stock options

 

1,113,847

 

353,565

Warrants

 

100,000

 

 —

 

In addition, common shares issuable upon the conversion of the $530,000 Notes were excluded for all periods in which the Notes were outstanding.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes
9 Months Ended
Sep. 30, 2020
Income Taxes  
Income Taxes

(12) Income Taxes

The Company’s income tax benefit (expense) was $0.0 million for the three and nine months ended September 30, 2020 and  2019. The Company has recorded a valuation allowance to reduce its net deferred tax asset to an amount that is more likely than not to be realized in future years. Accordingly, the benefit of the net operating loss ("NOL") that would have been recognized in the three and nine months ended September 30, 2020 and 2019 was offset by changes in the valuation allowance.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act ("CARES Act") was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on the Company due to its tax losses generated during all prior years.

Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. The Company has completed financings since its inception, including its January 31, 2020 IPO, which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code or could result in a change in control in the future.

As of September 30, 2020, and December 31, 2019, the Company had not recorded any liability for uncertain tax positions, accrued interest or penalties thereon, and no amounts have been recognized in the Company’s statements of operations.

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.20.2
Related-Party Transactions
9 Months Ended
Sep. 30, 2020
Related-Party Transactions  
Related-Party Transactions

(13) Related-Party Transactions

As discussed in Note 7, in March 2019 the Company issued Notes in the aggregate principal amount of $530,000.  Three of the Company’s directors purchased an aggregate of $305,000 of the Notes. On January 31, 2020, the Company closed its IPO, and the outstanding Notes plus accrued interest held by directors converted into 71,429 shares of Company common stock.

XML 32 R21.htm IDEA: XBRL DOCUMENT v3.20.2
Subsequent Events and Impact of COVID-19 Pandemic
9 Months Ended
Sep. 30, 2020
Subsequent Events and Impact of COVID-19 Pandemic  
Subsequent Events and Impact of COVID-19 Pandemic

(14) Subsequent Events and Impact of COVID-19 Pandemic

In March 2020, the clinical trial sites participating in the Company's Phase 2a trial in AD patients in collaboration with the Alzheimer's Disease Cooperative Study temporarily suspended enrollment of new patients because of the ongoing COVID-19 pandemic. Prior to suspension of enrollment, 14 patients had been enrolled and completed treatment, out of a total trial size of 24 patients. Most of the trial sites have reopened and treatment has begun in the 15th patient. In addition, not all the sites which are expected to participate in the Company’s Phase 2a clinical trial in AD and PD have opened for recruitment and treatment of patients due to restrictions related to COVID-19. Although the Company currently believes its clinical trials will be completed on time, the extent to which the COVID-19 pandemic could have a material impact on the clinical trials is dependent on the spread of the disease and government and healthcare system responses to such spread, which are presently highly uncertain.

 

 

XML 33 R22.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Policies)
9 Months Ended
Sep. 30, 2020
Summary of Significant Accounting Policies  
Basis of Presentation of Interim Unaudited Financial Statements

(a) Basis of Presentation of Interim Unaudited Financial Statements

The interim financial statements included herein are unaudited. In the opinion of management, these statements include all adjustments, consisting only of normal, recurring adjustments, necessary for a fair presentation of the financial position of Annovis at September 30, 2020, and its results of operations and its cash flows for the three and nine months ended September 30, 2020 and 2019. The interim results of operations are not necessarily indicative of the results to be expected for a full year. These interim unaudited financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2019 and notes thereto contained in the Company’s Annual Report on Form 10‑K for the year ended December 31, 2019. The accompanying financial statements have been prepared in conformity with U.S. generally accepted accounting principles (“U.S. GAAP") and the rules and regulations of the Securities and Exchange Commission ("SEC"). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”). Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations relating to interim financial statements.

Use of Estimates

(b) Use of Estimates

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including disclosure of contingent assets and liabilities, at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Due to the uncertainty of factors surrounding the estimates or judgments used in the preparation of the financial statements, actual results may materially vary from these estimates.

Significant items subject to such estimates and assumptions include share-based compensation expense, the valuation of the derivative liability and contingent liabilities. Future events and their effects cannot be predicted with certainty; accordingly, accounting estimates require the exercise of judgment. Accounting estimates used in the preparation of these financial statements change as new events occur, as more experience is acquired, as additional information is obtained and as the operating environment changes.

Basic and Diluted Net Income (Loss) per Share

(c) Basic and Diluted Net Income (Loss) per Share

Basic net income (loss) per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net income (loss) per share includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock, convertible promissory notes, warrants and stock options, which would result in the issuance of incremental shares of common stock. The computation of diluted net income (loss) per shares does not include the conversion of securities that would have an anti-dilutive effect.

Cash and Cash Equivalents

(d) Cash and Cash Equivalents

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. At times, the Company’s cash balances may exceed the current insured amounts under the Federal Deposit Insurance Corporation (“FDIC”). Total cash was $8,840,607 and $1,858 as of September 30, 2020 and December 31, 2019, respectively.

Offering Costs Associated with IPO

(e)  Offering Costs Associated with IPO

Included in long-term assets as of September 30, 2020 and December 31, 2019, were deferred offering costs of $0 and $369,595, respectively, incurred in connection with the Company’s IPO which primarily consisted of direct incremental legal, printing, listing and accounting fees. Offering costs of $601,635 were offset against proceeds received in the IPO and charged to additional paid-in capital in the nine months ended September 30, 2020. Of these offering costs, $78,611 was paid during the year ended December 31, 2019.

Fair Value of Financial Instruments

(f) Fair Value of Financial Instruments

The Company’s financial instruments include cash and cash equivalents, accounts payable, accrued expenses, a derivative liability and debt. Cash and cash equivalents and the derivative liability are reported at fair value. The recorded carrying amount of accounts payable and accrued expenses reflect their fair value due to their short-term nature. The carrying value of the interest-bearing debt approximates fair value based upon the borrowing rates currently available to the Company for loans with similar terms and maturities.

Research and Development

(g) Research and Development

Research and development costs are expensed as incurred and are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs.

Grant Income

(h) Grant Income

Grants received are recognized as grant income in the statements of operations as and when they are earned for the specific research and development projects for which these grants are designated. Grant payments received in excess of grant income earned are recognized as deferred grant on the balance sheets, and grant income earned in excess of grant payments received is recognized as grant receivable on the balance sheets.

Share-Based Compensation

(i) Share-Based Compensation

Share-based compensation cost is measured at the grant date based on the fair value of the award and is recognized as expense over the requisite service period, which is generally the vesting period. Forfeitures are recognized in compensation expense in the period when they occur.

Determining the appropriate fair value of share-based awards requires the use of subjective assumptions including, in the case of stock options, the expected life of the option and expected share price volatility. The expected life of options was estimated using the simplified method, as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post-vesting employment.

The Company uses the Black-Scholes option pricing model to value its option awards. The assumptions used in calculating the fair value of share-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, share-based compensation expense could be materially different for future awards.

Upon exercise of stock options, the Company issues shares first from treasury stock, if available, then from authorized but unissued shares.

Income Taxes

(j) Income Taxes

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits.

Recent Accounting Pronouncements

(k) Recent Accounting Pronouncements

In March 2018, the FASB issued ASU 2018‑5—Income Taxes (Topic 740): Amendments to SEC Paragraphs pursuant to SEC Staff Accounting Bulletin No. 118. This ASU provided guidance related to Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 118 (“SAB 118”), which addresses the accounting implications of the Tax Cuts and Jobs Act of 2107 (the “Tax Act”). SAB 118 allows a company to record provisional amounts during a measurement period not to extend beyond one year of the enactment date and was effective upon issuance. The Company has analyzed the Tax Act, and in certain areas, has made reasonable estimates of the effects on its financial statements and tax disclosures.

In August 2018, the FASB issued ASU No. 2018‑13, Fair Value Measurement (Topic 820)—Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. The new guidance improves and clarifies the fair value measurement disclosure requirement of ASC 820. The new disclosure requirements include the changes in unrealized gains or losses included in other comprehensive income for recurring Level 3 fair value measurement held at the end of reporting period and the explicit requirement to disclose the range and weighted average used to develop significant unobservable inputs for Level 3 fair value measurements. The other provisions of ASU 2018‑13 also include eliminated and modified disclosure requirements. The guidance is effective for fiscal years beginning after December 15, 2019 with early adoption permitted. The adoption of ASU 2018-13 in the first quarter of 2020 did not have a significant impact on the Company's financial statements.

In December 2019, the FASB issued ASU No. 2019‑12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments in ASU 2019‑12 simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740 and clarifying and amending existing guidance. The new standard is effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2020, with early adoption permitted. The Company is currently evaluating ASU 2019‑12 but does not believe the adoption of this standard will have a significant impact on its financial statements.

Reverse Stock Split

(l) Reverse Stock Split

On July 31, 2019, the board of directors (the “Board”) and shareholders of the Company approved a reverse stock split of the Company’s common stock at a ratio of one share for every 1.4 shares previously held. All common stock share and per-share data included in these financial statements have been retroactively adjusted to reflect the reverse stock split.

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements (Tables)
9 Months Ended
Sep. 30, 2020
Fair Value Measurements  
Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis

The following table provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of September 30, 2020 and December 31, 2019:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

 

 

    

Fair Value Measurement at

 

 

 

 

 

September 30, 2020

 

 

Carrying Value

 

Level 1

 

Level 2

 

Level 3

Cash and cash equivalents

 

$

8,840,607

 

$

8,840,607

 

$

 —

 

$

 —

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    

 

 

    

Fair Value Measurement at 

 

 

 

 

 

December 31, 2019

 

 

Carrying Value

 

Level 1

 

Level 2

 

Level 3

Cash and cash equivalents

 

$

1,858

 

$

1,858

 

$

 —

 

$

 —

Derivative liability

 

$

106,000

 

$

 —

 

$

 —

 

$

106,000

 

XML 35 R24.htm IDEA: XBRL DOCUMENT v3.20.2
Prepaid Expenses and Other Current Assets (Tables)
9 Months Ended
Sep. 30, 2020
Prepaid Expenses and Other Current Assets  
Schedule of prepaid expenses and other current assets

 

 

 

 

 

 

 

 

 

    

September 30, 

 

December 31, 

 

 

 

2020

 

2019

 

Prepaid insurance

 

$

110,057

 

$

 —

 

Prepaid expenses

 

 

19,941

 

 

4,135

 

Security deposit

 

 

6,444

 

 

6,444

 

Total prepaid expenses and other current assets

 

$

136,442

 

$

10,579

 

 

XML 36 R25.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued Expenses (Tables)
9 Months Ended
Sep. 30, 2020
Accrued Expenses  
Schedule of accrued expenses

 

 

 

 

 

 

 

 

 

    

September 30, 

 

December 31, 

 

 

 

2020

 

2019

 

Payroll and related benefits

 

$

16,493

 

$

131,530

 

Accrued interest expense

 

 

 —

 

 

36,041

 

Accrued professional fees

 

 

86,454

 

 

103,300

 

Accrued license payments

 

 

38,333

 

 

506,000

 

 

 

$

141,280

 

$

776,871

 

 

XML 37 R26.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies (Tables)
9 Months Ended
Sep. 30, 2020
Commitments and Contingencies  
Schedule of milestone payments

In further consideration for the licenses granted, the Company shall make the following milestone payments to the Licensor based upon the attainment of each milestone event indicated below.

 

 

 

 

 

Milestone Event

    

Amount

Commencement of Phase II

 

$

230,000

Commencement of Phase III

 

$

575,000

Filing of an NDA for Regulatory Approval (or equivalent in Europe or Japan)

 

$

1,150,000

Receipt of Regulatory Approval in the United States

 

$

5,750,000

Receipt of Regulatory Approval outside the United States

 

$

5,750,000

 

XML 38 R27.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss Per Share (Tables)
9 Months Ended
Sep. 30, 2020
Net Loss Per Share  
Schedule of basic and diluted net loss per share

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

 

September 30, 

 

September 30, 

 

    

2020

    

2019

    

2020

    

2019

Numerator

 

 

  

 

 

  

 

 

  

 

 

  

Net loss

 

$

(1,006,354)

 

$

(254,121)

 

$

(3,757,434)

 

$

(789,724)

Denominator

 

 

  

 

 

  

 

 

  

 

 

  

Weighted-average common shares outstanding, basic and diluted

 

 

6,871,554

 

 

282,614

 

 

6,113,400

 

 

282,614

Net loss per share, basic and diluted

 

$

(0.15)

 

$

(0.90)

 

$

(0.61)

 

$

(2.79)

 

Schedule of shares excluded from the computation of diluted weighted-average shares outstanding

 

 

 

 

 

 

 

September 30, 

 

    

2020

    

2019

Redeemable convertible preferred stock, as converted

 

 —

 

4,117,089

Stock options

 

1,113,847

 

353,565

Warrants

 

100,000

 

 —

 

XML 39 R28.htm IDEA: XBRL DOCUMENT v3.20.2
Nature of Business and Liquidity (Details) - USD ($)
3 Months Ended 9 Months Ended
Jan. 31, 2020
Jan. 28, 2020
Mar. 31, 2020
Sep. 30, 2020
Dec. 31, 2019
Nature of Business and Liquidity          
Revenue       $ 0  
Accumulated deficit       (12,534,462) $ (8,777,028)
Gross proceeds from issuance of common shares       $ 12,034,406  
Underwriters warrants          
Nature of Business and Liquidity          
Number of warrants granted 100,000        
Exercise price $ 7.50        
Percentage of exercise price to the share offering price 125.00%        
Over-Allotment Option          
Nature of Business and Liquidity          
Term of underwriters' option   45 days      
Common Stock | IPO and Over-Allotment Option          
Nature of Business and Liquidity          
Issuance of common stock 2,300,000        
Gross proceeds from issuance of common shares $ 13,800,000        
Net proceeds from issuance of common shares $ 12,000,000        
Common Stock | IPO          
Nature of Business and Liquidity          
Issuance of common stock   2,000,000 2,300,000    
Share price   $ 6.00      
Number of shares issued for the conversion of redeemable convertible preferred stock 4,117,089   4,117,089    
Conversion of convertible promissory notes, including embedded derivative, to common stock upon completion of initial public offering, shares 118,470   118,470    
Common Stock | Over-Allotment Option          
Nature of Business and Liquidity          
Issuance of common stock 300,000        
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.20.2
Summary of Significant Accounting Policies (Details)
9 Months Ended 12 Months Ended
Jul. 31, 2019
Sep. 30, 2020
USD ($)
Dec. 31, 2019
USD ($)
Summary of Significant Accounting Policies      
Cash and cash equivalents   $ 8,840,607 $ 1,858
Deferred offering costs   0 369,595
Offering costs offset against proceeds received in IPO   $ 601,635  
Payment of offering cost     $ 78,611
Reverse stock split, conversion ratio 0.7143    
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.20.2
Fair Value Measurements (Details) - USD ($)
1 Months Ended
Mar. 31, 2019
Sep. 30, 2020
Jan. 31, 2020
Dec. 31, 2019
Fair Value Measurements        
Cash and cash equivalents, Carrying Value   $ 8,840,607   $ 1,858
Derivative liability, Carrying Value       106,000
Fair value of derivative liability associated with issuance of convertible promissory notes $ 26,500   $ 132,500 106,000
Terms of convertible promissory notes, percentage of discount to be applied to conversion shares 20.00%      
Recurring | Level 1        
Fair Value Measurements        
Cash and cash equivalents, Fair Value   $ 8,840,607   1,858
Recurring | Level 3        
Fair Value Measurements        
Derivative liability, Fair Value       $ 106,000
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.20.2
Grant Receivable (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2020
Dec. 31, 2019
Sep. 30, 2019
Grant Receivable        
Grant receivable $ 424,952 $ 424,952 $ 735,075  
Grant income 586,903 952,602    
NIH        
Grant Receivable        
Notice of Award, grant amount       $ 1,900,000
Grant receivable 424,952 424,952 $ 735,075  
Grant income $ 586,903 952,602    
Proceeds from grants   $ 1,262,725    
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.20.2
Prepaid Expenses and Other Current Assets (Details) - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Prepaid Expenses and Other Current Assets    
Prepaid insurance $ 110,057  
Prepaid expenses 19,941 $ 4,135
Security deposit 6,444 6,444
Total prepaid expenses and other current assets $ 136,442 $ 10,579
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.20.2
Accrued Expenses (Details) - USD ($)
Sep. 30, 2020
Dec. 31, 2019
Accrued Expenses    
Payroll and related benefits $ 16,493 $ 131,530
Accrued interest expense   36,041
Accrued professional fees 86,454 103,300
Accrued license payments 38,333 506,000
Total accrued expenses $ 141,280 $ 776,871
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.20.2
Convertible Promissory Notes (Details) - USD ($)
3 Months Ended 9 Months Ended
Jan. 31, 2020
Mar. 31, 2020
Sep. 30, 2020
Sep. 30, 2019
Dec. 31, 2019
Mar. 31, 2019
Convertible Promissory Notes            
Debt discount         $ 22,762  
Common Stock | IPO            
Convertible Promissory Notes            
Number of common shares issued upon conversion 118,470 118,470        
Percentage of discount to the initial offering price of shares issued in the IPO 20.00%          
Convertible promissory notes            
Convertible Promissory Notes            
Aggregate principal amount     $ 530,000 $ 530,000   $ 530,000
Stated interest rate           8.00%
Debt issuance costs incurred           $ 8,622
Debt discount           $ 26,500
Effective interest rate           9.80%
Cash payments for interest     $ 0 $ 0    
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies - Leases (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Leases        
Rental expense $ 10,394 $ 10,007 $ 31,209 $ 24,344
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies - License Agreements (Details)
1 Months Ended 9 Months Ended
May 31, 2012
USD ($)
Nov. 30, 2008
USD ($)
Sep. 30, 2020
USD ($)
item
Dec. 31, 2019
USD ($)
License Agreements        
Accrued license payments     $ 38,333 $ 506,000
License Agreement | Horizon Therapeutics, PLC        
License Agreements        
One-time non-refundable fee   $ 50,000    
Minimum annual commitment   $ 40,000    
Amended License Agreement | Horizon Therapeutics, PLC        
License Agreements        
Deferrable minimum annual commitment $ 46,000      
Threshold amount of equity financing $ 2,000,000      
Payments in in satisfaction of deferred annual license commitments     448,000  
Accrued license payments     $ 38,333 $ 506,000
Number of milestones achieved | item     0  
Percentage of net sales used to calculate royalties payable     5.75%  
Percentage of reduction in royalties payable if third-party license is required     50.00%  
Percentage of sublicense income to be paid in addition to royalty payments     9.20%  
Period for advance notice of termination     90 days  
Term of license agreement     10 years  
Amended License Agreement | Horizon Therapeutics, PLC | Exercise of by-out option on or after commencement of first Phase II clinical trial        
License Agreements        
Buy-out option price     $ 500,000  
Amended License Agreement | Horizon Therapeutics, PLC | Exercise of by-out option prior to commencement of first Phase II clinical trial and prior to the commencement of the first Phase III clinical trial        
License Agreements        
Buy-out option price     1,000,000  
Amended License Agreement | Horizon Therapeutics, PLC | Exercise of by-out option prior to commencement of first Phase III clinical trial and prior to the filing of a NDA with the FDA        
License Agreements        
Buy-out option price     5,000,000  
Amended License Agreement | Horizon Therapeutics, PLC | Exercise of by-out option on or after the filing of a NDA for the first licensed product        
License Agreements        
Buy-out option price     8,000,000  
Amended License Agreement | Horizon Therapeutics, PLC | Commencement of Phase II        
License Agreements        
Amount of milestone payment     230,000  
Amended License Agreement | Horizon Therapeutics, PLC | Commencement of Phase III        
License Agreements        
Amount of milestone payment     575,000  
Amended License Agreement | Horizon Therapeutics, PLC | Filing of an NDA for Regulatory Approval (or equivalent in Europe or Japan)        
License Agreements        
Amount of milestone payment     1,150,000  
Amended License Agreement | Horizon Therapeutics, PLC | Receipt of Regulatory Approval in the United States        
License Agreements        
Amount of milestone payment     5,750,000  
Amended License Agreement | Horizon Therapeutics, PLC | Receipt of Regulatory Approval outside the United States        
License Agreements        
Amount of milestone payment     $ 5,750,000  
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.20.2
Commitments and Contingencies - Employment Agreements (Details)
Sep. 30, 2020
USD ($)
Executive Officers  
Employment Agreements  
Maximum aggregate severance payments $ 720,000
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.20.2
Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details)
3 Months Ended
Jan. 31, 2020
Vote
item
$ / shares
shares
Jan. 28, 2020
shares
Mar. 31, 2020
shares
Sep. 30, 2020
$ / shares
shares
Dec. 31, 2019
$ / shares
shares
Redeemable Convertible Preferred Stock and Stockholders' Equity          
Number of classes of stock designated | item 2        
Number of common and preferred shares authorized 37,000,000        
Common stock, par value (dollars per share) | $ / shares $ 0.0001     $ 0.0001 $ 0.0001
Preferred stock, par value (dollars per share) | $ / shares $ 0.0001     $ 0.0001 $ 0.0001
Number of common shares authorized 35,000,000     35,000,000 10,150,000
Number of preferred shares authorized 2,000,000     2,000,000 0
Number of vote for each share of common stock | Vote 1        
Series A Redeemable convertible preferred stock          
Redeemable Convertible Preferred Stock and Stockholders' Equity          
Conversion of redeemable convertible preferred stock to common stock, shares 5,133,159        
Conversion price | $ / shares $ 1.26        
Series A Redeemable convertible preferred stock | IPO          
Redeemable Convertible Preferred Stock and Stockholders' Equity          
Conversion of redeemable convertible preferred stock to common stock, shares     5,133,159    
Series A-1 Redeemable convertible preferred stock          
Redeemable Convertible Preferred Stock and Stockholders' Equity          
Conversion of redeemable convertible preferred stock to common stock, shares 630,722        
Conversion price | $ / shares $ 0.70        
Series A-1 Redeemable convertible preferred stock | IPO          
Redeemable Convertible Preferred Stock and Stockholders' Equity          
Conversion of redeemable convertible preferred stock to common stock, shares     630,722    
Common Stock | IPO and Over-Allotment Option          
Redeemable Convertible Preferred Stock and Stockholders' Equity          
Issuance of common stock 2,300,000        
Common Stock | IPO          
Redeemable Convertible Preferred Stock and Stockholders' Equity          
Issuance of common stock   2,000,000 2,300,000    
Number of shares issued for the conversion of redeemable convertible preferred stock 4,117,089   4,117,089    
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.20.2
Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details) - Underwriters warrants
Jan. 31, 2020
$ / shares
shares
Warrants  
Number of warrants granted | shares 100,000
Exercise price | $ / shares $ 7.50
Percentage of exercise price to the share offering price 125.00%
Warrant term 5 years
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.20.2
Share-Based Compensation (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Jan. 31, 2020
Dec. 31, 2019
Share-Based Compensation            
Options available for future grants 186,283   186,283      
Options granted       0    
Options vested and exercisable 1,063,847   1,063,847      
Share-based compensation expense, including stock issued to consultants and advisors $ 629,017 $ 0 $ 1,740,289 $ 8,859    
Options outstanding 1,113,847   1,113,847     352,282
Options valued Black Scholes option pricing mode            
Weighted-average grant date fair value of options (in dollars per share)     $ 2.19      
Executive Officers            
Share-Based Compensation            
Options vested     50,000      
Vesting period     1 year      
Contractual term     P10Y      
Executive Officers | Grant 1            
Share-Based Compensation            
Options granted     600,000      
Exercise price     $ 3.13      
Executive Officers | Grant 2            
Share-Based Compensation            
Options granted     210,000      
Exercise price     $ 4.39      
Consultants            
Share-Based Compensation            
Issuance of common stock to consultants, shares     5,000 0    
Fair value of stock awards granted     $ 21,950      
Stock Options            
Options valued Black Scholes option pricing mode            
Expected term (in years)     5 years      
Expected volatility (as a percent)     80.00%      
Dividend yield (as a percent)     0.00%      
Stock Options | Minimum            
Options valued Black Scholes option pricing mode            
Risk free interest rate (as a percent)     0.30%      
Stock Options | Maximum            
Options valued Black Scholes option pricing mode            
Risk free interest rate (as a percent)     0.40%      
2019 Equity Incentive Plan            
Share-Based Compensation            
Shares authorized         1,000,000  
Options outstanding         352,282  
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss Per Share - Basic and diluted net loss per share (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Jun. 30, 2020
Mar. 31, 2020
Sep. 30, 2019
Jun. 30, 2019
Mar. 31, 2019
Sep. 30, 2020
Sep. 30, 2019
Numerator                
Net loss $ (1,006,354) $ (2,309,490) $ (441,590) $ (254,121) $ (344,700) $ (190,903) $ (3,757,434) $ (789,724)
Denominator                
Weighted-average common shares outstanding, basic and diluted 6,871,554     282,614     6,113,400 282,614
Net loss per share, basic and diluted $ (0.15)     $ (0.90)     $ (0.61) $ (2.79)
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.20.2
Net Loss Per Share - Potential shares excluded from calculation (Details) - USD ($)
9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Mar. 31, 2019
Convertible promissory notes      
Net Loss Per Share      
Aggregate principal amount $ 530,000 $ 530,000 $ 530,000
Redeemable convertible preferred stock, as converted      
Net Loss Per Share      
Antidilutive securities excluded from computation of earnings per share   4,117,089  
Stock Options      
Net Loss Per Share      
Antidilutive securities excluded from computation of earnings per share 1,113,847 353,565  
Warrants      
Net Loss Per Share      
Antidilutive securities excluded from computation of earnings per share 100,000    
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.20.2
Income Taxes (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2020
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Income Taxes        
Income tax expense (benefit) $ 0 $ 0 $ 0 $ 0
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.20.2
Related-Party Transactions (Details) - Convertible promissory notes
1 Months Ended
Jan. 31, 2020
shares
Mar. 31, 2019
USD ($)
item
Sep. 30, 2020
USD ($)
Sep. 30, 2019
USD ($)
Related-Party Transactions        
Aggregate principal amount   $ 530,000 $ 530,000 $ 530,000
Issuance of convertible promissory notes to related parties        
Related-Party Transactions        
Aggregate principal amount   $ 305,000    
Number of directors who purchased convertible promissory notes issued by the Company | item   3    
Conversion of promissory notes to common stock | Common Stock        
Related-Party Transactions        
Number of common shares issued upon conversion | shares 71,429      
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.20.2
Subsequent Events and Impact of COVID-19 Pandemic (Details) - item
9 Months Ended
Sep. 30, 2020
Mar. 31, 2020
Executive Officers    
Subsequent Events and Impact of COVID-19 Pandemic    
Options, term (in years) P10Y  
Alzheimer Disease Cooperative Study    
Subsequent Events and Impact of COVID-19 Pandemic    
Number of patients enrolled for treatment   14
Total number of trial patients   24
EXCEL 57 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ð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Ĭ=7#$!W_T,F0(U@G'@V5^ 2:QTQ?MXC"2AE)+?AH5V:0<9-NS2<6@= M2K;J>S@DC1;2N;\/=T#';2;".-^E9+_C0P+2MZ5K4GGS']@8WAO_"2/+V'3' MTE3( V#LIT+'[#!=)5F"%X%_L@(R>VV09J2-$YD?M4#'872.?C]S\_ MV8T(5:@,<5[+7N[I3D=[#PQJF@.C>5MDRX MFTAVB$/NQ'SZ(M8/(*0\:-MZV!6&!\A?0(&]X;@SE9Z4.^,GX#2R%Z)&;O=U M-X\A7< $G&\XA%]5Q-PU';T.;7O0-LZSWRG5RJWIUU@H"H &_LE2^C;]XNN& M?^?4->>?BP&/7V/XK=0*NLZF+\$\'/\"BQ\:NZ5?/2UMT]B:/FX4,"Z'#>#] MRMHF/N $Z7=P[_X#4$L#!!0 ( I<9%'MYJR/O ( .8& 9 >&PO M=V]R:W-H965T>B^WS:*7-@RT ''F2 M0MEQ5#A7GL6Q30N0S![J$A2NY-I(YM UB]B6!E@60%+$":7'L61<19-1F+LV MDY&NG. *K@VQE93,K*<@]&H<]:+-Q U?%,Y/Q)-1R19P"^YG>6W0BUN6C$M0 MEFM%#.3CZ+QW-AWX^!!PSV%EMVSB*YEK_>"=[]DXHEX0"$B=9V X+&$&0G@B ME/'8<$9M2@_?8.FGB//EVIA MPY>LFE@:D;2R3LL&C HD5_7(GIK_\"^ I $D07>=**B\8(Y-1D:OB/'1R.:- M4&I HSBN_*;<.H.K''%NM,R#P#QX32E>F:P20'1.4F;,FJL%689,3&4D]XEK%P-RKIA* M.1.$60OXRWV(X&S.!7<<+)&UN(PP]PR*1QFO0UH9X^GQ2'*[:Y?V2[TK@.1: MX)WT),YO-BF-7O(,,SMF<] 9=H<#VCVF)W_9'S\,DU[R9#3<&E\*N@"# M\;XEMINU]@!ZW*64[H0<[+HB\5;OD6 6H<-:DNI*N;H-M;-M$S^O>]>?\/H% MN&)FP94E G*$TL.3HXB8NJO6CM-EZ&1S[; O!K/ APB,#\#U7&NW<7R"]FF; M_ 902P,$% @ "EQD4<8_$I%@ @ 604 !D !X;"]W;W)K&ULI51-;]LP#+W[5PC>,&R 47_$:9LN"="T';9#L:#IMK-B M,[%06?(DNDG__2C9\3*@[0;L(I$2']\C;6JZT^;!5@#(]K54=A96B,U%'-NB M@IK;$]V HIN--C5',L24[CF@L5SJ?^;&GF4]VB% J6AMFV MKKEY6H#4NUF8AH>#.[&MT!W$\VG#M[ "_-8L#7GQD*44-2@KM&(&-K/P,KU8 MY"[>!WP7L+-'-G.5K+5^<,Z7JZ!Y."6JANY_N^#T> \^0%0-8#,J^[(_(JKSGR^=3H'3,NFK(YPY?JT21. M*/=15FCH5A .YTL##1BXZ#D6'4?V L>$W6J%E64WJH3R3WQ,>@?1V4'T(GLUX0J:$S9*(I8E M6?)*OM'0A)'/-_K?)KS"E0]?*7]).8U6V$IC>L*;GA6->[7F+GI<_P]NU MZ"\TT"#4:\I$?0JNH>B=- I,SLMZ].<_2 M[.,0=5 9I)-HDJ=!'J6C<; "DBKPB4:AT59@=ZO]QJY_/&UL MC93;;MLP#(;O_12"-PP;8,3')$Z7!&AZP'91(&AWN%9L.A8J2YXD+^W;CY(= M-P/:;#<6*9&??LJBE@>I'G4-8,A3PX5>^;4Q[448ZJ*&ANJ);$'@2B550PVZ M:A_J5@$M75+#PR2*9F%#F?#72S>W5>NE[ QG K:*Z*YIJ'K> )>'E1_[QXE[ MMJ^-G0C7RY;NX0',]W:KT M'2LD:$)I)0114*_\ROMAD-MX%_&!PT"<^*:&B'3?W\O %AGJFEE=(KMV7'/K89.&3HM-&-D,R*FB8Z$?Z-)S# M24(>O9&0# F)T]UOY%1>4T/72R4/1-EHI%G#E>JR41P3]J<\&(6K#//,^K(H M5 )M4%@,J$V/2MY +^^]>!9DB]0:F#9-(^]8-1,&%&ASU.=]>)6D M!>CLAIYL51&J31"Y"SPG)(2Y^Q2W'S- _2-/6F$0(Q#B5D<9#DUIK/ M9T$^CU\[\?#D\C:@]JY%-2ED)TQ_C\?9\16X["__2WC_A-Q1M6="$PX5ID:3 M^=0GJF_+WC&R=:VPDP8;RYDUOF2@; "N5U*:HV,W&-_&]1]02P,$% @ M"EQD43!Z;J31 @ 6@8 !D !X;"]W;W)K&UL MG57?;]HP$'[GKSA%>V@E1$* ]8< "6BK,:T3@G5[-LF%6'7LU'9*^>]W=B!C M$J!I+\0^?_?==V??,=PJ_6IR1 L?A9!F%.36EO=A:)(<"V8ZJD1))YG2!;.T MU9O0E!I9ZIT*$<91]#DL&)?!>.AM"ST>JLH*+G&AP51%P?1NBD)M1T$W.!B6 M?)-;9PC'PY)M<(7VI5QHVH4-2\H+E(8K"1JS43#IWD_[#N\!/SENS=$:7"9K MI5[=9IZ.@L@)0H&)=0R,/N\X0R$<$+P^L#_YW"F7-3,X4^(7 M3VT^"FX#2#%CE;!+M?V"^WP&CB]1POA?V-;8WET 266L*O;.I*#@LOZRCWT= MCAQNHS,.\=XA]KKK0%[E [-L/-1J"]JABF\1QZ2YE936=9Z&%J*Y3S"9,\[K7GC,[QW\$Q,N8%' MF6+ZMW](&ANA\4'H-+Y(N,*R [VH#7$41Q?X>DWB/<_7^Y_$+_#W&_Z^Y^^? MTTOMDU8"065T;U1$JR1"R78^Y*F"7N:;2\@J;7/4D"CJB10U\^^:&A/(#((G MU"MT:1O-I,6T[:V49LGD#DS.A*"'\XK>G"E![4CYGM &5GG,-T^HZE>?0E52 M,&=GUE*S.ZC+#5F2'Y'@N[-SF?*$D0A8N[;OM)X;P*,#M":%JNCC+H$JC@>R M14ZA8#YO?6K%=-=1%)V%.,S@9N Q3URX5.B42?C^,/$U6>*F$LPJO8-)66KU MS@1A=4T[KU&VLS."?UO/@#KZ?N M,],;+@T(S,@UZMP, M#U)*LW5I5^>JR5I5GDESD-?]0.0.>94O:P<0&:OY/Q M;U!+ P04 " *7&11H$[B,@\# 3'"1J M8F>V4[I_O[,3,EI:UB]PMN^>>^XY^S+=<7$O)2LJ8++@C C8S.QS_^PB MUO[&X5S6Q/$X(24J41*/X]P"64I09"&K\[3+M/J0,/ M[3WZ5U,[UK*F$BYY>5=D*I_98YMDL*%-J6[X[AMT]1B"*2^E^26[SM>S2=I( MQ:LN&!E4!6O_Z6.GPUL"@BX@,+S;1(;E%55T/A5\1X3V1C1MF%)--)(KF&[* M2@D\+3!.S1?8]Q]<2K($058Y%4 ^WM)U"7(P=14FT&YNVH%=M&#!*V 3M#( M@$:OD<2'DC4E$+[1%Z1("649R8JR49 1ABE+G;+&E/(X92O#Z0RWN0!XHJVU M0)>G.ZB5@FJ-65"P9RLM'_[XDP-KT50@J.+"6G04K??61]_!U^R$<330JR". M'#_PC1TZ29PX4=B>)..)DP1H7P'C>"\-T)UY Y!]H@\(O062\JK"IV?*E@1G M@E2H3<&VSK%2UL@9)[X3QY$5C -GY$>XX_NA$WE>O[,X4O,E).3G#?UXT!H3 MKS-&;2'!,)D,3O0][OL>O[GO787PF)8--H-L!*^(RHT"=:.HF4#HM[\5N^=* M'4OTTC7Y#Z%7>GX#&> HQT>-=!@F5(6V<8AO0 AD@U,FO7<(E?MSU/##NW'@ M!Y\MO !^XGCCB;727H37NA9I^:8WXRBQPCATXE%LW5$A*%-XY'EXB[P]Q$M2 MNP<3"Z_AULQEG;YAJAU>_6X_^L_;B??/O?UN7%.Q+9@D)6PPU!LF*))H9W&[ M4+PV\V_-%4Y38^;X^0*A'?!\P[G:+W2"_H,X_PM02P,$% @ "EQD4<;U ME_:,! 6!( !D !X;"]W;W)K&ULM5C;;N,V M$/T5PFC172")15JVE85C()?--D6[">*F?::EL4U$$K4D92= /[Y#29'D6&:2 M%LY#3(D\=%._NU'0BN?TRS4;6T QXB\! M&]UJ$SN5N92/]N$F.NMYUB.((336!,>?-5Q"'%M+Z,>/RFBOYK3 =OO%^G4Q M>9S,G&NXE/'?(C*KLU[0(Q$L>!Z;>[GY%:H)#:V]4,:Z^$\VU5BO1\)<&YE4 M8/0@$6GYRY^J0+0 U-\#8!6 O1DK;OATHN2&*#L:K=E&L5P%&@,L4IM9,Z.P5R#.3+]SDRL@ M1N1W\2,7D3#/Y-,5&"YB_9DWOAUV[X%80O[/1T&]['Q:I7 MC-4KQ@I[@_^X8@Z*04TQ*"C\/13WL(8TAZY0ETLBPQ7M,V7#@^R-6\Y>KX>]X>!R,QV./!=V.#FM' MATY'ORF)H3('92E>_"9+ M^P-1E\8$.SE /?O7';[3VH=3IP]?GT"%0@,NK0B[HWN M>D[:.V2%U&#UMM.'+2>(D<2LH,PE[%Z $NEROX-O4.%&.?&\GQWK15OE@CIM MW:Y!'9_'L31XO##D-K/G Y?E1M;HP72--L)&W;_X8 W>D:'!PMXHTW4+4XW M'0II9]B9QJ.=#'_^-9T%56 M7)XUPDC=RKB;D:[C2Z-\S#M4WK%&IYA;ISZ0=Y>5J:V\>Q7!\IC9-="5H*QU MIF-.=V>%TN\3^,L*W5[D/8<&UD@A%LMBD\H4Y2>X@:) M8Q1$@'?:>?S2881MXVT6BQ-V[M_5E1OMH/F4CKW@]'5TWQZX/=5&6ME;TMJ> MRK;_,L%Y2_5,4FE 'Q&1AG$>V7(+&)\H*HZE2JRYO0$?V29]C$-UD, MIK(O4F$$CTF6SV,1UN7[R+&)V>[QEM+ '^\DX)OCMB/4U +F/MR^VNH?+3JL MJ0=L=+#-W\@]<\O]1XI.9:H=TLXMW6_=L>TW%[Q4+D6J20P+!'HG8[2@RL\8 MY8.167'MGDN#E_BBN0*.N60'8/]"8L)5#_8F7W],FOX+4$L#!!0 ( I< M9%%YS*Z@L0( $@' 9 >&PO=V]R:W-H965T=I!DM 4W: M"[&=>\X]]R2^;]@&*FJN5 T2[Y1*5]3B5J]] M4VN@10.JA!\%0>97E$MOEC=G2SW+U=8*+F&IB=E6%=5OMR#4?NJ%WOO! U]O MK#OP9WE-U[ "^U@O->[\GJ7@%4C#E20:RJEW$UXO1JZ^*?C%86\.UL1-\J34 ML]O<%5,O<() +..@>)E!W,0PA&AC)>.T^M;.N#A^IW]6S,[SO)$#5+'QY0PS2_9M[5IZA&V-595'1@55%RV5_K:^7 M"),3@*@#1)\ 47@"$'> ^%\!20=(&F?:41H?%M326:[5GFA7C6QNT9C9H'%\ M+MUC7UF-=SGB[&S5/FZB2K+B:\E+SJBTY(8QM966RS59*L$9!T,N%F I%^9K M[EOL[/ ^Z[KMGQ' M!4AKADQMJ;*&ROW]=[/Q. FR8)3[NT/;CNO"<3KNBSX(37JAR5FA"RA!:RC0 M%EPX%Y@RPS);HO2@??!)X'%%G$W223HL,>TEIF#V$A5(=]JD/L7H'@J#EG9R^$2O M1F$2?Y+C'\26^\;\I'J-WA,!)0(1@K[J-K?;C55UDV1/RF(N-LL-?NI NP*\ M7RIEWS:P4 , /T* 9 >&PO M=V]R:W-H965TAS@HLJ3Z7%0K[92-528WMJFVH*X4T]Z"2AS$A:5A2)H+Y MU(_=J/E4UH8S@3<*=%V65-U?(9?[61 %#P.W;%L8-Q#.IQ7=XAV:+]6-LKVP M8\E9B4(S*4#A9A9\B-ZOHL0!?,17AGM]U :WE+64WUSG_>+N8-=6XD/Q?EIMB%DP"R'%#:VYNY?X3 MM@L:.[Y,?P$>0374IA"PTKDF#_&AU9HIS9^4'L5#Q)>4W4.270&,8DN>_0LAN%W6%DX M^&H8O,7M*_",SDF[K$L^7O&[K!IA''?/(,X^>8%Y0 M70 5.62N@=]KMJ/<<9_!@BIUS\2VF;AO"QKJU%.[:VHWGTQ&)"47TW!W;-9I M7#093[J@1\+'G?#QH/ E*BO573W &5TSSLS]"S2O&M;QL1:KF)!^-6FG)AU4 MXS=HYS=(;NSM=:H-J-8R8]1@;O/>%,"TKJG(/""38H?*L#5'J)0L[3>I[D%( M@[HO%],30^-T?+2&YHB?1D5)?!*V2E_ER$7GR,6@(_^@*O5S:SN#"E5FCYM] MJ+QQ3&>R%@:,A#4"K2K.K%^VU[#X-TL75/7;,JPH)N>$_#&0,Y-N:9-!HEO, M:J7<*?L)?^,..40#K)<=Z^5OSO&('&Y^\JM9?IBV+\-;WN=3O T&PO=V]R:W-H965TK:#"_)*NH99O"LHJ+.20+4V^9H!S#56EZ5A68%:8U$82 MZVR7(EU ,SB==X"7,03^L9DR.S M4\E)!34GM$8,BJEQ;5_=V1K0$3\([/C!/5)6%I0^J\%]/C4LE1&4D DE@>5E M"[=0EDI)YO&K%36Z.15X>+]7_Z+-2S,+S.&6EC])+E938V*@' J\*<4CW7V# MUI"O]#):P?P6L ;"_@MH*V;C7>]<"D6.(D9W2&FHJ6:NM&KKVFY7J16C3(73+XEDA/) M5X9K@1XA [+%BQ+060H"DY*?H\_H:9ZBLT_GL2GD3"K>S%K5FT;5>4?510^T M%BN.[NH<\A[^=IB/!GA3.NQL.GN;-\Z@X!S6E\BU+I!C.59?/A_#TV$\A4SB MML+MJ >_&SW[,?YF,=RNYJ[6D-2K)W))L*-0J!5E#?KVWB M.5[D.[&Y/:S$N+#T-"QT?2OTN[ W/OS.AS_"!ZDS6O5Z:&C_8%9_$D26>^3A M-$P:""RG/[F@2RX83.[[_;>!4H6=2OB_JC_I)"?#B5%!,D"T0-<[S/(+M-1S MX(IN:M'7[Y.3XMF1I7[]"Q1U>40?[L+HI#2]73@N+(W^J0MMZ_6K;'VH#UL\ M^%LCMG%C.]$^V#;LP01GC&8 .4<%HU53;][[G;=/2^T$3N@<+Y%YL(=5P);Z M\,!1IEJHV'.Z>&PO=V]R:W-H965TUDJ1U;RRP5+7)6PUH2U585E4_7P$6W<'SG>>"&[4HT VZ6-G0'&\#;9BUU MSQU9"E9!K9BHB83MPKGR+Y>)J;<%OQET:J]-3)([(>Y-YWNQ<#QC"#CD:!BH M_CS $C@W1-K&WX'3&24-<+_]S/[59M=9[JB"I>!_6('EPOGLD *VM.5X([IO M,.2)#5\NN+*_I.MKD\ A>:M05 -8.ZA8W7_IX[ .>P _>@40#(#@O8!P (0V M:._,QEI1I%DJ14>DJ=9LIF'7QJ)U&E:;7=R@U+-,XS!;2V@H*\B71WTN%"A" MZX+\Q!(D6;920HWD2BE 1]7/"* MW ::&0F]CR3P F\"OCP-7T&NX;Z!^_.7<%<''],'8_K \H7_F_Z$5CAJA58K M>D.+U:J5M,YA:O5ZBL12F OXD/F^Y\47J?LP(1V-TM&[I&&(.:7<,\3[RO-Y MY(_"_?9$1_XB/XRGW<6CN_BDNPWDK63XI&]?(Q3#*7?QD;LDBJ(#$]#;2PX<#]1IC=^?F#?W;OJ MYIG]0>5.GRC"8:MQWNQ"QY?]T]5W4#3V]M\)U&^);9;ZM0=I"O3\5@A\[I@' M9?S_R/X!4$L#!!0 ( I<9%&?$8]N?@( ,D& 9 >&PO=V]R:W-H M965TP[GW.M0N:9V&K.&EA( MI+9U3>7[5^!B-_4";[_QQ-8;;3?\/&OI&I:@G]N%-)$_L)2LAD8QT2 )U=1[ M#!YFJ;/"SG'K8"@(.A;8,U#Q>80:<6R(CXU_/Z0VO MM,##]9[]N_-NO*RH@IG@?UFI-U-OXJ$2*KKE^DGL?D#O)[9\A>#*_:)=ETM2 M#Q5;I47=@XV"FC7=D[[U=3@ !-$90-@#PFL!I <09[13YFS-J:9Y)L4.29MM MV.S"U<:AC1O6V"XNM32GS.!T_E@4<@LE^O9F[H4"A6[FH"GCZA9]0<_+.;KY M=)OYVKS)YOM%S_JU8PW/L"ZAO4,$?T8A#O$(?'89/H?"P ,+#^X_PGWC;S 9 M#B9#QT>N-'F!D@R4Q%%&9R@7]%T*SA%M2G.9.=6&?@4-5$RKL7IU;(ECL_^L MUSQ(HGN2^:^'91G)(D%,\)#V06LT:(TN:MW;9XT&"4HCZ.HPUIB.*3Y00!(< M!>,"XD% ?)6 5HH*E!T E*,*CAO152H^43!)HC@ZJM1I5H )P6,$G].9#CK3BSI_"VTJ2'NU,'JM.Y7I MZ8V*@G""CV2>IJ5I,DF/^^X?#!H[Y']1N6:-0APJ \1WJ3$JN\'9!5JT;O:L MA#:3S"TWYEL#TB:8\TH(O0_L.!N^7OE_4$L#!!0 ( I<9%%B?_TF=@, M ) , 9 >&PO=V]R:W-H965TSVI/52T[6<3!F)M8J>VLW2E^_$W=K*![083M2H?($[F M>6;&SW@R3 ]"WJL,0)/O1<[5S,NT+J]]7Z49%%0-1 D6\GY5%0Z9QQ6DJBJ**A\? >Y.,R\T'NZ\9GM,VUN M^/-I2?>P!GU7KB2N_)9ERPK@B@E.).QFWMOP^C:,#+> M+#YL9UY@(H(<4FTH*/X\P +RW#!A'-\:4J_U:8"GUT_L[VWRF,R&*EB(_"O; MZFSF33RRA1VM/U+_W>;,0) M(!R= 40-(.H+&#: 85_ J &,^@+B!A#W!20-(.D+&#> L16KWETKS9)J.I]* M<2#26".;N;#Z6C0JPK@IQ;66^)0A3L\7@C^ U&R3 UE)43"EA'PDGX0&15XM M05.6J]?D#;E;+\FK/UY/?8U>#=9/&P_O:@_1&0__4#X@P_ O$@51T %?N.$? MJ73"EV[X&DJ$!V?A-[WAX54'_+T;OH3T*?A.^&WOW'^$^ZAS*W;4BAU9ON%/ MB.V@'[;T0TL_.IOM1I,M4ZFHN.[:K!J>6+CID0_S*!HGT=1_Z/ Z:KV.G%X7 MHBBPIZVU2._)?^3#ZE]'*G%+&O^.G4I:^L09\Z>JV( D8D?2.GJ548D'#MU4 ML"55B;=2&X)I^5UGKN:/3[8R#">C<=#N97VV+IH]"W_HY"ET>A^06AKUKZJ]]11V%P;-^!,_ZW^[V$/=4F>L935N+&T^+, 5PV M9*-C<][6XOVSU/Z^2M%#K36FM,R92(!JP8320N._NGFV9RH4K" M8^<,H\N]S10NY5C+J5 :ZYBGE92P[0PL>K$SDR0ZT^K"8X<-?ZW%WH8=/3:) MSPIR;+*AN\O>X&&V4V,/3=Q,5X.)6Y-CCPYC]]FE*B,E?<3)&-7 L;R-K;/V MXQ<[\Z+L729UD/[)J&5F=7Q%[QE7)(<=8H+!&"ED/?[6"RU*.WUMA,99SEYF M^)&ULI55=3]LP%/TK5K0'D+8Z M7\"*TDCT8]JD(2$JMF>3W#86CIW9+F7_GFLG#072"FTOB7U]SSD^-_9-ME7Z MP50 ECS50II)4%G;7%)JB@IJ9D:J 8DK*Z5K9G&JU]0T&ECI0;6@<1B>TYIQ M&>29C]WH/%,;*[B$&TW,IJZ9_CL%H;:3( IV@5N^KJP+T#QKV!J68.^:&XTS MVK.4O 9IN))$PVH27$67B]3E^X1?'+9F;TRO>%FS/+\DRK+=$N&]G7+ISLK0:5SGB M;#Y3=(;O$P M,4'@"7N9@:%CTN+//=XULL<\"I-QFM''_>(/987AQ>NL^?NL)(K#\>NLQ?NL M.$W2%\76*-V[1S7HM6]@AA1J(VU;R#[:]\@KWQK>Q*?1Y2P:B,^QI[8M\(6^ M;<]TVN79B5>-O\;VRV!/\L,+_ FB7@.LKI>QNX@3Z M/TW^#%!+ P04 " *7&11:$Y2QV@& !$'@ &0 'AL+W=OX>^8X4QX]"?LLC $5^)'&: M7_4BI;)W_7X>1)"P_%QDD.*;I9 )4W@K5_T\D\#"TBB)^]1Q+OH)XVEO,BZ? MW=6;NN]N_*$V*%O\S>$QW[DF.I2%$-_TS=B!T#VF5 :P/ZU,#M M,/!J ^^IP:##P*\-_)?V,*@-RM#[5>QEXN9,L943EH9D)E+%TQ6D 8>,LVQ'/?$NJX].O#G+SYK2VJF1WDLUB?$\_1*,ZH&V5N1WF ;(M"G1J% M*TA:D&[L2',(SK=17;;ZLY#@4+J-^ ^B6HWP$Z#0)90$CB M&CQCFQ;H*G\5TD6)I 5P/?%&GN>-^^O=W!RV&C@7CN,TS?;\'#1^#JQ^'@1/ M?I(/0O)_4>R^1"!9!H7B0?Z6W'V:6?)RT?1W<;ID#QO0H36(OU(X4RCS)!7I M&0IRD89L$0-9 K2-^F%+)CL3.6I\&%E]N.4I3XH$Q28M6$R"1G_:/!@=>.!W M>W#9>'!I'W+8&ZK'H;2]DE+7,5KKG(Y4=T?"76M ![P=6&+'G*L+2DJU9_Z($_U'&Z"7>- MU:.[6E4(3_4O9XKG2U8M5="YL$P@#HDZ;5LQ,NEKU:.ZT\%N_OQ1M[M& M$]W3B:+[,E5L:6:31=?HHFL7QL]%L@"ILYCP&'"]DN*Z@041AS5&\)-TE+!Y M#;N;O"Y?C&:Z%W::06+"%"YPM3\I+K-SACZ1(D=7E" !BX,B9@J(%!L6*[W$ MP=SJF=/JHKVWP?EP\+MM AM9=NVZO.\W#L2B&IHX5 \<)7Q)5,1E>)8QB3-J M.T9XCH8XR63'NLKNP< Y=QQK,$;?7;O [P>3%XO&PQ3G$V@>%GI(\U#'Q\*0 ME['BXRK6C7VXVSN_/*?V,$R1<.U5 L/@(B2X%4,?URA:NFIB.2BC4B!1:9EV MO-5)._2E0T*VL6D_-26%.G:M14^T1]LDLVUI:5V VK%U%Z M597%=S<_ULBLDJH\8=D+#'YI3+C'J4"Q)9++G-%[B+<,I*/ M'TF WG"<[41)SF);/*:H47JZVDU-9:+VRG1=[,682>RFE3JO?3'6H9G4U!KZ M3*TY.4\8 _*DY?88DLK=9V.J(C@PU\_V(8XAVA0T.C@AT:8V47NU>#'1%P=U MT;4M@JBI,M2N\?\;T\]3O>388*4M&?D\GY)'KJ+RQ?OYU)9]4Y3HZ(2DFB)! M[4K^8E(O#T@=V$CUC/Y[=LW^M3+;QHVNB&8JUG5'\RGTLL7VG<'4#L\]'5N> MD7#/OB]Y*5LUS"Y;(RM;.U]0[&K_6K9F3^;7=F;9TF(J@.>?,-M&1SW[QF#: M[/V:C<%V9=>:],/] /4L.3?"Z]F%]]0YMR;=B+$W/&'2CK2 M<-"==".,WB_XQH+OWANQ21NUN8>5WK4)N2'3#'5FC27D#3[7VQV\UJBXD[@I MI,A :]>?+&.I[8NG;^35/^$7&]\(G/_ M[B$ GI41M+&#=.@2\37%W7]('A1NN:V),P+JG_(;],Y'Z.<6P M4^:XAL7>JI.CYFES%#HM#P"?/+]VW\VJ TT#4YVOWC*YXFE.8E@BI',^1-9E M=619W2B1E6=R"Z&42,K+"%@(4C? ]TLAU/9&=] <'$_^ U!+ P04 " * M7&11JT,%E8RK*$O#VM9DJ6Y1< 5;0VPK)3.G%0C=+:-I=%YXY56-?H%F M:<,JV &^-5OC+#I2"BY!6:X5,5 NHZ?IXVKN_8/#;PZ=O9@37\E>ZW=O_"R6 M4>P3 @$Y>@)SPP'6((0'N33^#LQH#.F%E_,S_7NHW=6R9Q;66OSA!=;+Z%M$ M"BA9*_!5=S]@J.?>\W(M;/B2KO==S".2MQ:U',0N \E5/[+C< X7@F1Z19 , M@B3DW0<*66X8LBPUNB/&>SN:GX12@]HEQY6_E!T:M\N=#K.UEI*C.V6TA*F" MK+5"KBI0.0=+OI)GV0A]\OODJ3( O>?=!I!Q83^G%%T2'D7S(>"J#YA<";B# M9D)F\1>2Q$G\MMN0NT__4:@K8:PC&>M( G9^!?M\A+SU%TQ^E27/P=@;T-D( MG07H[!KTH^)O<.7QRG]'"9#;UH!_^R7IBIN+)$0.F$\>3A/B*F[];>0-V$#MEK=/T6 MIK5[X&"\@]LOM<:SX9MN_&5D_P!02P,$% @ "EQD4:J-J,B1! XA8 M !D !X;"]W;W)K&ULQ5AM;Z,X$/XK5G32[4IM MP2;D995&ZC8;74_::]7H]CZ[,&E0 ;.VD^RN]L>?#033 BZ16B4?$D-FQL^, M9YZQ/=LS_B0V !+]2.)47 XV4F:?'$<$&TBHN& 9I.J?->,)E>J1/SHBXT## M7"F)'>*Z(R>A43J8S_)W=WP^8UL91RG<<22V24+YS\\0L_WE \.+^ZCQXW4 M+YSY+*./L +Y;W;'U9-360FC!%(1L11Q6%\.KO"GI>=JA5SB6P1[41LC[ @JV0+"F5%8(D2HM? M^J,,1$W!FW0HD%*!O% @73-XI8+75V%8*@Q?0NI2\$L%OZ_"J%08Y;$O@I5' M>D$EG<\XVR.NI94U/7J0PSHFJ4[X#+2 MXSNUOL YA&@E6?"$:%J.-BP.@8L_T9?OVTC^1.=*+4ETBBB)EUH?%B!I%(N/ M,TR@DP9<0LC/1Q;VLTM(#A@PE.[.4>E2)4GI,H3 MDMOWWB=/+ B\"H&7(QAV(/AGFSP 1VR-@I@* 4(/13YK"")Z3*E4,'XCG2AM M^598]W/KFF]W(_RH0F;RI0UC,=.XAM&] M4 !QA;!(]WYBRU?%GOD[JOP=6?TU>?@F+H_ZN=Q/;/FJV#.7QY7+X^/2KU?" MC9L)Y[](N,*WOH++IB!VL=^=PI/*OTE/_XZLJ4FST%L]["FW;,IU>#:M/)OV M]&RG&AM2VT,$--@4WM47-">WWTBWOS9'I\W(MP/#KMD-N%9H*^"1"O 5JO%] M4./[['F=66@=UW8@^$2M!9ONALDK?*DGSK?+*OZ\E_-(LF/Z2+8WD8.ZW:.WZ#F#;?CR:G6S+ PMM/P MN]=\DY]'GCLF'=M.8DB:V$GZZ)(O[4V>[4#&'3 ,;Q/\MIGS:LV3VFGD5,<1 M8IB7]&;>=ZEYTCRQ6//'4#6Q4W5Y.%B9-6A(E+X5:3T;EQN#D5\7'6W M7CNX#0^&&(_=R?2%JST$"U>=VFV?OOW]2OECE H4PUII*F)7)GAQH5H\2);E M%X /3$J6Y,,-4)4 6D#]OV;J@%$^Z#O%ZEI[_C]02P,$% @ "EQD4==3 MCE!H @ SP4 !D !X;"]W;W)K&UL?91M:]LP M$,>_RF$VML$6.4Z=EN(8UH>Q#39"2]?7BGV)167)E90XA7WXG6372\&)7U@G MZ>ZOW^GALE:;)ULA.MC74ME%5#G77#)FBPIK;B>Z044S:VUJ[JAK-LPV!GD9 M@FK)DCB>LYH+%>59&%N:/--;)X7"I0&[K6MN7JY0ZG813:/7@3NQJ9P?8'G6 M\ W>HWMHEH9Z;% I18W*"JW X'H1?9U>7LV]?W#X(["U!S;X3%9:/_G.CW(1 MQ1X()1;.*W!J=GB-4GHAPGCN-:-A21]X:+^J?PNY4RXK;O%:RT=1NFH17410 MXIIOI;O3[7?L\TF]7J&E#7]H>]\X@F)KG:[[8"*HA>I:ON_WX2!@=BP@Z0.2 MP-TM%"AON.-Y9G0+QGN3FC="JB&:X(3RAW+O#,T*BG/Y'99(Q[R2"-=:[= X MX>TE[0T:@R7<.UT\ 5>]56E9HK$?X/9Y*]P+?(%';@Q7SL+'&W1<2/N)!A\4 M>;5&./*%MO?(F"-BORXK>KJKCBXY0O>3JPG,II\AB9/X'3"P%3=HN_];.4:) M#]DG0_9)T)\=T7\<)7LC-1ND9D'J[(C4[VV]0@-Z/:0+&]_0%OZ%,> N_TXT M#:+^ >WR:>R_C.U&8,X&F+.3,+=[-(6P"(T1!1+ _[T;@^C$+@X@SB?I.$$Z M$*0G"98$@,K1N_9;@F]YG 9780=$TW33A-IT:)NDDCM^?.,+YP#P_ MJ=3?!J!+6X]QG(Y.X06Y&;U*[.!]^E+WBYN-4!8DKDDJGIQ3AJ8K'UW'Z28\ MV95V5 ""65'%1>,=:'ZMM7OM^"HPU/#\'U!+ P04 " *7&11C_\^3] % M !)&@ &0 'AL+W=O2 MB\]WKOG.B3/>,?XDUH1(\)PFF;CJK*7<7/9Z(EJ3%(LNVY!,W5DRGF*I3OFJ M)S:5Z_EV*:=29C<^V>3\8LEPG-R#T'(D]3S%^N2<)V5QW8>;WP M0%=KJ2_T)N,-7I$%D=\V]UR=]2J4F*8D$Y1E@)/E5>63L29]\B:\ZGK:()"22&@*KGRV9DB312,J.GR5HI]*I!>O'K^@WQGGE MS",69,J2'S26ZZO.L -BLL1Y(A_8[B]2.A1JO(@EPOP'NW*MUP%1+B1+2V%E M04JSXA<_EX&H"2B<=@%4"J!#@>"(@%\*^.=J"$J!X%P-82D0GBO0+P7ZYPH, M2H&!258179.:&99X,N9L![A>K=#T@5'#OF>\K1R%[VZ>XV<@ NRZ0+?^PB0A[P6>Z9GB\-1FSMO MTSY_F_8;M_C?.%/B\*CV6[?XC$2OXH?:]U+A5Y7G&SS_%RO/ 1U4T(&!#HY M?]UH( 'P5E4P?DP(4)P-EKG,.0$KCC,IVFJY T-J*;P[00.^VCHCWO;>HY/ M+MNS.:QL#L^RV9C7^JS,PX9BKUUGO]+9/TOGE@BE$N L!N29\(@*';2V$/6; MOGM]?Q@,#F)T>MV>P8/*X('3X*)F'DW-1'6V(L_ZF'P$-(N2/*;9"BCJC)X M%2)7BR53ZS.A^I-.OO$4QULJ&&^MA,**?LW\/AIY\,#+:7.9=Q"'Y@HX"#PT M'.VOFS?7#8?AJ#U8PRI8P[.RJP80H=S606GS==A,%80M*3USW6USG1\B-$3M MSHPJ9T9.MJA*%2,X \S MR)#X$]X2K@:SXN$$,9:*43#EA36 +4L+!+B@&8A9DF NP(:HD4\7;%OCG)6J MA[4XH2X\DG)8:^?0:?+\F42YGN[ U^621N2POO=AD85%[TW6T#8"Z/\"#;4& MRV\45>BIOR/1LGT"NAO%=Z515XQ*%67MFMT $+P0S%U1L/P/W0U@JB8=KB;S M'"= $IZV6N.&N(?>/RY;;%^ [L;0K"+P'[@UQ0]="BR/P\&[UY/E/7@>\1UO MI3/89*F^YZ@H2U-P="IRNG\20T9M+716 M0??+\+CTP/R'(5^>(4L)R$T)7]0@A;/(=#LU>J6JWQ83UOYH];%H>6U3U0PUI\*P MGK_R':BYZEB*+=T@]]QXL]>L"[OQ#O/877'-J0S!47C,&LM/R,U/"Z._+'E7 M<$5%B(NLRR/.6?FH!*L[8L M4>6?4/D"+K":^767CT@FVPUT@PZ]KN?]Z;+/4IWOIKH9W=*8J!>0%TJ2^!S3 MW'@G+:N]D+N)<*\N5?>XHQE-\]2%;;G.#WY;A5I"]-WST ,53V#)"5&OA:I( MU; 'N)[=SXBY&]CK^NZ86UKUW;3:B#E^/A5SRWJ^>\AZSYA;_38=)]@Y]Z3Y<7 >_>-+7.:>T_A)FC.:JV; +W:QG5*^,I\DQ!J MGL@S6>PD5E>K[QZ?S6[_P?5K>#F%+==G\')>?-6P\,5'ECO,5U1YDI"E4N5U M!\I87GRW*$XDVYAM\T&ULI59=;]HP%/TK5K2'5EK)=T(J0"J%%J9UJHJZ/KO$0-3$9K8IW;_?M9.F MD)DTVE[ =LXY]OVP[QWL&7\1&T(D>BMR*H;61LKMI6V+Y8846/38EE#XLF*\ MP!*F?&V++2P"9]0:#?3:/1\-V$[F&27W'(E=46#^>TQRMA]: MKO6^\)"M-U(MV*/!%J_)@LC'[3V'F5VKI%E!J,@819RLAM:5>SF/%5X#?F9D M+P[&2%GRS-B+FLS3H>6H Y&<+*52P/#W2JY)GBLA.,:O2M.JMU3$P_&[^HVV M'6QYQH)UGI+(G5'I+E@O]B_8E-@;P\05&M340&>09D/,,ZIR?2$Y?,V M)T<_X#I]9T*@>\+18H,Y01=HC$6V1)BF*,WRG20IH@#+%6P+,*%A9Q,B<9:+ M';X(K: M']Z[/\9>J^"";'O(=[XBS_$(< R<&8!"X81,W-0F&@>NY MQ[@; \X/@MAIZ-V:+$F&X QOTD]CYP1]$(ZVB$K9&= M$,K@)?TDME&M%K7&]DF74Y)>X%?(ES5!2U844,7U(RD0M!="PDN:T?57596/ MWU530I3;A0=61_W8#9OY,/T;Y_6]R&W 9@8YU_6#9O3FG\H=>2>NO1-WROR/ MNM'1"Z5L_S#V3L\-&SXPHI*&!XR@J)'E

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

&PO=V]R:W-H965T&UL4$L! A0#% @ "EQD4?6MWU$[ @ 7P8 !D M ("!G=D 'AL+W=O&UL4$L! A0# M% @ "EQD42\/3JM @ P@H T ( !'N( 'AL+W-T M>6QE&PO=V]R:V)O;VLN>&UL4$L! A0#% M @ "EQD4;@VQ-RI 0 +AL !H ( !L.D 'AL+U]R96QS M+W=OL %M#;VYT96YT7U1Y<&5S72YX;6Q02P4& / #4 -0!J#@ =.T end XML 58 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 59 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 60 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 136 280 1 false 41 0 false 6 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://annovisbio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 00100 - Statement - Balance Sheets Sheet http://annovisbio.com/role/StatementBalanceSheets Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Balance Sheets (Parenthetical) Sheet http://annovisbio.com/role/StatementBalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Statements of Operations Sheet http://annovisbio.com/role/StatementStatementsOfOperations Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Statements of Changes in Redeemable Convertible Preferred Stock Sheet http://annovisbio.com/role/StatementStatementsOfChangesInRedeemableConvertiblePreferredStock Statements of Changes in Redeemable Convertible Preferred Stock Statements 5 false false R6.htm 00301 - Statement - Statements of Changes in Stockholders??? Equity (Deficit) Sheet http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit Statements of Changes in Stockholders??? Equity (Deficit) Statements 6 false false R7.htm 00400 - Statement - Statements of Cash Flows Sheet http://annovisbio.com/role/StatementStatementsOfCashFlows Statements of Cash Flows Statements 7 false false R8.htm 10101 - Disclosure - Nature of Business and Liquidity Sheet http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity Nature of Business and Liquidity Notes 8 false false R9.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 9 false false R10.htm 10301 - Disclosure - Fair Value Measurements Sheet http://annovisbio.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 10 false false R11.htm 10401 - Disclosure - Grant Receivable Sheet http://annovisbio.com/role/DisclosureGrantReceivable Grant Receivable Notes 11 false false R12.htm 10501 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 12 false false R13.htm 10601 - Disclosure - Accrued Expenses Sheet http://annovisbio.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 13 false false R14.htm 10701 - Disclosure - Convertible Promissory Notes Notes http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes Convertible Promissory Notes Notes 14 false false R15.htm 10801 - Disclosure - Commitments and Contingencies Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 15 false false R16.htm 10901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity Sheet http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity Redeemable Convertible Preferred Stock and Stockholders' Equity Notes 16 false false R17.htm 11001 - Disclosure - Share-Based Compensation Sheet http://annovisbio.com/role/DisclosureShareBasedCompensation Share-Based Compensation Notes 17 false false R18.htm 11101 - Disclosure - Net Loss Per Share Sheet http://annovisbio.com/role/DisclosureNetLossPerShare Net Loss Per Share Notes 18 false false R19.htm 11201 - Disclosure - Income Taxes Sheet http://annovisbio.com/role/DisclosureIncomeTaxes Income Taxes Notes 19 false false R20.htm 11301 - Disclosure - Related-Party Transactions Sheet http://annovisbio.com/role/DisclosureRelatedPartyTransactions Related-Party Transactions Notes 20 false false R21.htm 11401 - Disclosure - Subsequent Events and Impact of COVID-19 Pandemic Sheet http://annovisbio.com/role/DisclosureSubsequentEventsAndImpactOfCovid19Pandemic Subsequent Events and Impact of COVID-19 Pandemic Notes 21 false false R22.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 30303 - Disclosure - Fair Value Measurements (Tables) Sheet http://annovisbio.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://annovisbio.com/role/DisclosureFairValueMeasurements 23 false false R24.htm 30503 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 24 false false R25.htm 30603 - Disclosure - Accrued Expenses (Tables) Sheet http://annovisbio.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://annovisbio.com/role/DisclosureAccruedExpenses 25 false false R26.htm 30803 - Disclosure - Commitments and Contingencies (Tables) Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) Tables http://annovisbio.com/role/DisclosureCommitmentsAndContingencies 26 false false R27.htm 31103 - Disclosure - Net Loss Per Share (Tables) Sheet http://annovisbio.com/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://annovisbio.com/role/DisclosureNetLossPerShare 27 false false R28.htm 40101 - Disclosure - Nature of Business and Liquidity (Details) Sheet http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidityDetails Nature of Business and Liquidity (Details) Details http://annovisbio.com/role/DisclosureNatureOfBusinessAndLiquidity 28 false false R29.htm 40201 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies 29 false false R30.htm 40301 - Disclosure - Fair Value Measurements (Details) Sheet http://annovisbio.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) Details http://annovisbio.com/role/DisclosureFairValueMeasurementsTables 30 false false R31.htm 40401 - Disclosure - Grant Receivable (Details) Sheet http://annovisbio.com/role/DisclosureGrantReceivableDetails Grant Receivable (Details) Details http://annovisbio.com/role/DisclosureGrantReceivable 31 false false R32.htm 40501 - Disclosure - Prepaid Expenses and Other Current Assets (Details) Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets (Details) Details http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables 32 false false R33.htm 40601 - Disclosure - Accrued Expenses (Details) Sheet http://annovisbio.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://annovisbio.com/role/DisclosureAccruedExpensesTables 33 false false R34.htm 40701 - Disclosure - Convertible Promissory Notes (Details) Notes http://annovisbio.com/role/DisclosureConvertiblePromissoryNotesDetails Convertible Promissory Notes (Details) Details http://annovisbio.com/role/DisclosureConvertiblePromissoryNotes 34 false false R35.htm 40801 - Disclosure - Commitments and Contingencies - Leases (Details) Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLeasesDetails Commitments and Contingencies - Leases (Details) Details 35 false false R36.htm 40802 - Disclosure - Commitments and Contingencies - License Agreements (Details) Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesLicenseAgreementsDetails Commitments and Contingencies - License Agreements (Details) Details 36 false false R37.htm 40803 - Disclosure - Commitments and Contingencies - Employment Agreements (Details) Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesEmploymentAgreementsDetails Commitments and Contingencies - Employment Agreements (Details) Details 37 false false R38.htm 40901 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details) Sheet http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityCommonAndPreferredStockDetails Redeemable Convertible Preferred Stock and Stockholders' Equity - Common and Preferred Stock (Details) Details 38 false false R39.htm 40902 - Disclosure - Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details) Sheet http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquityWarrantsDetails Redeemable Convertible Preferred Stock and Stockholders' Equity - Warrants (Details) Details http://annovisbio.com/role/DisclosureRedeemableConvertiblePreferredStockAndStockholdersEquity 39 false false R40.htm 41001 - Disclosure - Share-Based Compensation (Details) Sheet http://annovisbio.com/role/DisclosureShareBasedCompensationDetails Share-Based Compensation (Details) Details http://annovisbio.com/role/DisclosureShareBasedCompensation 40 false false R41.htm 41101 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details) Sheet http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails Net Loss Per Share - Basic and diluted net loss per share (Details) Details 41 false false R42.htm 41102 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details) Sheet http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails Net Loss Per Share - Potential shares excluded from calculation (Details) Details 42 false false R43.htm 41201 - Disclosure - Income Taxes (Details) Sheet http://annovisbio.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) Details http://annovisbio.com/role/DisclosureIncomeTaxes 43 false false R44.htm 41301 - Disclosure - Related-Party Transactions (Details) Sheet http://annovisbio.com/role/DisclosureRelatedPartyTransactionsDetails Related-Party Transactions (Details) Details http://annovisbio.com/role/DisclosureRelatedPartyTransactions 44 false false R45.htm 41401 - Disclosure - Subsequent Events and Impact of COVID-19 Pandemic (Details) Sheet http://annovisbio.com/role/DisclosureSubsequentEventsAndImpactOfCovid19PandemicDetails Subsequent Events and Impact of COVID-19 Pandemic (Details) Details http://annovisbio.com/role/DisclosureSubsequentEventsAndImpactOfCovid19Pandemic 45 false false All Reports Book All Reports anvs-20200930.xml anvs-20200930.xsd anvs-20200930_cal.xml anvs-20200930_def.xml anvs-20200930_lab.xml anvs-20200930_pre.xml http://fasb.org/us-gaap/2020-01-31 http://fasb.org/srt/2020-01-31 http://xbrl.sec.gov/dei/2020-01-31 true true ZIP 62 0001558370-20-012511-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-20-012511-xbrl.zip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

PE:H%CX\@$I"<9Q&&WNP_H;-5K;^H1H9VFQDD76 MHG=,/V0F=Q^TX8EAF7?,^G$SM/?/F#4_ZS)-+I&/N$&])!D,:9ZW2%UKC(2X MROC/WHCP:#R@AS+SY"G=2H^ZW(>!FV9);)I .%5ZJN+6K!D/P971+/I'#)+I MBP.#.,F/9_(]L=N@,:A9& -MB \.+ 1%:T U-& ME9[BI35KMCZ75D^2CMW:6J+TG8?\B)5"78](4^HI#E1SK.TEM3UGEY=;3!S5 M%Q/4]/+]6#D,(K^\;(YS5 #Y5E$IY3FN3\ U!^YK@%;L@)E"1F>3I0$W.3@8 M'QF^D"J;?7[OPK$W5\E6%!>;@GFXB^8Z(/-O%VY#%O0HM4M1;#Z-8ZG.GO0T1J5A+[+DU2IH MFJ1$,30;=1NLUDE,Y#@6F]3J->S%3&LU,Z CR/^ @7(D#92C#PX4%O_&SZ&L MWD2ZXV0?T-VLO9"UP-/:I\PU'*L9]^[V&[8Q8/2RH:,B'D3QM&[9)<=F>33L M6TN!L:'^)R!E "DJ0*TI Q!\@I$2 SX@8^"0J@!3H*U/N'7#+\V8M.<+,"4 M)=Q%_EZ!YZ3IZ(YF _DU*W(\&9\FWRIV)XL4T/*1QO-4\;(RH MI-[OVW\O/D= >038I(;]Y)#0%TM'LF6DP<4.F?1DHNB.ZU%TA-YH1U!_^!S% M6)".Q 7.>&\#"]BC#H<1,>I3?/'Z!>0OZ&(_F?)S(5>%X(MJJAJR MQGI)PJ+YB36M4K$W=&F.&I@M"@PQ @<:RUJ#@CVKM(XEZE)QFP3#/ MYR2I6 66>3SCON5=F$=4 U-CEJEZK6 PKIV5AP M[8*6JR31TO2G$WG3)5ZHBBQ>&JI9AS3M"J_8R[8R&F(R_JHL+ID'6I3296F- M#\8GYQ\&46U$H]4 '2DR0+=(3$ORGD#*6I.UJ9;YR$ 0%XC6X"%5&^W%K-MT M -1+?7@("(I$ZVGA'C:-'R*P"LCM))_4=Y*S M1D9Y*R,G\$:DG5'6T"AMJ2\WM/-D'R15PZ6S@HGCP[^ ES&:2S$3'V^[6AE5 M,P\AD,ZAI>DZPMDK*+Q5BUEG7Q2IM/SB@0#/6F+_C#SMBL53-B=L+Y1>X2. M0Y+[@03T9V>ZFRNP"F/J>TV54A\!#B(L&T\"1?4QBRBN$&@$= 'J(B3X'(@CF8GL(0H7((X)"S> 9RO8E88'BQ;\VNIC;F7A MXLD[SYS)\":9%8:CZI:\VII)M%$.N75#'V6]!#5$APH7I?)0=>]@CTL,>D"Y MW&KCK+[:*) >[6B/"/&^K#SPM2F)S>OFPF:N>3XG.%8J6I,C($:,=$-)ZP8[ M6PWE&Y=BW-@;C7H7!B_(#BTQ)S@FDQ&;W%342MV):*2N2V'V^J-,9D*QYL+6 M*518+7R-,C@6-9Z]3-T6 > .(L#T?\3T@V)PD@3VU^&RU48 MD)@-NEEGUK$.#^WMNSR?]B:4K+# M/.-9:W3J[QV&K9IA3D=R'!'K"[#@+Q9 MP3'UE7+6J5]<=4U67H2[@:C\:?T<0P\ZT:;PQCK+NM/*6P>!#I9=BD?&AJMA MJU[H_;VS1!\+L91,$\^O:)VVY736H/-V+ _$"MP^S)@&?_N[?7IOI[>&$S@F MBP/1<]DFWG&NU5%*6X>!]I9>AD.M@>*&9H@R_S>."QIOM/&*6XX(MEYYJ."P MJ?4RFO0=(AVPR ^6'M&*BBRKO%VV'B&@L B497HR/AJ?#0WZR;H'T%C6.@O1>8809]/>J/)')'8D,ORR MV15^!C5A!%A/+[8<.X4**%M'6S$M5Y'C#Z) M#!)AW&L.2FA;AS!]*%&*2(X$!^(95UTA\GH.,SZ+46-(4..HOV%!)2D7XP"B M;!@V\C%=$E?XN[,Y/!@?TI/V"U?^D%!1("([,W+$45(P.>A?57.#OD(.Z1H? M_"!5)!L6-EZ2%'-[N[\CI+I'L%JCL>$48%OEI-&1D:I;EL/I M^.CXR(R2I115UF\W9FV=$OX#(>ZO,)@CS#LKL$Z@&S_X+GT68)6W2LO=U%4Q M[-)<&U>W&A=2\1MA!B&A8@TLSJ&]EWDL>.;+ A2(:[*. A6\&S+" M):S,%@_8>LY_AO39@%7>.J6K4%SM+%^2_SXI'E4 J91?@.])OC(R;I8)"I_Q&@T5D>MJ9?? 0O:Q^7 MWB">HA#Q\2. "?#(M91FGT&XWD< 1FLYV)JHL<[0;)W$T -M<4&M_C'A(2<. M#6'U^]J'VF9:>7(!$B0,*7N(C>6LPT;;341Q[A@&P< N8M[='T&\ BY<0.!1 M=PVI9:W1HIPF*AJ4XL[6]4#.Q<5Z@RS0C'3K=G']#B(7QL";(3]FNDA2B.]\ MX!L8Q4F^"KI$K2"GQY]'T/'I,X">ENR"DA0D*E/"'N734S ^8(,W#T4%@*9J M7@V\BE,#W[WU[<, WJQ$;5W =Q1:300[L=&7LC]^B7^Y"4/\F!'YQ5LB CCF M$/^H;<3HZNKG #(A8%OW.41G7;I$;L*("#6+"<&/;WAKE[&'IKG)#X-O+8(R MOOVB)Q3^CI.ZBUK>&C2I.->5XU)KZ@+I);M@I!_M83AV8>NUS-84)SJ/S::B MQ9!/O2';];'-['4?9,NJC-V'P2-8K ,/CX'L=O -:+S#+4_%&DRTT&D%$(J8 MUWJ;3A5:+C2D M2<0PUCO@@DMDP AIQ[O6;&S221]%+PV@TO%KZ'MI-LO9(DV2GN:?0PZWT-T! M#HT!(Z45ZUJ3L&GP2/*DA!GS!8^-XX30*PX($NWYU;KV4(4#;4]TGA\<'(S/ M3@TE!>ZN=WD^>Y$JK0#:[] '<1(&.7.TP$%*\0'I6I9+12G']([LR_42AZ? M-W"_QEMEL\66MWB*Q C>=BDU2BH7J#+^2N,O =\O2LC<1L_ N1>1\UF24<['P2#2L63;Z =]&$=W"B.)Y)[D; : MN.$2S,,+@%/@W@93SX.8FWF8RFF3NWVR@&S1Q ?!HBK)Y#"T>R.W>.J9_DE- MT$HI.B!8R'"8J[=?.[-IFN/98NJ]X><=[L,$%9@M<&8)&! EB>RW\:D,"!2* MF,_QHF=W5A=>,%>(U?R?0INQY2H#1H((I[G:->^U&DF.>;U<^2&9 =OGQSR2 MS8^Y:_0S1::M*3*?W%?DT.,G$/,-:?SF+1H[V3C?7FOZ$R:OMX$'WZ"W=OSK M=]=?>X@;DH;_PL$.6N9AX:#!$+$$$N3VXV\N0 6,,%YWC"89HL=&50VS?[6 MW#PK7Z?]'2\;F?'X^&QL-H:F<_+0GLI\;WDFA2Y,U?EJON[66,XZ3/44$CML MRXG:T&P(M5%D&AP33=F*@]?.:VNSV'?>5Z'UUP!KL#F;V MM$2'U-!+"P<4+2!?MKIU8#:, 6E0LB6YGY=2.NX!?G?>2 - M1'BKDW76Q*W4-V2Q%5G9&6S'_7XB_?5M#3X"#X E-NBE-^:ROI,G%M&P(W_C M"%74S30X%6\9(%GC>Z#%LG);AY/Z0VN[_HP*'1IM6QF19LBN8K%3_SI*NY5M M/H8!*5&MU9,=QKJT\5-_G-F!5\GL'B+IW<7FTG=BYF,[C!K6&1\Q-35ODXEQ M9^\[*-M4.%MKL H#8G'IV8"9=>S3KJ2N&K0MS:^]^JZPP'S'IK&L??J5UDY= MP^*<&M\28 1JAT$^S9?GZSYS5ZP7M MTZJ43AH&MQB+QD&<\9T 4E'MNW*!:'(3U@_Q]"#3K3!EY $_ 1:>>N HL!/D.+5 MWD>""KW'[V3-%H5LYDR_@5_1/JU+Z:Q!Y^U8MM6OR'(=/9 [-;,%Z@H,7M R M:H:,W]3W0Q(XF%ZUH,\9TD3L0T4[K58F$35R, X5-4;E]F'&W%78_FX-&!3J ML&XWV.P.1.=%WXL7 -18UAHLJ',2Q/G4FO7'V%D28OLVCM? NUKCH93>SB+Q M'_$]^$E^HN\YB52V#C/B&F_:>FK-LB(;@NS<<]@ H%-%'L<<+%=AA/RO=-<^ MY2Q=;<7X6N>BO-Q*,U=GV[)-SD<7>M9!IX/Z*[Z(4>!4YY@BL@-;+"A,]=VY6%5'O7QX$2SB!RL>G\X_AJ@.9J(A1\'0JLY".QT MY5=KUE;I+)YJ4%,>/)+ $:L\*.QT8-FN)+#*C0YGNA*H,2B@R/*I*'$L;=UC MA7D1A,@'<&,ZL*HHN:PRH'!6-'^$"< 9TJ\=]Y7PA[<&F!M_8C7+LCD:GQQ. M^@>#KOSN)PVL?1?9_B0OM,LFO9H<'*J_N99WY?.>FIDSR4S^L^@1OKPFK&MJ M] K6V1+Y6VJ2S-E[::F1$49<&K6\=4J55)&@CJFL]DS%(G'L337ZH6:JE@2U MS.#5>(@)Q0'\@>;@Z"<"&B*<3Y+T4#-ZZ7XHF*&@BKLGR:EQ]6H<\W=BH424 M2OT 1F<#S^97Z^F63?-#ODK:'29?.KX/O(OM8B K* 4F<:K]0!L;+(*(ZR@4 MK5=JI%^!T C)_*ER#">T'=TF16L529#,Y65B#Q_QE6K M9NRF=@JUPK#3I3+6*7O?AIHO#7MS3;67T([KP!.R]SJ:L@Y[?"PT.(3[$LQ M+%3Z5!T )(R"D>2"6]XZ].P-"740R@G)3B3M^TFOL_'IX>G'F.OD)+*WG$E] M>'G+($KDM,;1=@N>>VPFE+Z\91L$6JBR# X)IHUC@'HW,XC7?L*.6ZH5&K!> M)1C6$):RKW&]34C[A%;V#IJ.*--_8SEKM&]B^A>7".,TS<#TGW?W1Q"O@ L7 M$'C4B9Y:UAK-RVFBHD$I[FPUW+^3P^$ T*UVN81=JI-20<4X"_!EM=+F/T.. MTK8E!J8T-E\]GDX?\?1"F4*WOUFC3!/3)EL*C*0#!J9*TE?J2J?P:YF7\_'I MB:%;NGP)-VB#P8-Q^]E>>=]A@!]+I*JO]+M]"F3TJZQ"/A]]5F+ZXB5=B<7? M^ZQ$+A]V3HKJ#]AH\\L=Y_9,=\+6P,?4P:TF$6K-!&/K.3%-5-O;)F+)092W M8Q_(]8!.(;JE1*DYOZSTX]MVP?W-@3XV2#=A1-:!FE%?;>X3_'N1J-9;FGT; M 6GL0$RD%=\&:0+AWZ,P5N[(T%OZQ+UN82JZ9J4LC[/I:+A&\?T)\ 4DX$T1 MF\X+*%UH4QXD)]V#ST%B2LB*;IM9E@RPJ^GY \18B(%W_;X"+OHX#_%7F3CQ M))S.S9JF$='F/X>-$0EKS85+BUEL@?6'3;=TEH.3A4-O'!4:Y3BL-,BMQ:;#@[03Q;D,^J M@5VD_8EH]>*S+6VSPFRRM.>@TN]OPN@)1&]HJ=/J.< :D0\,SNYR4I0P6OMC M;VU%FE_*C9-H3=;IL^051/-7)R@NS(&7K\QO'!B1EQN: L[VWXN/AVV;!)V? M5!T,*354LVREO(>/A\H6\LC!HR?M8=\\U6SX%3)K:=V:J[7S"5F]HLS1/JB\ MLZU%MYU6IL@)6Z9RG ;>=Y"\AE[HAR\;WOL*^EO^'!'[%FX^1G0=@9J<$]IL M;3:)<[O1CY;/S+TZ+0T.9TQTA*K"#>QV0M<<)-8W]ZE)B(\P_J^;"(!;M*!! MR$P>G:1UC$#7=C\'#GO@[%WVFM-?#V'\Y$;HCQ!??_<17_L:0DK)$C:"<2>6_\<2^J70@HTH"BHC3NB]#T\< ^2NS".\Y?1D;J@B]1Q!?TU MCG J_RKW'L&X_AX!HC?"!$>(8OHX ?J2M$G>O)@ MP;43!3!XV4J,L[%(+ZXF*72%?%6[ZR4".R)&Z64K&M99*IY*=AFC57!JY]5U M:1RC@7H;(',![NCW?DIEK%&[.E76IQH^QUH?5U,5OL&1SA4(PB4,.AJ&!BK6 M8$2U:1#E=2 I$2J^4BD,NG ^61$2Q8JT(V8-E%3"HVYP% IGF/>\.9(7=+L^ M)KC:2*&K!9ND*$(./GUVV]MBYR%$*Y<$.GX:HGG][OIKM)"Y0;*_='QWG>9A ME5WT' HM>K9MI^N;> 2RUD=8]2-WU_[GTFU1%/:^KM61Y8M-,P'6>S_Z6K0. MAGN 5AW/^Q9PW\#-?5R(5\TZF.U;XZ*8XXAL(/M3EV& 5B()1"/T"CPG._:9 M#PEQ:O4$8QP-UX'2ANV!X$3/4U,#PH86MX2MIEC[AQ M7#9":<4_.NBDY*(U%_8> EK3 *VY\PYBN9/;PWJX:DIK1(CUY1AVR_^.$\Y) M++.&B6&_[1"^V1#$X ($8 &YW2^7MF[0"RBF.&AEV-+FF^L;IN256QR/'R6; M>>0$,1(#CL:7&[-']3&;$?Y**(^*I/LR@FFBX0QC?C6S@16T_EUL2K\(Q4]( MT"H/F-/Q^=F)63L@JM[F<(FNG-M[<$SAC+%3RZAAG=;5:;".#EDY] X#S%U: M9AWK<""K*V%M,_@UOG5'N8= X02GRG0"%PV5PN[D Y(BC.,PVMR'">687PW1 MOD"&H? =:#2*I&>H2GF,R8*ZPN0\1,OM91B0,W!I9,D1_C#H4B"6@40;*#U[ MM@ Q.ET980$('#$;\F&4'S%;H')AM;0[8K9E1K'RB-E"]0M-#O(L#D3_3T@W M)/%$FOX:;^6' ?HG*T"?6<0EP3C(-3P55%A@S@2-9>W3O+1VZAH6 MYW0@!H&WNJ"6LT[]XJIKF@_@';7R?87,$(N(ADU9BT(3$T;"B3@=9P M&.DW9VCO,;%>GBINQ!768KNX(_KN;Q.P=+4U2 3N55B:T^/N(3_'T_HY!O]< MX^7%&UE4!-XM&J-N@@7T!KWQY,$)/+"$KER8R'$]3&37U"AMBR0@3%L;A8O1 MY>R/VZNOX\DH;[$OT2,U&7*>-J$4QP@[/#H_/CHY/SDZ/#L^.C.5WK7<069\ M2$/1\D@Y&T\.#@U[S#(";]@>$>71WD-^O(,X6Q02M#+VQ1K+VJY3NE+J^A1G MT%Z%%GJ/3?8]ZM;NF^):D+G[(4G%.A"(:[*. A6\&]\YH3BG4_^O5P"7($+S M+T"3XF48KG#V31S[GJR]#?W 7:RF=4!0HCL3;*>]/F+R2-16&_BM< MS+7VS59HL%=$'4 M.#?0"Y;%<71X<&(H<:-6\)G2MR M$?,=V0>D ^PU70>H61]X-V$TCX"38,>IR4$4J6>[[MD*K/B!K1G6>NPA[550 M8# /$\?/69Q'T/%S/IN43R\]*)5+LJGUO,+6AY]CSJ/9Y#6?^#9(=]\K2=71 MK!JY:%GU$*$YE3:Q[*\'0P&O+:+3/ 4:RGO?^ODM_,9O/%N0SVW!+D+[P\&X MM5"T1JR<, _M_OXMU7]V7/7O_Q]02P$"% ,4 " *7&11)J'6UGR8 L MY @ $0 @ $ 86YV&UL4$L! A0#% @ M"EQD45^YOJ\<)0 (GL" !4 ( !Y+( &%N=G,M,C R,# Y M,S!?9&5F+GAM;%!+ 0(4 Q0 ( I<9%$4;$6\>EL (["!0 5 M " 3/8 !A;G9S+3(P,C P.3,P7VQA8BYX;6Q02P$"% ,4 " * M7&11@4R4Q$0\ X000 %0 @ '@,P$ 86YV&UL4$L%!@ & 8 B@$ %=P 0 $! end